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Abstract 
Chlamydia trachomatis is one of the most prevalent sexually transmitted diseases. 
Previous work has shown that C. trachomatis IgG antibody is correlated with tubal 
factor infertility and reduced pregnancy rates. There has been little research on 
Mycoplasma genitalium and the incidence in infertile couples remains unknown. 
This study has investigated 250 infertile couples as well as 250 fertile women. The 
presence of these organisms was detected by polymerase chain reaction and an 
analysis of serum IgA, IgM and IgG antibodies to C. trachomatis. 
Low prevalence of C. trachomatis, low level of concordance within couples and no 
evidence of M. genitalium was found. Elevation of IL6 and 8 were observed in C. 
trachomatis positive men and this varied with diagnostic method. Seminal IL-8 was 
correlated negatively with semen volume and positively with age. Sperm DNA 
fragmentation (TUNEL) and chromatin structure (AB, AO & CMA3) were not 
correlated with C. trachomatis infection. TUNEL results correlated negatively with 
semen volume and the percentage of protamination was related to age. Urethritis 
was more common in men diagnosed with C. trachomatis by urine DNA. Men who 
work as drivers were more likely to be positive for IgG. PCOS was more common 
in women with positive serology for IgM and IgG. C. trachomatis infection in men 
or women did not affect pregnancy rate and pregnancy outcome in either assisted or 
spontaneous conception. 
In conclusion, this thesis does not support the hypothesis that there is a strong 
relationship between C. trachomatis infection and infertility. Nor does it support 
the idea that C. trachomatis is linked to poor semen quality. Study limitations 
include the lack of fertile men as control group and difficulties with some 
methodology. A number of future studies are suggested along with some 
recommendations of C. trachomatis screening programmes both in Iran and the 
world.  
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1.1 Sexual transmitted disease (STD) 
Sexually transmitted diseases (STDs) are considered worldwide as major public health 
issue, often affecting young adults (Low et al., 2006). They can affect male and female 
fertility, compromise reproductive fecundity and their complications constitute a great 
socio-economic burden (Piot et al., 1988; Cates, 1996). Although there have been 
advances in managing these infections (Low et al., 2006), with regards to the morbidity 
and mortality associated with them, only limited success has been achieved (Molyneux, 
2004). STDs are primarily caused by bacteria and viruses: Chlamydia trachomatis, 
Neisseria gonorrhoeae, Mycoplasma genitalium, Treponema pallidum, are considered 
bacterial causes of STDs, whereas Cytomegalovirus (CMV), human papillomavirus 
(HPV), herpes simplex virus type 2 (HSV-2) and human immunodeficiency viruses 
(HIV) are viral causes.  C. trachomatis, N. gonorrhoeae, HSV-2 and HIV are the most 
common STDs with the main health and socio-economic impact (Beagley et al., 2000). 
In this thesis C. trachomatis (the most prevalent of the STDs) and M. genitalium (a 
bacterium about which little has been published) have been selected to study.  
According to the World Health Organization (2001), 92 million new cases of C. 
trachomatis infection occur every year worldwide with 16 million of new cases found in 
Sub-Saharan Africa. C. trachomatis is the cause of the most prevalent bacterial STD 
worldwide, and is also  as being responsible for at least 50% of an 
identifiable cause of pelvic inflammatory disease (Scholes et al., 1996; Khalaf, 2003). 
In 87% of untreated men and women there is established persistence of genital 
chlamydial infections (Joyner et al., 2002). In contrast, M. genitalium is a STD human 
pathogen that has been relatively poorly studied. It can lead to urogenital tract disease 
and has been isolated from the male genital tract in patients with urethritis (Tully et al., 
1981). M. genitalium can act in similar way to C. trachomatis in men with non-
gonococcal urethritis and women with cervicitis (Gdoura et al., 2007).  
One of the major causes of female infertility is tubal factor infertility (TFI) and one of 
the major causes of TFI is damage of Fallopian tubes following infection due to STDs 
(Clausen et al., 2001).  Major complications of chlamydial and mycoplasma infections 
are pelvic inflammatory disease (PID), ectopic pregnancy, infertility, and infant 
pneumonia. The association between C. trachomatis and M. genitalium infections and 
infertility in developed countries has been demonstrated by different studies (Paavonen 
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& Wolner- Hanssen, 1989; Vigil et al., 2002). However, the role of these infections and 
infertility among infertile couples remains to be determined which this is the focus of 
this thesis. 
1.2 History of Chlamydia trachomatis 
Chlamydia was discovered in 1907 by Halberstaedter and von Prowazek (Everett et al., 
1999). They observed it in the epithelium of a conjunctival scraping from an infected 
orangutan which was inoculated with human trachomatous material (Budai, 2007). 
Before this discovery, trachoma was well known for thousands of years as a blinding 
ocular human disease. The Ebers Papyrus from 1550 BC is the first written medical 
document that mentioned it (Horn et al., 2004). Halberstaedter and von Prowazek 
(1909) detected an agent similar to trachoma in a case of neonatal blennorrhoea. 
Heyman and also Frietsch et al., (1910) found trachoma-like inclusions in scrapings 
from neonate conjunctival and cervical of their mothers. Linder et al., (1911) described 
the same intracytoplasmic inclusions in infants with ophthalmia neonatorum that was 
observed in urethral cells of their parents and since then chlamydia was diagnosed as 
cause of sexually transmitted infections. A description of lymphogranuloma venereum 
(LGV) pathology and its role in sexual transmission was published in 1913 (Durand et 
al., 1913). 
Macchiavello reported the successful culture of trachoma agent in the yolk of an 
embryonated egg (Macchiavello, 1944). However, trachoma agent culture was 
confirmed and is usually credited to T'ang and co-workers 1946 (reviewed in Wang, 
1999). In 1965 Gordon and Quan reported the use of irradiated McCoy cells for the 
isolation of C. trachomatis and this was a major step in the understanding of chlamydial 
infections (Ripa, 1982). In comparison with the isolation from eggs, their technique 
made it possible to perform cultures from genital specimens. The understanding of the 
basic biology of chlamydia, as well as the clinical aspect of chlamydia, increased 
following the use of McCoy cells. The role of C. trachomatis in infant pneumonia and 
its involvement in pelvic inflammatory disease (PID) was proposed by Schachter et al 
(1974) and Mardh et al (1977). C. trachomatis was recognised as an important 
aetiological factor in acute salpingitis and pelvic inflammatory disease in females 
(Treharne et al., 1979) and after that more studies reported the complications of this 
organism in women rather than men. 
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1.2.1 Taxonomy and classification of C. trachomatis 
Prior to 1999, there was only the genus Chlamydia (Moulder et al., 1984). Today, the 
taxonomy currently includes two major genera, Chlamydophila and Chlamydia, which 
belong to the family Chlamydiaceae, and was recognized in 1999 on the basis of 
sequence data in the ribosomal genes (Everett et al., 1999).  The species within the 
family Chlamydiaceae have 16S rRNA gene sequences which are more than 90% 
identical (Everett and Andersen, 1997; Figure 1.1). The genus Chlamydophila includes 
Chlamydophila pneumoniae, Chlamydophila pecorum, Chlamydophila psittaci, 
Chlamydophila abortus, Chlamydophila felis, and Chlamydophila caviae. Species in the 
genus Chlamydia include Chlamydia muridarum, Chlamydia trachomatis, and 
Chlamydia suis (Everett et al., 1999). 
1.2.2  Developmental cycle 
Chlamydiae are obligate intracellular bacteria with a unique biphasic developmental 
cycle. They are unable to synthesis their own ATP (Paavonen and Eggert-Kruse, 1999), 
thus they need to use their host cell’s energy resources to multiply and demonstrate a 
two- stage developmental cycle of replication (Black, 1997; Paavonen and Eggert-
Kruse, 1999). Accumulation of glycogen in inclusions and sensitivity to sulfadiazine are 
characteristics of C. trachomatis (Everett et al., 1999). The elementary bodies (EBs) 
have a complex of disulphide cross-linked envelope proteins which include two 
cysteine-rich lipoproteins (Everett et al., 1999): with a molecular weight 60Kda and 
second one a low molecular weight (12 Kda). These are called outer membrane complex 
protein A and B respectively (OmcA and OmcB) and a major outer membrane protein 
(MOMP) with a molecular weight of 40 Kda (Hatch, 1996; Everett et al., 1999). That 
complex includes Heat–Shock protein in addition (Hatch, 1996; Everett et al., 1999). 
During transformation of elementary bodies (EBs) into reticulate body (RB) chemical 
reduction in the disulphide cross-links may occur at the time of chlamydial cell 
infection (Everett et al., 1999).  
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Figure 1.1: Universal phylogenetic tree based on 16S rRNA sequences. Reproduced 
from Pace (1997) with kind permission of Professor Norman Pace (University of 
Colorado, USA). The scale bar corresponds to 0.1 changes per nucleotide.  
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The serovars are classified into two biovars: trachoma and lymphogranuloma venereum 
(Manavi, 2006). Serotypes A-C are related to ocular disease, serotypes D-K with 
ophthalmic and genital infections and L1-L3 with LGV (Batteiger, 1996; Manavi, 2006). 
There is evidence from a number of studies that show serovars D, E, F are usually a 
more frequent cause of genital infection (Manavi, 2006). Interestingly, there is a 
suggestion that some serovars or serovar variants might be more strongly related with 
disease than others (Manavi, 2006). C. trachomatis serotyping showed the particular 
association of some serovars with ocular and urogenital infections although for serovars 
B was shown overlapping for both ocular and genital infections (Wang and Grayston, 
1970; Jalal et al., 2007). However, there is controversy and further work is required to 
investigate these claims. 
The unique life cycle or developmental cycle of C. trachomatic includes two distinct 
morphological forms of the microorganism: the intracellular reticulate bodies and the 
extracellular (infective) form called elementary bodies (Wolner-Hanssen and Mardh 
1984; Black, 1997). Attachment of EBs to host cells is the most important event in 
chlamydial pathogenesis (Zhang and Stephens, 1992; Fawaz et al., 1997; Stamm, 1999). 
The possible mechanism of infection (Taraktchoglou et al., 2001) is using host cell 
heparin sulfate and the putative mechanism of attachment to cells such as sperm is 
through C. trachomatis lipopolysaccharide (Hosseinzadeh et al., 2000; Eley et al., 
2005a; 2005b) and it determines entry of chlamydia into target cells and formation of 
inclusions or vacuoles. EBs are protected from host cellular defence mechanism by this 
unique process (Zhang and Stephens, 1992; Fawaz et al., 1997; Stamm, 1999). 
The developmental cycle of C. trachomatis is unique in microbiology (see Figure 1.2). 
It is characterised by a small (approximately 0.3µm in diameter) infectious elementary 
body (EB) and a larger (1µm) dividing intracellular reticulate body (RB).  
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Figure 1.2: Developmental cycle of C. trachomatis. EBs are responsible for attachment 
to host cells, so the first step in the infection process is attachment of EBs to mucosal 
epithelial surfaces of host cells (a), then the EB is endocytosed into the host cell and a 
vacuole develops in the cytoplasm (b). Two hours post infection, EBs change to RBs. 
Then replication of RBs through binary fission occurs. Over 8-12 hours, the RBs 
increase in size and volume, and then an inclusion membrane is formed (c). Afterwards 
the inclusion bodies are expanded and at 18 hours post infection, RBs are differentiated 
to EBs. Finally, EBs are released from the infected host often by lysis of the host cell 
(d). The time of lysis and release of EBs are dependent on serovars of chlamydia. These 
events take place 36 to 72 hours post infection (Paavonen & Eggert-Kruse, 1999). 
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1.2.3 Effect of C. trachomatis infection in men 
C. trachomatis, as a cause of the most prevalent STD in the world, has been studied 
more with regard to its effect on the female genital tract. Moreover, the clinical effect of 
infection is thought to be greater in the female compared with male infections. To 
investigate the effect of C. trachomatis infection in male patients, more studies have 
been focused on its effect on semen parameters rather than direct effects on the male 
reproductive tract (Keck et al., 1998; Norman, 2002).  There is controversy about 
relationship between C. trachomatis infection and semen quality: some studies have 
shown that infection is associated with poor semen quality (Witkin et al., 1995; Cengiz 
et al., 1997) and some of them have claimed this is not (Eggert-Kruse et al., 1990; 
Hosseinzadeh et al., 2004). However, because the methodology for C. trachomatis 
detection and semen analysis techniques are not comparable (Pacey and Eley, 2004) it is 
difficult to make comparisons between studies.  
Direct exposure to C. trachomatis can affect the function of human spermatozoa (Eley 
et al., 2005b) and in infected individuals might contribute in subfertility by an 
independent route of any damage to the reproductive epithelium (Pacey and Eley, 
2004). Although most infected men are asymptomatic, urethritis is the most prevalent 
symptom (Eley et al., 1992). In younger men epididymitis is often seen with C. 
trachomatis infection (Eley et al., 1992). Epithelial damage of C. trachomatis infection 
can reduce spermatogenesis and induce immunological responses that destroy sperm 
(Gonzales et al., 2004). According to Wan et al., (2003) and Eley et al., (2005) C. 
trachomatis infection can cause sperm DNA fragmentation because sperm apoptosis is 
triggered. Lipopolysaccharide (LPS) extracted from C. trachomatis elementary bodies 
(EBs) cause apoptosis by a caspase-mediated mechanism (Hosseinzadeh et al., 2001). 
Also sperm motility and viability decrease when live C. trachomatis EBs are incubated 
with spermatozoa from normal men.  LPS extracted from C. trachomatis EBs had the 
same effect (Hosseinzadeh et al., 2001; 2003). In a different study, C. trachomatis 
serovar E was shown to cause sperm death within a few hours of exposure, and also 
stimulated the tyrosine phosphorylation of 2 major sperm epitopes (Hosseinzadeh et al., 
2000). Two toxic components of LPS including lipid A and 3-deoxy-D-manno-
octulosonic acid have also shown an apoptosis effect similar to LPS by a caspase-
mediated mechanism (Hakimi et al., 2006). High levels of sperm DNA fragmentation 
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are seen in infected patients and decreases after antibiotic therapy (Satta et al., 2006; 
Gallegos et al., 2008).  
All these effects are probably mediated by the attachment of EBs to sperm. Wolner-
Hansen and Mardh (1984) were the first to report attachment of C. trachomatis to 
human spermatozoa in vitro using fluorescence and transmission electron microscopy. 
They reported that the number of EBs attached to spermatozoa depends on the 
concentration of EBs in which with the spermatozoa were incubated. Mavrov (1995) 
reported the attachment of C. trachomatis to different regions of spermatozoa as seen by 
transmission electron microscopy, and there is also one report analyzing patient 
spermatozoa following chlamydial infection in vivo (Erbengi, 1993). However, none of 
these results have fully defined the attachment of C. trachomatis to spermatozoa at the 
molecular level.  
The presence of bacteria inside of seminal leucocytes indicates that infection can be 
persistent and lead to a chronic phase of infection (Gallegos-Avila et al., 2009). In 
infertile men higher pH and seminal leucocytes as well as lower percentage progressive 
motile spermatozoa were associated with chlamydial infection (Hosseinzadeh et al., 
2004; Kokab et al., 2010). High seminal plasma IL6 and IL8 were associated with C. 
trachomatis infection (Eggert-Kruse et al., 2001; Kokab et al., 2010).  
C. trachomatis IgG antibody is known as a marker of previous or persistent infection 
(Mol et al., 1997).  Immunoglobulin G antibody to C. trachomatis in the male partner is 
related to presence of IgG antibody in the female partners and decreased pregnancy rate 
(Idahl et al., 2004). There were no differences in outcome of pregnancy (either 
spontaneously or related treatment) between IgG positive and IgG negative groups 
(Idahl et al., 2004). Also Idahl et al., (2007) found that C. trachomatis IgA antibody in 
infertile men was correlated with reduced sperm motility and pregnancy rates. IgA in 
combination with IgG was associated with decreased in sperm concentration, the 
number of progressive spermatozoa, and increasing in the teratozoospermia index. A 
high percentage of dead spermatozoa and high prevalence of leucocytes in semen were 
seen in IgA positive men (Idahl et al., 2007). 
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1.2.4 Clinical appearances of C. trachomatis infection in men 
1.2.4.1 Urethritis 
Although chlamydial genital tract infections are asymptomatic in approximately 50% 
men (Taylor and Haggerty, 2011) non-gonococcal urethritis (NGU) is the most common 
clinical syndrome in chlamydial infection. This was established by Holms et al., (1975). 
Urethritis following chlamydial infection may lead to prostatitis, vesiculitis or 
epididymitis (Gonzales et al., 2004). Post gonococcal urethritis (PGU) refers to a 
persistent non-gonococcal urethritis following treatment for gonococcal urethritis. C. 
trachomatis should be considered in treatment of PGU because it is responsible for 70-
80% of PGU as well (Schachter, 1999). 
1.2.4.2 Prostatitis 
C. trachomatis has been detected in the seminal vesicles and prostate and it is suggested 
that it may affect their function (Bornman et al., 1998). High prevalence of chlamydia 
was reported in the male with prostatovesiculitis (Soffer et al., 1990). According to 
Weinder et al., (1991), one-third of unspecific accessory gland infection is due to 
chlamydial prostate-vesiculitis. In prostatitis patients C. trachomatis has been detected 
in up to 30% of prostatic or semen secretion samples and in 2.2% to 33% of prostate 
tissue samples (Taylor and Haggerty, 2011). Young male fertility has been affected by 
C. trachomatis infection in chronic prostatitis patients and recovery of semen quality 
has not always been seen in C. trachomatis infection after antibiotic therapy (Cai et al., 
2011). 
1.2.4.3 Epididymitis 
Many studies have reported that STD-associated infections in the male can lead to 
occlusions in the genital tract, which in the acute phase via the spread of 
microorganisms from the urethra, can cause damage to tubular tracts and to the cells 
involved in spermatogenesis (Berger, 1990; Villegas et al, 1991). C. trachomatis is a 
cause of idiopathic epididymitis, and Moller and Mardh (1989) provoked 
experimentally C. trachomatis epididymitis in a male monkey model. When orchitis is 
seen with epididymitis, decreasing sperm production and testicular atrophy is observed 
(Berger, 1990). Approximately 45%–85% of men with epididymitis have had a prior C. 
trachomatis infections and/or gonococcal infections (Taylor and Haggerty, 2011). 
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1.2.5 Effect of C. trachomatis infection in women 
Chlamydial infections are predominantly asymptomatic in women and can disseminate 
through sexual contact (Pacey and Eley, 2004). Although C. trachomatis is a main cause 
of cervicitis, in half of the cases it is seen with urethritis (Paavonen and Eggert-Kruse, 
1999). Both the lower and upper genital tract can be involved in this infection 
(Paavonen and Eggert-Kruse, 1999). Furthermore, asymptomatic infection may lead to 
severe complications such as PID, salpingitis, chorioamnionitis, ectopic pregnancy, 
premature delivery, neonatal infections and infertility (Paavonen and Eggert-Kruse, 
1999; Gonzales et al., 2004). Generally C. trachomatis infection in women has more 
visible effects or complications. 
 
Tubal factor infertility as a result of PID has been seen in women who have never been 
diagnosed because infection is silent and there is no history of PID (Gonzales et al., 
2004). Subclinical PID is the cause of a greater proportion of PID-related sequelae 
(Sweet, 2011) and increasing C. trachomatis infection as a cause of clinical and 
subclinical PID is a concern. Approximately 20% of women with lower genital tract 
infection due to C. trachomatis will develop PID, 4% will develop chronic pelvic pain, 
3% infertility, and 2% adverse pregnancy outcome (Paavonen and Eggert-Kruse, 1999). 
This is why chlamydial infections are considered as primarily a woman’s health care 
issue (Paavonen and Eggert-Kruse, 1999). The most important preventable cause of 
infertility and adverse pregnancy outcome is PID following chlamydial infection 
(Westrom et al, 1994). 
 
There are some studies that have verified a strong relationship between serum 
antibodies (Ab) to C. trachomatis and tubal factor infertility or ectopic pregnancy both 
in women with or without history of PID. These studies suggested that chlamydial 
infection might be a cause of a large percentage of tubal factor infertility and ectopic 
pregnancy (Cates et al., 1991). Ectopic pregnancy in the first trimester of pregnancy is 
the main cause of maternal mortality in developing countries. In comparison with 
women with no history of PID, women with a history of PID have a 7 to 10 fold 
increased risk of tubal pregnancy (Westrom et al, 1981; Westrom, 1994). 
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According to a research by Eggert-Kruse and colleagues, titres of antichlamydia 
immunoglobulin were elevated in subfertile couples and these antibodies (Ab) are more 
frequent in the women who had seropositive partners (Eggert-Kruse et al., 1997). 
Punnonen et al., (1979) were the first to study the link between tubal factor and past 
chlamydial infection and they found that patients with normal hysterosalpingography 
had significantly lower titres of antichlamydia Abs compared with those that had 
bilateral tubal obstruction. Obstructed Fallopian tube is four times more likely to be 
found in women with previous chlamydial infection (Gonzales et al., 2004). 
 
Some studies reported C. trachomatis may also contribute to pregnancy complications, 
including premature rupture of membranes, preterm birth, low birth weight and still 
birth (Gravett et al., 1986; Hollegaard et al., 2007). Asymptomatic C. trachomatis 
infections are thought to induce early pregnancy loss through the stimulation of immune 
mechanisms (Witkin et al., 1998). 
 
There is an association between C. trachomatis infection and pregnancy loss especially 
in the first-trimester. This is explained in two ways: (1) direct infection of the oocyte or 
zygote or the immune response to heat shock proteins expressed by the zygote that is 
triggered by a previous C. trachomatis infection (Vigil et al, 2002); and (2) stimulation 
of toll-like receptor 4 (TLR4) in vitro by chlamydial heat shock protein 60 antigen that 
is responsible for inducing apoptosis in primary human trophoblast, placental fibroblast 
and human syncytiotrophoblast cell lines (Equils et al., 2006). This may help 
understand the molecular mechanism of pathogenesis for poor pregnancy outcome in 
women with persistent chlamydial infection. 
 
In the host defence mechanism against C. trachomatis genital tract infections it seems 
that toll-like receptors (TLRs) play a role, because some of them are expressed in 
epithelial cells in the human genital tract and are able to recognise C. trachomatis 
pathogen-associated molecular patterns (PAMPs). Measuring C. trachomatis IgG 
antibodies in serum has been introduced in the fertility work-up and is nowadays 
recommended to assess the risk of tubal pathology in subfertile women in an 
inexpensive and non-invasive way (den Hartog et al., 2006; Akande et al., 2010).  
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1.2.6 Clinical appearances of C. trachomatis infection in women 
1.2.6.1 Lower genital tract infection 
The cervix and urethra are the main location of C. trachomatis infection that can lead to 
cervicitis and urethritis respectively. Mucopurulent discharge (37%) and hypertrophic 
cervical ectopy (19%) have been reported in the infected women. Abdominal pain, 
inter-menstrual bleeding can be seen as well. Serious complications (e.g. tubal factor 
infertility, ectopic pregnancy and pregnancy loss) have been seen after ascending C. 
trachomatis infection to the upper genital tract (Stamm et al., 1980; Stamm, 2008; 
Taylor and Haggerty, 2011). 
1.2.6.2 Pelvic Inflammatory Disease (PID) 
Acute PID is a major complication of genital C. trachomatis infection (Gonzales et al., 
2004; Taylor and Haggerty, 2011) that is isolated in 25% of patients. However 
progression rates vary widely. Studies have shown that 2.0% - 4.5% of genital 
chlamydial infection developed clinical PID during 14 days among untreated women 
(Morre et al., 2002; Geisler et al., 2008). Also in longer follow-up studies the rates 0% - 
9.5% PID have been reported among untreated women (Bakken et al., 2009; Oakeshott 
et al., 2010). In Norway, the largest study conducted (1990-2005) showed 1.09% 
(48/4413) of cases that tested positive for C. trachomatis were hospitalized for PID 
(Bakken et al., 2009). The magnitude of PID is due to its subsequent sequelae including 
chronic pelvic pain, ectopic pregnancy, and infertility (Brunham et al., 1988; Chow et 
al., 1990; Westrom et al., 1992).  
1.2.7 Pathogenesis of chlamydial infections 
1.2.7.1 Epidemiology 
Chlamydiae cause a wide variety of disease. The highest infection rates are found 
among the young and the poor (Schachter, 1999). Because women are more likely to be 
screened the reported rates in females are higher than the reported rates in males 
(Schachter, 1999). Prevalence of C. pneumoniae in adults is about 70% and infects a 
majority of humans as an important respiratory pathogen (Grayston et al., 1986; 
Schachter, 1999). C. psittaci is a common pathogen of avian species that are the source 
for human disease as they act as potential reservoirs. Moreover, C. psittaci can infect 
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mammals (Schachter, 1999). Trachoma is still a major cause of blindness in 
hyperendemic areas (tropical and subtropical countries) in 2
nd
 and 3
rd
 year of life. 
However its blindness is preventable (Thylefors et al., 1995; Schachter, 1999).  
1.2.7.2 Immunity in chlamydial infections 
As the genital tract, respiratory system and eyes may be involved in chlamydial 
infections, the immune responses depend on the variety of tissues that are involved in 
infection and their response. Humoral and cell mediate immune responses are involved 
in chlamydial infections (Paavonen and Eggert-Kruse, 1999).  
1.2.7.2.1 Innate defence mechanisms 
Researchers have more recently focused on the role of innate immune mechanism in the 
early response to C. trachomatis infection (Tiitinen et al., 2006; Taylor et al., 2012). 
The involvement of Toll-like receptors (TLRs) has been investigated (den Hartog et al., 
2006; Equlis et al., 2006; Taylor et al., 2012) and 4 TLR genes (TLR1, TLR2, TLR4, and 
TLR6) were associated with C. trachomatis infection among women with clinically 
suspected PID (Taylor et al., 2012). TLRs act as pattern recognition receptors to enable 
cells to identify pathogen-associated molecular patterns (Beatty et al., 1993). The most 
important factor in host defence against C. trachomatis infection is interferon γ (INF γ) 
a typical product of T helper cells (Th1). Expression of the IL-10 marker of Th2 cell 
activation is related to disease susceptibility (Beatty et al., 1993). Different pro-
inflammatory cytokines such as IL-1, IL-6, IL-8, IL-10, IL-12, IL-18, and TNFα were 
seen in vitro and in vivo studies of epithelial cells infected with C. trachomatis (Mpiga 
et al., 2006; Al-Mously and Eley, 2007). 
1.2.7.2.2 Humoral response 
IgA is considered a critical protection factor in epithelial cells. In chlamydial infection 
of the genital epithelium IgG and IgM have been detected in serum, and both IgA and 
IgG have been measured in secretions (Agrawal et al., 2007). Patients with both ocular 
and genital chlamydial infection have a higher level of IgG in serum compared with 
patients who have genital or ocular infection (Patel et al., 1992).  In a study of primary 
and recurrent genital chlamydial infections, cervical IgA and IgG were higher in 
primary infection than recurrent infection (Agrawal et al., 2007). IgG antibody is 
detectable more than two years after infection, its level dramatically decreased 50 days 
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after infection, whilst IgA levels are detectable up to 100 days (Batteiger and Rank, 
1987). Eggert-Kruse et al., (2011) showed IgG, IgM and IgA antichlamydial antibodies 
in serum were interrelated and associated with IgA in seminal plasma (Eggert-Kruse et 
al., 2011).  
1.2.7.2.3 Cell mediated immunity (CMI) 
CMI plays a key role in defence against intracellular pathogens. In the murine model, 
localized C. trachomatis genital infection is mediated by chlamydial- specific CD4 cells 
(Ramsey et al., 1991). CD4
+
 cells play a significant role in adaptive immunity to C. 
trachomatis infection (Ramsey et al., 1991; Su and Caldwell, 1995).  Studies have 
shown the role of CD4
+
 and CD8
+
 cells in chlamydial infection that lack of these cells 
has been observed (Gervassi et al., 2004b; Marks et al., 2007). Although the role of a 
CMI response has been shown in animal models (murine, guinea pig, primate) the 
important role in genital infection by C. trachomatis has been observed in primates for 
CD8 cells (Van Voorhis et al., 1996). Kelly and Rank (1997) investigated the 
mechanism of CD4 cells during a natural infection and their results supported the role of 
CD4 cells to protect against vaginal C. trachomatis in mouse, also CD8 lines and clones 
protect in the mouse pneumonitis biovar of C. trachomatis (MoPn).  
 
In women without inflammation in the genitalia, the CD8 cells were predominantly 
intraepithelial lymphocytes whereas increasing numbers of intraepithelial CD8, CD4 
lymphocytes and antigen presenting cells were seen in women with cervicitis (Pudney et 
al., 2005). Wyrick (1999) stated that a CMI response has been observed in both 
trachoma patients and in animal models. In viral, parasitic and bacterial infections, NK 
T cells have a role in host defence (Wyrick et al., 1999).  
 
1.2.8 Laboratory methods for detecting C. trachomatis 
1.2.8.1 Cell culture 
This was performed in the early days of C. trachomatis screening by inoculation of 
specimens such as urethral swabs onto monolayer cell cultures (Mardh et al., 1980). 
Chlamydial inclusions can be observed in the monolayer 48-72 h post infection by 
different staining methods according to the presence of sufficient viable micro-
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organisms in the swab. The specificity of the test is 100% to detect C. trachomatis in 
urogenital specimens whilst sensitivity is about 70-80% (Lee et al., 1995; Black, 1997; 
Carder et al., 2006). Although in clinical specimens McCoy is the most common cell 
line used to grow C. trachomatis (Ehert and Judson, 1989) many cell lines including 
Hela-229, BHK-21, Hec1B and green monkey kidney cells have been used (Kuo et al., 
1972; Stamm et al., 1983). After using non-invasive samples such as urine to detect C. 
trachomatis and discovering that semen components are toxic to growth and 
maintenance of the monolayer, it was determined that cell culture was too insensitive 
and the method was abandoned (Taylor-Robinson and Thomas, 1991). 
1.2.8.2  Direct Immuno Fluorescence (DIF) staining 
DIF has been used to detect C. trachomatis in clinical samples. Although the number of 
elementary bodies is a factor to define a positive sample (Tilton et al., 1988; Thomas et 
al., 1993) the technique is based on the ability to visualize chlamydial particles or 
inclusions by microscopy. Monoclonal antibodies against MOMP of C. trachomatis, in 
both clinical and laboratory strains, produce a specific fluorescent brightness of EBs in 
this technique (Cles et al., 1988).  Advantages of the test in comparison with tissue 
culture and EIA (see below; section 1.2.8.4) are its simplicity and rapidity. The 
specificity of the test is 82% to 100% and sensitivity 68% to 100% (Black, 1997). The 
test is often applied as a confirmation test for positive results of non-culture tests (Chan 
et al., 1994). 
1.2.8.3  Other chlamydial staining methods 
To detect chlamydial inclusions, Gram, Giemsa or Iodine staining have been 
traditionally used. Neonatal inclusion conjunctivitis is diagnosed by Giemsa staining 
due to the simplicity of the test (Black, 1997). However, the test is not used commonly 
because of low sensitivity and specificity compare with DIF (see section 1.2.8.2). Since 
staining artifacts can be considered as chlamydial inclusions, the reading of the stained 
slides needs to be performed by expert staff (Schoenwald et al., 1988). Due to the 
variable results, Gram staining has little practical value, although chlamydia is 
considered a Gram negative micro-organism. Iodine staining is a selective stain of 
glycogen, therefore is not able to distinguish infections in the cells which normally 
contain glycogen and has low sensitivity in detecting the inclusions (Black, 1997). 
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1.2.8.4 Serological tests 
An approach to detect C. trachomatis in clinical specimens is the identification of 
antibodies to chlamydia. In general, the use of chlamydial serology to detect C. 
trachomatis has several limitations. There is no single sensitive and specific C. 
trachomatis antibody test (Johnson & Horner, 2008). Also, there is often cross-
reactivity with pneumoniae that cause variable specificity and sensitivity. Infections are 
long lived, thus a positive antibody test cannot distinguish between a current and a 
previous infection (Black, 1997; Johnson & Horner, 2008).  The tests which have been 
developed for detection of antibody to chlamydial infections include: 
i) Micro-Immuno Fluorescence (MIF) which is considered a gold standard for 
chlamydia species and serovars among the serological tests (Wang and Graystone, 
1970; Bax et al., 2003). 
ii) Complement Fixation Test (CFT) which is the most common test used for diagnosis 
of chlamydial infections by recognising the genus-specific LPS antigen via 
complement-fixing antibodies. It is not specific for any chlamydial species (Black, 
1997). 
iii) Enzyme Immuno Assays (EIAs) that detect the immune response to chlamydial 
genus-specific LPS of EBs or RBs. The test has cross-reactivity with C. pneumoniae, 
Bacteroides species and Escherichia coli due to high prevalence of these pathogens 
(Black, 1997; Eggert-Kruse et al., 1995; Ivanov et al., 2009). Therefore the sensitivity is 
poor compared with molecular methods. Recently a new assay that showed no cross-
reactivity with C. pneumoniae has been developed (Wills et al., 2009).    
1.2.8.5 Molecular methods 
Using in situ hybridization (ISH) in clinical samples was an early method to detect C. 
trachomatis DNA. However, the test was not sensitive enough and when nucleic acid 
amplification testing (NAAT) became available, ISH was abandoned (Yoshida et al., 
1998). NAATs are the most sensitive test for detection of chlamydial infections 
(Schachter, 2001; Schachter et al., 2006). 
Polymerase chain reaction (PCR) and ligase chain reaction (LCR) have better 
sensitivities than non-molecular methods also these are more effective in detecting 
 
  
 
32 
 
chlamydial infection in asymptomatic and low prevalence populations (Watson et al., 
2002; Skidmore et al., 2006). The tests have sensitivities of greater than 90% and 
specificities approaching 100%.  Since NAATs detect nucleic acid targets, their 
advantage is that they do not need viable micro-organisms (Black, 1997). LCR was a 
commercial system in the 1990s, and has been used to detect C. trachomatis in semen 
(Eggert-Kruse et al., 1997; 2002a,b; Hosseinzadeh et al., 2004) but is no longer 
available. 
The first detection of C. trachomatis in semen samples using PCR was in 1993 (Van 
den Brule et al., 1993). Afterwards a number of other studies also used it (Ochsendorf et 
al., 1999; Hosseinzadeh et al., 2004; Gdoura et al., 2008). A more recent development 
has been the introduction of real-time or quantitative PCR, that detect C. trachomatis 
DNA copy numbers (Al-Mously et al., 2009). Amplification and quantification of the 
target nucleic acid take place in a single step and closed system (Jalal et al., 2007). 
Therefore, the advantage of this method includes high sensitivity and specificity, 
quantitative assay, providing faster result than gel-based PCR and avoiding 
contamination (Alexander et al., 2007; Jalal et al., 2007a). 
1.3 History of Mycoplasma genitalium 
M. genitalium is not well studied. The first time M. genitalium was isolated by culture 
was in 1980 when it was isolated from two of 13 men with non-gonococcal urethritis 
(Tully et al., 1981). However, in spite of several efforts the organism has not been 
isolated by culture since that time (Jensen et al., 1993; Fraser, 1995) and in 1999 it was 
again performed by Luo et al., (1999) successfully. M. genitalium is considered as a 
cause of non-gonococcal urethritis (NGU) in both males and females, although it is 
difficult to isolate from clinical samples, and cross reactivity with M. pneumoniae has 
hampered the development and use of serologic tests (Jensen et al., 1993).  
1.3.1 Taxonomy and classification of M. genitalium 
M. genitalium is a small bacterium which is a member of the family Mycoplasmatacae 
and Mollicutes class (Fraser, 1995). Mycoplasmas live on the ciliated epithelium of the 
primate genital and respiratory tracts (Fraser, 1995; Peterson, 1995). M. genitalium, 
after the endosymbiont Carsonella ruddii, is the second-smallest bacterium and the 
smallest known free-living bacterium (Fraser, 1995; Peterson, 1995). It was also 
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considered to be the organism with the smallest genome before the discovery of 
Nanoarchaeum equitans in 2002 (Huber et al., 2002; Westers et al., 2003).  
The genome of M. genitalium consists of 521 genes (428 protein encoding genes) in one 
circular chromosome and was studied by Peterson in 1993 with random sequencing 
(Peterson, 1993; 1995; Fraser, 1995). It was the second complete bacterial genome ever 
sequenced, after Haemophilus influenzae. Therefore, these characteristic of M. 
genitalium made it the organism of choice in the Minimal Genome Project (Glass et al., 
2006). In humans several mycoplasma species have been isolated. For seven of them, 
the genital tract is the main site of colonization: M. hominis, M. genitalium, M. 
fermentans, M. penetrans, M. pneumoniae, M. primatum and M. spermatophilum 
(Uuskula, 2002; Patel et al., 2010).  
1.3.2 Cell structure 
The lack of a cell wall is typical of mycoplasma species and M. genitalium only has a 
plasma membrane (Razin, 1998). Neutral lipids, phospholipids and glycolipids are 
located in the cell membrane. M. genitalium as a motile mycoplasma connects to 
surfaces using a complex terminal attachment organelle known as specific tip structure 
and moves across the tip (Razin, 1998). Tip construction causes M. genitalium to attach 
to eukaryotic cells and the adhesin protein (MgPa) is responsible for attachment to cells 
(Peterson 1995; Razin, 1998). Invasion of mycoplasmas into the host cell cytoplasm 
affects cell function and eventually results in cell disruption and necrosis (Uuskula, 
2002). 
Many biosynthetic pathway mechanisms are lacking in M. genitalium due to a lack in 
many genes coding for them. However, M. genitalium needs only small amounts of 
ATP for its limited biosynthetic pathways and therefore it grows well in vivo (Razin, 
1998). To produce ATP, M. genitalium depends on glycolysis, which is less efficient 
than oxidative phosphorylation. There are no quinones and cytochromes in any of the 
mycoplasmas and also there are no genes for synthesizing any fatty acids; therefore, 
they use their host fatty acids (Razin, 1998).       
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1.3.3 Effect of M. genitalium infection in men 
M. genitalium is considered as a cause of inflammatory lower genital tract syndrome 
(McGowin, 2011). Majority of patients with genital tract infections are not symptomatic 
and asymptomatic infections of the male urogenital tract are difficult to detect because 
taking samples are unacceptable to many asymptomatic men (Mardh et al., 1981, 
Gdoura et al., 2008). The impact of M. genitalium colonization of the genital tract on 
semen parameters and male fertility remains unclear and M. genitalium has seldom been 
investigated in the semen of infertile men. Gdoura et al., (2007) investigated the 
frequency of M. genitalium in semen sample of infertile men by PCR and found 5% 
positivity, as well as a very high concordance between detection of mycoplasma DNA 
in semen and first void urine. By comparison, Kjaergaard et al., (1997) showed 0.9% 
positivity by culture and this difference could be because the two studies used different 
methods for detection. In some studies there is a discrepancy between the detection of 
mycoplasma DNA from semen and corresponding FVU specimens which may indicate 
an asymptomatic infection in the seminal vesicles and the epididymis or urethra (Tully 
et al., 1981). Wang et al., (1997) stated that during ejaculation semen might be 
contaminated by genital Ureaplasma (U. urealyticum and U. parvum) and genital 
mycoplasmas (M. genitalium and M. hominis) as they are natural inhabitants of the male 
urethra. In susceptible populations genital opportunistic organisms including M. hominis 
and Ureaplasma species are related to invasive genitourinary infections (Jensen et al., 
1991).  
Spermatozoa have been suggested as vectors for bacterial spread from the male to the 
female genital tract and in vitro experiments have revealed U. urealyticum, N. 
gonorrhoeae, Escherichia coli and C. trachomatis and Mycoplasma (hominis and 
genitalium) attach to human spermatozoa (Friberg and Fullan, 1983). Taylor-Robinson 
and Manchee (1967) reported non genital mycoplasma (e.g. M. pneumoniae) could bind 
human spermatozoa. M. genitalium is able to attach to many different cell types 
including: erythrocytes, cells of the Fallopian tube, Vero cells, airway cells, HEp-2 
cells, and even plastic (Morrison-Plummer et al., 1987; Collier et al., 1990; Jensen et 
al., 1994; Baseman et al., 1996). The attachment of M. genitalium to spermatozoa has 
been reported by Svenstrup (2003) and it has been noted that this did not cause any 
morphological change (Svenstrup, 2003; Baczynska et al., 2007). The preferred site of 
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attachment was the sperm midpiece/neck. There is a suggestion that the host cell 
receptor for M. genitalium is probably a sialoglycoconjugate (Svenstrup, 2003). Also 
Czuppon (1984) stated spermatozoa receptors, which could function as receptors for M. 
genitalium, expose sialoglycoproteins at their surface (Svenstrup, 2003). As shown by 
x-ray microscopy, the attachment of M.genitalium to spermatozoa seemed to be 
mediated by tips (see section 1.3.2). Further experiments are needed in order to find 
whether the attachment is specific (Svenstrup, 2003).  
The effects of genital mycoplasmas on semen parameters are controversial. Andrade-
Rocha (2003) and Soffer et al., (1990) showed that there was no effect on semen 
quality; Pannekoek et al., (2000) showed that low sperm concentration was only seen in 
the male partner of infertile couples with mixed infection (mycoplasmas & 
ureaplasmas). Gdoura et al., (2007) stated the ability of mycoplasma to attach to 
spermatozoa can affect directly via cellular interactions that lead to influence on semen 
parameters (Gdoura et al., 2007). Sperm concentration has negative correlation with M. 
genitalium infection (Gdoura et al., 2007). Since there was no significant association 
between mycoplasma infection and semen leukocytes, the absence of leukocytospermia 
does not exclude the presence of genital mycoplasmas (Pannekoek et al., 2000). Samra 
et al., (1993) investigated the prevalence of C. trachomatis and M. hominis among 
infertile couples and found the prevalence of M. hominis was significantly higher in the 
infertile men and women (Samra et al., 1993). Its role on fertility can be cause of 
urethritis and also can be sexually transmitted with rates similar to C. trachomatis that 
lead to female partner infection as well (Jensen et al., 2006). 
1.3.4 Clinical appearances of M. genitalium infection in men  
Urethritis is the most common symptom in men although most cases are asymptomatic 
(Jensen et al., 1993). In men with non-gonococcal urethritis (NGU), the M. 
genitalium incidence is considerably higher than those who are without symptoms 
(Jensen et al., 1993). M. genitalium has been isolated from men with NGU and without 
urethritis, and also was isolated from rectal swabs from both heterosexual and 
homosexual men (Taylor-Robinson et al., 1985). Also data from a study of non-
chlamydial non-gonococcal urethritis (NCNGU) patients show a higher number of M. 
genitalium DNA copies in first void urine (FVU) than from asymptomatic men 
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(Yoshida et al., 2002). Unlike the situation for C. trachomatis, there are no studies 
suggesting a role for M. genitalium in prostatitis and epididymitis. 
1.3.5 Effect of M. genitalium infection in women 
Although the bacterium has been identified in urethral and cervical samples, the role of 
M. genitalium in women has been less well studied in comparison to men (Jensen et al., 
1991; Palmer et al., 1991). Moreover, in comparison with C. trachomatis, the role of M. 
genitalium in female infertility is less well studied and its role on human infertility is 
still not clear. Although N. gonorrhoeae and C. trachomatis are the most common 
agents of PID, some studies suggested that infertility is more common in non-
gonococcal infections such as M. genitalium (Westrom, 1975; Eggert-Kruse et al, 
1997). M. genitalium has been implicated in infertility due to compromised function of 
the uterine tubes, and the role of M. genitalium in non-gonococcal PID (Clausen et al., 
2001) and PID is a cause of several major complications including chronic pelvic pain, 
tubal factor infertility and ectopic pregnancy (Westrom, 1975). New studies will be 
necessary that focus on the dynamic development of diagnostic procedures, especially 
the more common use of molecular methods, in discovering the role of mycoplasmas 
in female infertility. Antibodies to MgPa (adhesin protein) were found in the patients 
with TFI to investigate the role of M. genitalium in infertility. The study indicated that 
uterine tube function was compromised and led to infertility (Uno et al., 1997).   
Clausen et al., (2001) found antibodies to M. genitalium in 22% of their patients with 
TFI. Haggerty et al., (2006) reported prevalence of M. genitalium among women with 
non-gonococcal non-chlamydial PID. They found overall 14% positivity by PCR among 
an urban US population that was similar to PCR investigations in Kenyan women 
(Cohen, 2002) with endometritis (16%), and United Kingdom women (Simms, 2003) 
with clinically suspected PID (13%). Sera from TFI patients were positive to MgPa 
(adhesin protein) that indicates capacity of M. genitalium to create an infection 
independently of C. trachomatis (Clausen et al., 2001).  
During pregnancy, M. genitalium infection can lead to chorioamnionitis and further 
pregnancy complications (Jurstrand et al., 2007). M. genitalium had been transmitted 
from mother to the newborn, but the magnitude of this finding is vague. There is no 
statistical correlation between PID or EP and M. genitalium antibodies (Jurstrand et al., 
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2007). When younger individuals were investigated for an association between PID or 
EP and M. genitalium antibodies, a slight association was found using the lipid-
associated membrane protein-enzyme immunoassay (Jurstrand et al., 2007). Also other 
adverse pregnancy outcomes have been investigated including stillbirth, small for 
gestational age and preterm birth. An independent association has been found between 
preterm birth and M. genitalium infection (Edwards et al., 2006; Hitti et al., 2010). A 
study of 1014 women showed 6.2% M. genitalium infection among women who gave 
birth or aborted but not related to pregnancy outcome (Labbe et al., 2002). Luki et al., 
(1998) reported one premature child with acute respiratory distress where M. genitalium 
had been transmitted from mother to the newborn. 
1.3.6 Clinical appearances of M. genitalium infection in women  
1.3.6.1 Lower genital tract infection 
A significant association between M. genitalium and microscopic urethritis in women 
has been found in a study of a large number (n=7604) of Scandinavian women (Moi et 
al., 2009). A positive association of urethral inflammation with M. genitalium was 
found in three of four studies considering microscopic signs of urethral inflammation 
(Anagrius et al., 2005; Hogdahl and Kihlstrom, 2007; Moi et al., 2009). They had 
considered either >4-5 polymorphonuclear per high power field, or >10 as a sign of 
inflammation respectively. Some studies had different inclusion criteria, such as vaginal 
symptoms or discharge as non-microscopic signs as well. Significant associations were 
observed between M. genitalium and vaginal discharge (Falk et al., 2005; Moi et al, 
2009).  
Among studies which found positive association between microscopic signs of urethral 
inflammation and M. genitalium only one showed significant association (Moi et al., 
2009).Where microscopic signs were considered independent of non-microscopic signs, 
M. genitalium has been positively associated with cervical inflammation (Falk et al., 
2005; Moi et al, 2009). Studies have also found microscopic or non-microscopic signs 
are predictors for M. genitalium cervicitis (Manhart et al., 2003; Falk et al., 2005).  
M. genitalium was reported in both industrialized and developing countries. One study 
in Washington (USA) detected M. genitalium in 7% of women attending STD clinics 
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who had 3.3 times greater risk of mucopurulent cervicitis (Manhart et al., 2003). A 
Swedish study showed an incidence of 50% in infected women with signs and 
symptoms of urethritis and/or cervicitis (Falk et al., 2005). In West Africa the 
prevalence of M. genitalium among female sex workers was 26.3% and was 
significantly associated with cervicitis (Pepin et al., 2005). 
1.3.6.2  Bacterial vaginosis (BV) 
In one of the early reports, M. genitalium was found in 30% women with bacterial 
vaginosis (Palmar et al., 1991). However, Keane et al., (2000) did not find M. 
genitalium in any women with bacterial vaginosis (BV). Lack of association between M. 
genitalium and BV has also been studied in women with cervicitis, showing that BV is 
no more common in patients with M. genitalium (Manhart et al., 2003). 
1.3.6.3  Pelvic inflammatory disease (PID) 
Mycoplasma infection can extend to the upper genital tract and lead to PID (Fraser, 
1995). Sexually transmitted microorganisms can extend to the uterine tubes by invasion 
through the female genital tract or via the mesosalpingeal lymphatics (Eschenbach, 
1984). The main site of M. genitalium colonization is the genital tract which results in 
infection ascending from the lower to the upper genital tract due to presence of M. 
genitalium in the cervices of women with adenexitis (Uno et al., 1997; Clausen et al., 
2001). In 1984, M. genitalium was first known as a cause of PID (Moller et 
al., 1984).  Laparoscopically confirmed tubal infertility has been investigated by two 
Danish studies where they found an association between M. genitalium-specific serum 
antibodies and laparoscopic data (Clausen et al., 2001; Svenstrup et al., 2008). There is 
a significant correlation between antibodies against M. genitalium and C. trachomatis 
seropositivity in women with TFI (Svenstrup et al., 2008). In a retrospective study a 
correlation was found between IgG against MgPa of M. genitalium and women with TFI 
(Clausen et al., 2001). Some women with PID have shown an antibody response to M. 
genitalium (Moller et al., 1984). 
 
 
 
  
 
39 
 
1.3.7 Pathogenesis of M. genitalium infection 
1.3.7.1 Epidemiology  
There are relatively few epidemiological studies of M. genitalium, due to difficulties in 
culturing and diagnosing the infection. The first clinical study using PCR showed M. 
genitalium DNA (17%) in the urethral swabs of men attended a STD clinic (Jensen et 
al., 1993). M. genitalium in men with urethritis was found more often in the C. 
trachomatis negative NGU patients (35%) compared with chlamydial NGU (7%) 
indicating that M. genitalium and C. trachomatis act as separate causes of urethritis 
(Jensen et al, 1993).  
The prevalence of M. genitalium varies among urology patients and STD patients at 8% 
and 29% respectively, among these who have urethritis. In asymptomatic patients 
prevalence rates are 0% to 9% in urologic and STD patients respectively (Jensen et al., 
1993). Evidence has shown high prevalence rates of M. genitalium infection among 
male partners of infected women (56%) and 32% among female partners of infected 
men with NGU (Manhart et al., 2003; Cohen et al., 2008).  
Prevalence of M. genitalium was 18% among women attending a STD clinic in the UK 
(Palmer et al., 1991) while Tsunoe et al., (2000) found a prevalence of 12.6% in 
commercial sex workers in Japan as compared to 1.1% of pregnant women. Two 
different studies in Japan reported the prevalence of M. genitalium in young 
asymptomatic men and women as 1% and 2.8% respectively. The risk factors of 
infection were more lifetime sexual partners and co-infection with C. 
trachomatis (Cohen et al., 2008). Also the prevalence of M. genitalium in women from 
Kenya with endometritis was 16% compared with 2% in a control group (Cohen et al., 
2002). Women with PID showed 13% positivity by PCR for M. genitalium in a British 
study compared with none in the control group (Simms et al., 2003).  
In the review article by McGowin and Anderson-Smits (2011) the prevalence of M. 
genitalium was 2% among women from low-risk populations (n=27,272). Also the 
review showed a prevalence of M. genitalium among high-risk patients of 0% to 42% 
(n=18,838 women with urogenital infections). The including criteria were specific 
symptom or sign, co-infection with other STDs, high-risk behaviour, study geographic 
 
  
 
40 
 
location, specificity of NAAT assay which used. Low-risk women were those not 
attending a STD clinic and high-risk were those attending STD clinic, or enrolled in a 
study for urogenital disease, or women classified as sex workers.  
1.3.7.2  Immunity in M. genitalium infection 
Specific and nonspecific immune reactions are involved between mycoplasmas and host 
immune system. Humoral and cell mediate immune responses are involved as described 
below.  
1.3.7.2.1 Innate defence mechanisms 
Innate immune responses in M. genitalium infection were observed through Toll-like 
receptor expression (McCowin et al., 2009). M. genitalium can active NF-қ B (Nuclear 
Factor-Kappa B) via TLR-2/6. Epithelial cells of genital tract are responder to STDs and 
express high levels TLR2 and TLR6 (McGowin et al., 2009). 
1.3.7.2.2 Humoral response 
During persistent infection, M. genitalium reactive cervicovaginal IgA and IgG 
antibodies were detected in women (Iverson-Cabral et al., 2011). They investigated 
antibody response in initial site of infection. Infected mice with M. genitalium have 
shown high level of antibody to MgPa that indicating persistent infection (McGowin et 
al., 2010). 
1.3.7.2.3 Cell mediated immunity (CMI) 
Mycoplasmas are able to induce cell to produce different types of interferon (Cole et al., 
1985). Stimulation of host immunocytes by mycoplasmas is reflected by producing of 
different pro-inflammatory cytokines (Razin et al., 1998) such as: TNF-α, NK cells, IL-
1, IL-2 and IL-6. 
1.3.8 Different methods for detecting M. genitalium   
1.3.8.1 Cell Culture 
The first time M. genitalium was isolated (Tully et al., 1981) from two men with NGU 
using cell culture, its growth was extremely slow and further studies, by Taylor-
Robinson et al., (1985) and Samra et al., (1988) failed to culture M. genitalium. 
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However, in a Chinese study 8 strains of M. genitalium were isolated from urogenital 
specimens by culture (Luo et al., 1999).  The strains G-37 and M-30 were chosen as the 
type strains of M. genitalium (Taylor-Robinson et al., 1983). 
1.3.8.2 Serology tests 
In epidemiological studies, the use of specific serology for diagnosis has been hampered 
due to cross reactions between mycoplasma species especially M. genitalium and M. 
pneumoniae (Lind, 1982). Jensen et al., (1993) used ELISA to detect IgG, IgA, and IgM 
from serum specimens as a part of a prevalence study. The method for antigen 
preparation was the same with Uldum et al., (1992) and no correlation could be shown 
between the PCR status and antibody response.  
Using Triton X-114 extracted Lipid Associated Membrane Protein (LAMP) to measure 
M. genitalium antibodies (Wang et al., 1997) showed 38% positivity (40 of 104 
patients). The results showed that 15% of LAMP positive patients were also PCR 
positive. The assay was validated with serum and urine specimens. Another study by 
Baseman (2004) followed patients using a modified method of LAMP ELISA (over 22 
months follow-up): 83% of culture positive women had a positive ELISA results. 
1.3.8.3 Molecular methods 
The first two studies to use PCR to detect M. genitalium were published in 1991 (Jensen 
et al., 1991; Palmer et al., 1991). It was believed that MgPa DNA had an important role 
in pathogenesis of the infection at that time and the assays were based on a MgPa DNA 
sequence (Jensen et al., 1991). The hemi-nested PCR is an extremely sensitive assay 
was developed by Palmer et al., (1991). The studies on male urethritis, endometritis and 
cervicitis used a modification of a MgPa1/ MgPa3 assay (Totten et al., 2001; Cohen et 
al., 2002; Manhart et al., 2003). This assay was a confirmatory test of 16S rRNA PCR 
(Jensen et al., 2003).  Sasaki et al., (1992) described another 16S rRNA assay that was 
used on clinical specimens. 
Real time PCR is a more recent development in M. genitalium diagnosis. Yoshida et al., 
(2002) published the first quantitative paper that used real time PCR with wide dynamic 
range PCR for detection of M. genitalium 16S rRNA. Specific and sensitive primer 
design was difficult due to cross reaction between M. genitalium and M. pneumoniae 
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(Yoshida et al., 2002). Diagnosis of M. genitalium based on real time PCRs is highly 
sensitive and specific (Yoshida et al., 2002).  
1.4  Conclusions 
This introducing chapter has reviewed the background biology, epidemiology and 
pathology of C. trachomatis and M. genitalium. It has shown that these are bacterial 
infections of both the male and female reproductive systems, with important 
consequences for health and fertility. Even so, our knowledge of both organisms in an 
infertility setting is incomplete and the work described in this thesis aims to fill some of 
these gaps. 
As a study population, infertile couples in Iran have been chosen. That is because there 
are significant cultural and political sensitivities about sexually transmitted infection in 
Iran. Since non-marital sex is prohibited by Islam’s religion, the reported prevalence of 
STDs in countries such as Iran could be different from other countries. However, 
infertility remains a significant problem with 12-15% of couples is affected in Iran. This 
present study intended to find the prevalence of these STDs in infertile couples in Iran 
by different specimens and methods. This is the first study of its kind, given that 
cultural sensitivity of STDs, that there are no STD clinics in Iran and no national 
statistics are collected. There is no study with this scale to evaluate both males and 
females that consider semen parameters, sperm DNA measurements, serology tests, past 
reproductive and medical history regards with the presence of possible infection in male 
and female partners of infertile couples. Therefore, the present study for first time will 
find prevalence and relationship of these STDs and infertility.  
These studies were carried out at the Research and Clinical Centre for Infertility Yazd/ 
Iran which is a referral centre. Although the prevalence would vary among different 
population and area and culture, however, this study can reflect the overall prevalence 
of these STD in Iran.  
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2.1 Study population and samples obtained 
2.1.1 Infertile couples 
Three hundred and twenty-four couples with primary or secondary infertility attending 
the Research and Clinical Centre for Infertility, Yazd, Iran were screened between 
September 2009 and October 2010. The centre is the most famous public centre of 
Iranian Medical Universities because of the high success rates in ART and the lowest 
rate of expense among other public centre in Iran. The centre location and also its 
reputation lead to 25-30 daily consultations by gynaecologist and urologist. People 
mostly come from the rural area of Yazd and other Southern provinces. Also the centre 
is known as a referral centre for problematic or undiagnosed cases of infertility. 
Therefore the centre often sees couples from all regions of Iran and even abroad.  
All couples were approached with information about the study and were asked to 
participate unless they had: (i) abnormal karyotype; (ii) history of chemotherapy or 
radiotherapy treatment; (iii) previous vasectomy; (iv) low semen volume (<1.0 ml); (v) 
retrograde ejaculation; (vi) hypogonadotropic hypogonadism; (vii) genital tract 
anomaly; or (viii) female age >35 years. 
Seventy four couples were excluded, leaving 250 to enter the study. Of the 250 couples 
enrolled (see Figure 2.1) each partner gave informed consent and completed a 
standardized questionnaire during an interview (see Appendix I). This included 
information about: age, type of infertility (primary or secondary), past history of genital 
tract infection in both male and female, their career, the history of using ART, tubal 
factor damage, endometriosis, miscarriage, having a child from the current or any 
previous marriage, history of varicocele and mumps in the male. In addition, all 
individuals provided a 2-ml blood sample (1.5-ml serum) and a 20-40 ml urine sample. 
Male partners also provided semen sample. The male partners were examined by a 
urologist and the data for any urogenital abnormality and varicocele was obtained from 
patient notes. The interviewer observed vaginal sonography of female partners recruited 
in the study and laparoscopy results are from patient notes. 
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Figure 2.1: Study population and samples obtained (infertile group). 
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2.1.2 Control group 
Two hundred and fifty pregnant women attending the antenatal clinic in the Akbary 
Public Health centre, Yazd, Iran were also recruited as a control group between May 
2010 and September 2010. Written informed consent was obtained from all individuals 
and each individual provided 2 ml of blood and a 20-40 ml urine samples that were 
processed and stored as described in 2.2.1. Extensive attempts were also made to recruit 
fertile men but this was not successful.       
2.1.3  Ethical approval 
The study was approved by the Ministry of Health Research Ethics Committee, Iran 
(Declaration no=11P/88k-A, 9
th
 Sep 2009), as well as The University of Sheffield, 
School of Medicine Research Ethics Committee (SMBRER147, 10
th
 October 2010) see 
Appendix II.  
2.2 Sample processing and transportation 
2.2.1 Sample processing 
Serum was separated from blood sample the same day that it was collected. Briefly, a 
tube without any anticoagulant was used to collect the blood and then the tube was left 
in a standing position for a maximum of 20-30 minutes. After that, the tube was 
centrifuged (blood was clotted) at 1500 g for 10 minutes then the serum removed very 
quickly and stored at -20ºC in the Yazd IVF centre within 6h of collection.  
Semen analysis was first performed on the ejaculate on the same day (see section 2.2.2). 
For each patient two semen smears were prepared to assess sperm morphology and the 
dried slide was fixed in equal volume of Ethanol-Ether for 10 minutes, before being 
stored in the fridge and then stained by Papanicolaou staining method (WHO, 1999).  
Stained morphology slides were stored at room temperature (RT) for transportation to 
Sheffield and assessment by CASMA (section 2.3.6). Seminal plasma was removed 
after centrifuging fresh semen at 1000g 5 minutes then was stored at -80ºC before 
transportation back to Sheffield to measure inflammatory markers. 
Two slides were also prepared for each patient to assess sperm DNA fragmentation, to 
achieve this the sample was first centrifuged at 1000 g for 5 minutes and the pellet 
resuspended in tris-buffered saline (TBS) to give an appropriate sperm concentration of 
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1x10
6
. A 100µl aliquot was used for preparing the smear and slides were dried 
overnight. Methanol 100% was used for fixation for 1 minute; fixed slides were stored 
at -80ºC before transportation back to Sheffield and staining for TUNEL assay (see 
section 2.3.7.1).  
Three semen smears were prepared to evaluate sperm chromatin assessment. The sperm 
concentration was adjusted again to 1x10
6 
sperm per ml, however 10µl was used to 
prepare the smear and air dried slides were then fixed in Carnoy’s solution 
(methanol/glacial acetic acid, 3:1) at 4ºC overnight for Acridine Orange (AO) and  
Chromomycin A3 (CMA3) staining. Air dried slides for Aniline Blue (AB) staining 
were fixed in 3% (v/v) buffered glutaraldehyde in 0.2 M phosphate buffer (pH 7.2) for 
30 minutes at RT. The prepared fixed slides were stored at 4ºC in Yazd to stain and 
evaluate later in the study (see sections 2.3.7.2; 2.3.7.3 and 2.3.7.4). The rest of semen 
sample was stored at -80ºC to extract DNA (see section 2.2.3).  
Urine samples for both male and female partners were stored at fridge immediately after 
collection and DNA extraction (see section 2.2.3) was performed within 2 days and the 
DNA stored at -20ºC before being transported to Sheffield for subsequent PCR (see 
section 2.3.2 & 2.3.3).  
Semen analysis, preparing fixed slides to assess sperm morphology and sperm DNA 
measurements and all DNA extraction (from urine and semen) were performed in Yazd. 
Serology tests to detect IgA, IgG and IgM antibodies to chlamydia, PCR to detect C. 
trachomatis and M. genitalium (urine and semen DNA), ELISA test on seminal plasma 
to measure IL-6 and IL-8 levels, TUNEL assay for sperm DNA fragmentation, 
assessment of sperm morphology by CASMA were performed in Sheffield. Patient’s 
follow up and sperm nuclear chromatin assessment were performed at the end of the 
study in Yazd (Figure 2.2). 
2.2.2 Collection and examination of human semen 
Men produced their ejaculates after at least 48 hours sexual abstinence and semen 
analysis was performed according to World Health Organisation (1999) guidelines. 
Briefly, after 60 min liquefaction of semen at 37ºC the microscopic and macroscopic 
examinations were performed. Macroscopic examination included liquefaction, 
appearance, volume, viscosity, pH of the semen sample. Semen pH was measured by 
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pH paper and semen volume was measured by reading from the base of the meniscus in 
a graduated test tube (BD Biosciences, Bedford, USA). 
Microscopic investigation included concentration, motility, agglutination of 
spermatozoa and the presence of cellular elements. For the assessment of sperm 
concentration the haemocytometer (Hawksley, London, UK) method was used. Motility 
was assessed by classifying 200 spermatozoa, and grading them to progressive motility; 
non-progressive motility and immotility. Motility was assessed at x400 magnification 
on a light microscope (Carl Ziess axiostor plus, Kirchdorf, Germany).  
IgA and IgG antibodies were assessed by the mixed antiglobulin reaction (MAR). The 
MAR tests were performed by mixing semen (5µl) with latex particles coated with 
human IgG or IgA (5µl). Then, a mono specific anti–human-IgG antiserum (5µl) was 
added to the mixture using spermMar kit (Fertipro N.V., Aalter, Belgium). The presence 
of IgG or IgA is shown with the formation of a mixed agglutination. The number of 
sperm with beads attached was counted and expressed as a percentage of the total. The 
diagnosis of immunological infertility is possible when 50% or more of the motile 
spermatozoa have adherent particles. 
2.2.3 DNA extraction from urine and semen samples 
DNA was extracted from first void urine obtained from infertile couples (see 2.1.1) and 
fertile women (see 2.1.2), as well as semen samples from infertile men (after routine 
semen analysis had been completed and all slides had been made) using the QIAGEN 
kit (GmbH, Hilden, Germany) following the manufactures instruction. All DNA was 
stored at -20˚C prior to performing PCR in Sheffield (see sections 2.3.2 and 2.3.3).  
2.2.4 Transfer of specimens  
Sera, seminal plasma, DNA and fixed slides for sperm DNA fragmentation assessment 
were transferred on dry ice to UK at the end of the recruitment phase of the study. Fixed 
slides for sperm morphology assessment (were stained in Yazd) were shipped separately 
at RT. Upon arrival in Sheffield the fixed slides for sperm DNA fragmentation were 
kept at -80˚C, whereas the rest of the samples were stored at -20˚C prior to analysis.  
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Figure 2.2: Sample processing 
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2.3 Analysis of stored samples 
2.3.1 Immunofluorescence assay for the detection of antibodies to C. trachomatis          
To detect specific IgG, IgA, IgM antibodies to C. trachomatis an immunofluorescence 
assay (SeroFIA
TM
 C. trachomatis) kit was used (Savyon, Ashdod, Israel). Briefly, 
purified elementary bodies (EBs) of C. trachomatis (supplied by the kit) were fixed onto 
the SeroFIA
TM
 slide wells. First serum samples were thawed, and diluted; according to 
the kit instructions: the dilution rate for IgG serum antibody was 1:64, IgA serum 
antibody titre was 1:32 and IgM serum antibody titre was 1:20. Diluted patients sera 
were incubated for 30 minutes at 37˚C with the antigen. Unbound serum components 
were removed by washing and then a fluorescein-conjugated anti-human IgG, IgA, IgM 
were added and incubated for 30 minutes at 37˚C. After washing to remove any 
unbound conjugate, slides were dried and mounted and then were examined using a 
Leica fluorescence microscope DMIRB (Lasertechnik Gmbh, Heidelberg, Germany). 
The whole well was first scanned at magnification of ×400 to observe any evidence of 
typical fluorescence and the well was then observed further at a magnification of ×1000 
using oil immersion to confirm presence or absence of typical fluorescence in EB like 
morphology (small granules). Positive reactions appear as bright apple-green 
fluorescent EBs against a dark background (see Chapter 3, Figure 3.2). Each slide was 
observed by two people and a positive sample was defined when both were in 
agreement. Positive and negative controls were included from the kit in each slide. 
2.3.2 PCR to detect C. trachomatis on urine and semen DNA 
Two serovars were used as a positive control. Serovar E of C. trachomatis was isolated 
from a clinical source (cervical swab from Department of Genitourinary Medicine, 
Royal Hallamshire Hospital, Sheffield), and serovar LGV was provided by the 
University of Southampton (Southampton, UK). Confirmation of genotype was 
conducted by nested PCR according to method of Lan et al (1994). The DNA extraction 
QIAGEN Kit (Gmbh, Hilden, Germany) instructions were used to extract DNA from 
purified EBs (see sections 2.3.2 and 2.3.3) to use as a positive control in PCR. DNA 
extracted from EBs was checked by nested plasmid PCR and stored at -20ºC until used 
as a positive control. 
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Nested plasmid PCR was conducted according to method of Claas et al., (1990) and two 
pairs of primers were used to detect C. trachomatis (see Table 2.1). T1 and T2 were 
derived from sequences of the common endogenous plasmid of C. trachomatis, and 
generated a species-specific 517 bp product with all serovars of C. trachomatis. Primers 
T3 and T4 are internal to the primers T1 and T2 and amplified a 320 bp product. Primers 
were ordered from Eurofins MWG/Operon (Eurofins MWG/Operon, London, UK). The 
PCR program of 25 cycles included: denaturation 94ºC 30 seconds, annealing 42ºC 30 
seconds, and extension 72ºC 30 seconds. The extension time was increased to 9 minutes 
(Class et al., 1990). Semen DNA was first tested for β-globin according to the method 
of Saiki et al., (1985) to check there were no PCR inhibitors in the samples. 
2.3.2.1 PCR equipment 
Micro-centrifuge tubes (Eppendorf, 0.5 & 1.5 ml), and positive displacement tips (PCR 
microsyringes) were purchased from Alpha Laboratories (Hampshire, UK). Laboratory 
pipettes were purchased from Gilson Pipetman (Villers Le Bel, France). Tech gene PCR 
machine with heated lid was used for all PCR applications (Teckne, Cambridge, UK).      
2.3.2.2 Water  
Water for PCR reactions was purified using a Milli-Ro system (Millipore Ltd, Watford 
Herts, UK) and this was sterilised at 15 lbs sq inch
-1
 for 15 min before use. 
2.3.2.3 ReddyMixTM PCR Master Mix (1.5mM MgCl2) 
Reddy mix (1.1 x) was purchased from Thermo scientific (ABgene, UK). The 
ThermoPrime Taq DNA polymerase; dNTPs, reaction buffer and magnesium chloride 
were all present in the mix. The final reaction 1X contained: ThermoPrime Taq DNA 
polymerase (0.625units), Tris-HCl (pH8.8 at 25ºC) (75mM), (NH4)2SO4 (20mM), 
MgCl2 (1.5mM), Tween 20[0.01% (v/v)], each of dATP, dCTP, dGTP and dTTP 
(0.2mM). It was stored at -20º C until ready for use for up to 1 year. Primary single 
plasmid PCR mixture was made up with Reddy Mix (43 µl), T1 (forward) 1 µl, T2 
(reverse) 1 µl, and DNA sample 5 µl. Nested plasmid PCR reaction mixture was made 
up with Reddy Mix (43 µl), T3 (forward) 1 µl, T4 (reverse) 1 µl, and DNA sample 5 µl 
that was PCR product from first stage. 
 
 
  
 
52 
 
 
                      Table 2.1: Primers for nested PCR of C. trachomatis DNA 
Primers 5’      3’ Sequence 
T1 (Forward) 5’-GGA CAA ATC GTA TCT CGG-3’ 
T2 (Reverse) 5’-GAA ACC AAC TCT ACG CTG-3’ 
T3 (Forward)      5’-ATC CAT TGC GTA GAT CTC CG-3’ 
T4 (Reverse)     5’-GCC ATG TCT ATA GCT AAA GC-3’ 
 
 
                Table 2.2: Primers for PCR to detect M. genitalium MgPa (adhesin) 
 
                              
 
                                       
                 Table 2.3: Primers for PCR to detect M. genitalium 16S rRNA 
  
Primers 5’      3’Sequence 
Mg Pa-1 (Forward) 5’-AGT TGA TGA AAC CTT AAC CCC TTGG3’ 
Mg Pa-3 (Reverse) 5’- CCG TTG AGG GGT TTT TCC ATT TTT GC3’ 
Primers 5’      3’ sequence 
MG16-45(Forward)      5-TAC ATG CAA GTC GAT CGG AAG TAG C 
MG16-447(Reverse) 5-AAA CTC CAG CCA TTG CCT GCT AG 
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2.3.2.4 Electrophoresis 
Electrophoresis grade agarose was obtained from Melford laboratory Ltd (Ipswich, 
UK). A gel solution was prepared in 50 ml tris–acetate buffer (TAE) and heated in a 
microwave oven at 100ºC for 2 minutes. Agarose gel 0.8% (w/v) was prepared by 
adding 50 ml TAE buffer to 0.4 g agarose, and microwaving for 1-2 minutes. Qstep 4 
DNA Ladder, and 5x DNA loading buffer were used (Yorkshire Bioscience Ltd, UK). 
2.3.2.5 Tris –acetate EDTA buffer (TAE 50x) 
This was made by adding to 1 litres of water the following: Tris-base (242g), Na2EDTA 
(37.2g), Glacial acetic acid (57.1 mL). 
2.3.2.6 Ethidium bromide stock solution (10mg/ml) 
This was prepared by adding 1g of ethidium bromide to 100 ml water. The container 
was wrapped in aluminium foil and stored at RT. Either 5µl of this solution was put into 
the gel when it was being made, or after electrophoresis. 
2.3.3 PCR to detect M. genitalium on urine and semen  
PCR was looking for 16SrRNA gene (Jensen et al., 2003). The DNA template was 
supplied by the Health Protection Agency (HPA) London. The PCR is based on 
previous work (Jensen et al., 1991; 2003). The sequence of the 16S rRNA gene was 
determined for M. genitalium G37 (type strain) by Jensen et al., 2003. From regions 
showing the least homology to M. pneumoniae, primers were chosen to amplify DNA 
from M. genitalium, and then confirmed by the MgPa primer (see Table 2.2) set (Jensen 
et al., 1991). This program included a preheating 80ºC (hot start) period and 40 cycles 
including, denaturation 94ºC 30-seconds, annealing 55ºC 30-seconds, and extension 
72ºC 1 minute. A band of 427 bp was expected. MG16-45 and MG16-447 were used as 
primers, see Table 2.3. The mixture for PCR was made up with Reddy Mix (43 µl), 
forward primer 1 µl, reverse primer 1 µl, and DNA sample 5 µl. M. genitalium DNA 
(Health Protection Agency, London, UK) was used as a positive control. 
2.3.4 Chlamydia culture 
Chlamydia trachomatis was cultured and purified to use as positive control. In brief: 
Semi confluent cells (McCoy cells) and culture medium (EMEM+FCS+ Cycloheximide 
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+ antibiotic) were used to grow chlamydia before purification of EBs according to 
method Schachter & Wyrick (1994). After inoculation of semi confluent cells with 50µl 
EBs (from frozen aliquot, the concentration of which has been previously estimated to 
give a sufficient level of infectivity), the cells were centrifuged (Sigma, Philip Harris, 
UK) at 2130 g for 1 hr at 4ºC, and the cells were incubated at 37ºC and 5% CO2 in a 
Sanyo (MC015-AC) incubator (Sanyo, Osaka, Japan) for 2-3 days. Infection rate was 
assessed by estimating the number of cells containing inclusion bodies. Infection rate 
above 50% was considered successful passage. For purification and storage of C. 
trachomatis EBs, sufficient flasks were needed to harvest a total of 180 ml. This was 
sonicated (MSE, Liverpool, UK) on ice to disrupt the cells and release EBs and 
centrifuged at 500 g for 10 minutes at 4ºC to deposit unwanted debris. Then the 
supernatant was collected and in high-speed centrifuge tubes, was centrifuged at 28,000 
g for 1 hr at 4ºC to obtain a pellet of EBs. The supernatant was removed and the EB 
pellet was washed gently with ice-cold PBS. Then the pellet was resuspended in ice-
cold Sucrose Phosphate Buffer. The EBs were aliquoted in centrifuge tubes and stored 
at -80ºC or in the vapour phase of liquid nitrogen.  
2.3.5 Chlamydia purification reagents and equipment  
2.3.5.1 Media 
Eagle’s minimal essential medium (EMEM) was purchased from Lonza (Slough, UK) 
and foetal calf serum (FCS) was purchased from Autogen Bioclear (Calne, UK). After 
the sterility checks the media were stored at 4ºC until used. 
2.3.5.2 Cell lines 
The McCoy cell line was used and was derived from mouse fibroblasts. It was obtained 
from Flow Laboratories (Rickmansworth, Herts, UK). The cell line was grown in 
EMEM medium. Maintenance medium for McCoy cells included EMEM and FCS. 
2.3.5.3 Chlamydia culture medium 
This consists of the basal medium EMEM supplemented with 10% (v/v) FCS. The 
following antibiotics were added to minimise the possibility of contamination: 
Amphotericin B (final concentration: 0.5µg/ml), Gentamicin (20µg/ml), Vancomycin 
(10µg/ml) and Streptomycin (200µg/ml). The other addition to growth medium was the 
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chemical Cycloheximide, with a final concentration of 2µg/ ml. This is an anti-mitotic 
agent which improves the infectivity of the Chlamydia in the McCoy cells. The pH of 
the culture media was adjusted to pH 7.4 by adding HCl. 
2.3.5.4 Trypsin and Versene 
This was purchased frozen in 500 ml volumes (supplied by Invitrogen Ltd, Paisley, 
UK). It was aliquoted into 2-4 ml volumes and stored at -20ºC until used. 
2.3.5.5 Cycloheximide: [3-(2-3,5-Dimethyl-2-oxocyclohexyl glutarimide] 
It was supplied by Sigma Chemical Co (Poole, UK) and dissolved in sterile purified 
water, to a concentration of 2µg/ml. It was stored at -20ºC. 
2.3.5.6  Urografin 
Urografin was obtained from Schering Health Care Ltd (West Sussex, UK) and stored at 
4ºC before chlamydia purification, contains sodium and meglumine diatrizoate at 
concentrations of 40 mg/ml and 260 mg/ml respectively. 
2.3.5.7 Sucrose Phosphate Buffer 
This was made by adding to 1 litre of glass-distilled water the following: Sucrose 
(74.62g), Potassium di-hydrogen phosphate (0.51g), Di-potassium hydrogen phosphate 
(1.23g) and glutamic acid (0.72g). This was filtered to sterilise through 0.2µm pore-size 
membrane and then stored in aliquots at -20ºC. 
2.3.5.8 Phosphate buffered saline (PBS) 
PBS tablets were from Oxoid (Basingstoke, UK) and the solution prepared according to 
the manufacturer’s instructions. The solution was sterilised. The final concentration of  
PBS buffer solution was 136 mM NaCl, 2.7 mM KCl, 81 mM Na2 HPO4, 1.47 mM 
KH2P04, pH 7.3. 
2.3.5.9 Mycoplasma contamination   
Cell lines were regularly checked for the presence of Mycoplasma spp used the Gen-
Probe Mycoplasma T.C. rapid system from Laboratory Impex System Ltd (Wimborne, 
Dorset, UK). 
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2.3.6 Assessment of sperm morphology 
The stained morphology slides were assessed in Sheffield using the Hobson Sperm 
Tracker (Hobson Tracker Limited, Sheffield, UK). This computer-Aided Sperm 
Morphology Analysis (CASMA) system calculates the percentage normal forms 
according to WHO (1999) criteria. For each slide 200 sperm was assessed, for those 
slides with low sperm concentration the duplicate was assessed to count 200 sperm 
totally for each sample. According to WHO guidelines, a 7% sampling error occurs by 
counting 200 sperm (95% CI=172-228) while 10% sampling error occurs by counting 
100 sperm (95% CI=80-120). 
2.3.7 Sperm DNA measurements 
To assess sperm DNA fragmentation and sperm nuclear chromatin condensation 
assessment four different techniques were used: 
2.3.7.1 Detection of double strand DNA breaks (TUNEL assay) 
Sperm DNA fragmentation was assessed using Calbiochem (Terminal deoxynucleotidyl 
transferase dUTP Nick End Labeling (TUNEL) assay) kit (Merck Chemicals Ltd, 
Nottingham, UK). Fixed sample was covered with 1ml TBS for 15 minutes at RT then 
the excess liquid was tapped off. The rehydrated fixed sample was covered with 100 µl 
of 20µg/ml Proteinase K, and incubated at RT for exactly 5 minutes. The slide was then 
washed 2-3 times with 1 ml of TBS. The rehydrated permeablised sample was covered 
with 100 µl 1x TdT eqilibrium buffer and was incubated at RT for 30 minutes. The 
permeablised equilibrated sample was then covered with 60 µl of TdT labeling reaction 
mix, covered with a cover slip, and place in humidified chamber at 37˚C for 60-90 
minutes. After removing the cover slip, slide was twice incubated in TBS for 1 minute 
at RT, and the labelled sample covered with 15 µl mounting medium with propidium 
iodied. The slide was then covered with a cover slip and observed under FITC 
fluorescence at final magnification of ×1000 using oil immersion (Olympus, Tokyo, 
Japan). Positive and negative controls were included in each slide. 
2.3.7.2 Detection of residual histones (Aniline Blue staining) 
Aniline blue stains lysine-rich histones. Staining was performed using the method of 
Talebi et al., (2008) in Yazd. Briefly, air-dried smears were prepared from fresh semen 
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samples of each study participant (section 2.1.3), fixed in 3% (v/v) buffered 
glutaraldehyde in 0.2 M phosphate buffer (pH 7.2) for 30 min at RT. Each smear was 
stained with 5% (w/v) aqueous Aniline Blue stain in 4% (v/v) acetic acid (pH 3.5) for 5 
min. Slides were assessed with light microscopy (Olympus, Tokyo, Japan), at final 
magnification ×1000 using oil immersion. Unstained or pale blue stained were 
considered as normal spermatozoa whereas dark blue stained were classified as 
abnormal spermatozoa. A total of 200 spermatozoa were counted in each slide. Positive 
and negative controls were included in each slide. 
2.3.7.3 Evaluation of protamination (Chromomycin A3 staining) 
Staining was performed using the method of Talebi et al., (2008) in Yazd. Smears were 
first dried and then fixed in Carnoys solution (methanol/glacial acetic acid, 3:1) at 4ºC 
overnight. Each slide was treated with 100 µl of CMA3 (Sigma, St Louis, MO, USA) 
(0.25 mg/ml in McIIvain buffer consists of 7 ml citric acid, 0.1 M + 32.9 ml 
Na2HPO4,7H2O, 0.2 M, pH 7.0 containing 10 mM MgCl2) for 20 min. After staining, 
the slides were washed in McIIvain buffer and mounted with buffered glycerol (1:1). A 
total of 200 spermatozoa were counted in each slide. Bright yellow stained were 
considered abnormal (Chromomycin-reacted spermatozoa-CMA3+) and yellowish green 
stained were classified normal (non-reacted spermatozoa-CMA3−). The slides were 
viewed under fluorescent microscope (Zeiss Co., Jena, Germany) with a 460-nm filter at 
final magnification of ×400 using oil immersion. Positive and negative controls were 
included in each slide. 
2.3.7.4 Detection of sperm chromatin condensation anomalies (Acridine Orange 
staining) 
Sperm DNA integrity was determined by Acridine Orange (AO) staining using the 
method Talebi et al., (2008) in Yazd. The smears were first air-dried and then fixed 
overnight in Carnoy’s solution. Each sample was stained for 10 min in freshly prepared 
AO (Sigma Chemical Co, St Louis, USA) 0.19 mg/ml in McIIvain phosphate– citrate 
buffer (pH 4) for 10 min. Smears were assessed on the same day with the aid of 
fluorescent microscope (Zeiss Co., Jena, Germany)  with a 460-nm filter at final 
magnification of ×400 using oil immersion. The duration of illumination was limited to 
40s per field because the fluorescence faded after this time. A total of 200 spermatozoa 
were counted in each slide. The percentage of green (normal double-stranded DNA) and 
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orange/red (abnormally denatured DNA) fluorescence spermatozoa per sample were 
calculated. Positive and negative controls were included in each slide. 
2.3.8 Assessment of seminal interleukins 
2.3.8.1 Human Interleukin-6  
Seminal plasma was first thawed and then was diluted with PBS (1:2) before testing. 
Each diluted sample (100 mL) was tested with a commercial quantitative sandwich 
enzyme immunoassay (R & D Systems, Abingdon, United Kingdom) according to the 
manufacturer’s instructions. A monoclonal antibody specific to IL-6 had been pre-
coated onto a microplate. Standards and samples were pipetted into the wells, and any 
IL-6 present was bound by the immobilized antibody. After washing to remove any 
unbound substances, an enzyme-linked polyclonal antibody specific for IL-6 was added 
to the wells. After a further washing step to remove unbound antibody-enzyme reagent, 
a substrate solution was added to the wells for 30 minutes and the color was developed 
in proportion to the amount of IL-6 bound in the initial step. Color development was 
stopped by adding 50 mL of stop solution to each well, and the intensity of color was 
measured. The optical density of each well was determined within 30 minutes, using a 
microplate reader (Dynex technologies, Chantilly, USA) set to 450 nm. The average 
reading for each standard, control and sample was subtracted of zero standard optical 
density. A standard curve was constructed for each 96-well plate by plotting the mean 
absorbance for each standard on the y axis against the concentration on the x axis: a best 
fit curve was drawn through the points on the graph. The minimum detectable dose of 
IL-6 was less than 0.7pg/ml. 
2.3.8.2 Human Interleukin-8  
Seminal plasma was first thawed and then was diluted with PBS (1:4) before testing. 
Each diluted sample (100 mL) was tested with the use of a commercial quantitative 
sandwich enzyme immunoassay (R & D Systems, Abingdon, United Kingdom) 
according to the manufacturer’s instructions. Essentially, the assay method for IL-8 was 
as described above for IL-6. The minimum detectable dose (MDD) was 1.5- 7.5 pg/mL 
the mean MDD was 3.5 pg/ml. 
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2.4 Follow Up 
 
Patients were followed up 24 months after their enrollment into the study. Briefly this 
involved collecting from their medical records what kind of treatment and diagnostic 
procedure were performed including the result of: vaginal sonography, laparoscopy, 
hysterosalpingpgraphy, which type of ART was undertaken (if applicable). The final 
result of pregnancy outcome (live birth; miscarriage; ectopic pregnancy and still birth) 
mode of delivery (natural or caesarean) and sex and weight of baby were obtained by 
telephone interview.  
2.5 Statistical Analysis 
The Statistical Package for the Social Sciences (SPSS) 18.0 software (SPSS Inc., 
Chicago, IL, USA) was used for data analysis. During the follow up all of clinical data 
were recorded in a spreadsheet then entered into SPSS. The power of the study was 80% 
with a P-value ≤ 0.05 used as the level of significance. See Appendix III for calculation 
(it was calculated according to literature based on reported C. trachomatis infection 
prevalence in Iran).   
The data were first printed out and after comparing with raw data and confirming it was 
accurate, analysis was performed. Chi-square test was employed to compare positivity 
of C. trachomatis by different tests between couples (Chapter 3). Distribution tests were 
performed in the SPSS package as a routine pre requisite to testing by the t-test (Chapter 
4). Descriptive statistic and an independent sample T test were used for data with 
normal distribution. Mann-Whitney U test was used for non- parametric data (Chapter 4 
& 5). Spearman rank correlation test was used to evaluate the relationship between the 
levels of IL-6 and IL-8 with semen parameters (Chapter 4). To investigate the 
correlation between variables Pearson correlation test was used (Chapter 5). Odds ratio 
and 95% Confidence Interval (95% CI) were used to investigate relationships between 
past medical and reproductive history and infection (Chapter 6). Logistic regression was 
used to examine confounding factors among clinical data obtained in the study 
population (Chapter 6). A P-value of ≤0.05 was considered as indicating a significant 
difference.  
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3 Chapter 3: Prevalence of C. trachomatis & M. genitalium in infertile 
couples & fertile women 
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3.1  Introduction 
The prevalence of STDs including C. trachomatis and M. genitalium depends on sex, 
age, sexual activity, study population and the diagnostic methods used (Casin et al., 
2002; Dorey et al., 2012). Therefore their incidence in many different papers published 
is highly variable. Many studies have investigated the prevalence of C. trachomatis in 
subfertile women and/or men by different methods, specimens and population (see 
Appendix IV).  
Researchers in Brazil found the prevalence of C. trachomatis to be 52.8% among 
infertile women using PCR of endocervical samples (de Lima Freitas et al., 2011). The 
prevalence of this infection in asymptomatic subfertile women in Germany was 1.0% by 
PCR on urine sample (Eggert-Kruse et al., 2003).   
In Nigeria study on student and non-student population showed overall prevalence of C. 
trachomatis 29.4% using ELISA. However, multi partnership was seen more in student 
(71.2%), compared with non-student (28.8%) populations (Ikeme et al., 2011). When 
Ligase Chain Reaction (LCR) was used on semen from men in infertile couples Eggert-
Kruse et al., (1997) found no positive results from semen samples, whereas Bollmann et 
al., (2001) found 4.0% positivity by PCR.  In a study by Eggert-Kruse et al., (2003) a 
large number of asymptomatic subfertile men (n=707) were investigated for C. 
trachomatis using urine samples and the prevalence of this infection was 1.8% by PCR 
(Eggert-Kruse et al., 2003). 
Seroprevalence study of women of reproductive age in Bangladesh indicates high 
prevalence of C. trachomatis infection among both symptomatic (21.6%) and 
asymptomatic (44.1%) women (Mahmud et al., 2011). Their data shows specific C. 
trachomatis IgG antibody in pregnant (24.1%) and non-pregnant (4.6%) women that 
indicates high prevalence of chlamydial infection in pregnant women in Bangladesh 
(Mahmud et al., 2011). Elevated titre of IgG anti-chlamydia is considered as a sign of 
previous infection and was found in 20.8% of subfertile women and 12.6% of their 
partners moreover it was more frequent in patients with seropositive partner (Eggert-
Kruse et al., 1997).  
C. trachomatis as an important bacterial cause of infertility is diagnosed by testing urine 
sample in men (Eley and Pacey, 2011) and among 11 studies, 56% of subjects showed 
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C. trachomatis positivity in urine and semen samples, 23% in semen, and 20% in urine 
in infertile men (Eley and Pacey, 2011). Two studies by Idahl and colleagues (Idahl et 
al., 2004; 2007) investigated prevalence of IgG, IgA, IgM antibodies to C. trachomatis 
and also DNA positivity in infertile couples. They showed in 2004 that the IgG 
prevalence was 24.2% and 20.1% in infertile women and men respectively. Urine DNA 
positivity was 6.8% and 7.1% in infertile women and men respectively. 
The lowest reported male infertility was a cohort study in Canada (Domes et al., 2012) 
which showed 0.3% positivity when urine and semen samples were tested by strand-
displacement amplification (SDA) assay. Since the criterion for screening should be 
considered based on the prevalence of C. trachomatis in studied populations (Domes et 
al., 2012), screening is not recommended in such a low prevalence population. 
Studies from Iran showed C. trachomatis prevalence was 12.6% among women 
attending obstetrics and gynaecology clinics in Tehran/Iran using PCR (Chamani-Tabriz 
et al., 2007) whereas Fatholahzadeh et al., (2012) showed 20.76% and 9.23% in 
symptomatic and asymptomatic women respectively (Fatholahzadeh et al., 2012). A 
prevalence of C. trachomatis of 9.3% in Iranian males with urethritis, was reported 
using cell culture (Ghanaat et al., 2008) and prevalence of C. trachomatis in women 
with cervicitis was 11.6% using serum antibody measurement (Bakhtiari et al., 2007). A 
new study has revealed the 20% C. trachomatis in symptomatic men using PCR on 
urine samples and 4% in asymptomatic men (Yeganeh et al., 2013) .A recent study in 
North East of Iran on male patients with urethritis observed 10.6% positivity by PCR 
(Ghazvini et al., 2012) and in the same province the incidence of C. trachomatis and M. 
genitalium in pregnant women was 13.7% and 1.02% respectively (Haghighi-
Hasanabad et al., 2011). Regional differences are considered later (3.3.1).  
In contrast to C. trachomatis, M. genitalium is not well studied in infertile couples and 
its prevalence as an STD is also highly variable. Although the prevalence among male 
partners of infertile couples was reported 18.3% in Tunisia (Gdoura et al., 2008), the 
prevalence among patients from STD clinic or genito-urinary (GU) clinic is different 
(McGowin and Anderson-Smits, 2011): 7.3% positivity among women attending STD 
clinic and less than 5% among women attending GU clinic who were considered low 
risk patients (McGowin and Anderson-Smits, 2011).  
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Study from Iran showed M. genitalium prevalence in asymptomatic men (2%) and 
symptomatic (12%) men (Yeganeh et al., 2013) and The prevalence of M. genitalium in 
Iranian men with NGU was reported to be 0.8% (Salari et al., 2003) and in Iranian 
women with genital tract complain was reported 3.3% (Mirnejad et al., 2011).  
Given this heterogeneity, the aim of this first chapter is to investigate the incidence of 
C. trachomatis and M. genitalium infection in the 250 infertile couples recruited to this 
study as well as the 250 pregnant women recruited as controls. This was undertaken 
using different methods (NPPCR, serology) on three clinical samples (blood, urine and 
semen). The serology tests (IgA & IgM) indicates the acute or current infection. PCR 
shows current or persistent infection and IgG shows past exposure or infection. The 
demographic characteristics of the study participants are shown and the prevalence data 
compared to controls. The concordance within couples is also examined. 
3.2 Materials and Methods 
To examine the prevalence of both organisms in the study population and control group, 
NPPCR to detect C. trachomatis was undertaken as described in section 2.3.2 and PCR 
to detect M. genitalium undertaken as described in section 2.3.3. PCR was performed on 
all urine samples and on the semen samples from male partners of infertile couples. In 
addition, serological examination of IgG, IgM and IgA antibodies to C. trachomatis was 
performed as described in 2.3.1 on sera obtained from both partners of infertile couples 
and on sera from fertile women. Basic demographic data was obtained from the 
questionnaire administered on enrollment (see section 2.1.1).  
3.3 Results 
3.3.1 Demographic characteristics of study participants 
Table 3.1 shows the demographic characteristics of the 250 infertile men and women 
and the 250 fertile women that participated in the study. Their ages ranged from 15 to 
52 years of age, with the median age of infertile males being 32 (range 21-52), the 
median age of infertile women being 28 (range 15-35) and the median age of the fertile 
women in the control group being 28 (range 16-39). Most of the infertile (70.4%) or 
fertile (78.4%) women were aged between 20-30 years, whereas most of infertile men 
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(71.2%) were over 30 years old. The table shows primary infertility was seen in 182 
couples (72.8%) and secondary infertility was seen in 68 infertile couples (27.2%). The 
duration of infertility was 5.78 ± 3.48 and 6.27 ± 3.58 years among couples who had 
primary and secondary infertility respectively. Among infertile couples 1.2% of men 
and 16.0% of women were unemployed in comparison to 22.0% of fertile women. A 
total of 140 (56.0%) of the men were non-manual worker and 107 (42.8%) were manual 
worker. In contrast, 60 (28.6%) of the infertile women were non-manual worker and 
150 (71.4%) of them were manual worker. Therefore the couples considered mostly 
were from a working class population. Among infertile couples 1.2% of men and 16.0% 
of women were unemployed in comparison to 22.0% of fertile women. A total of 49 
(19.6%) of the men were smokers and 32 (12.9%) were drivers. In contrast, none of the 
infertile women were smokers or drivers. 
3.3.2 Prevalence of C. trachomatis in the study population 
To determine the prevalence of C. trachomatis among the study population NAAT and 
serology tests were performed on DNA (from FVU and semen samples) and serum of 
infertile couples and fertile women. Detection of chlamydia using PCR on urine DNA 
showed 4.4% positivity in the male partners of infertile couples (Table 3.2). The 
extracted DNA from semen was first tested for β-globin according to the method Saiki 
et al (1985) to check there were no PCR inhibitors in the samples. All of semen DNA 
was negative for C. trachomatis testing by PCR. The prevalence of C. trachomatis in 
female partners of infertile couples by PCR on urine samples showed 4.8% positivity 
(Table 3.3). Figure 3.1 shows an example of a 1% (w/v) agarose gel with NPPCR that 
includes a positive and negative control as well as positive and negative samples. The 
expected band for the positive sample was shown at 320 bp which is the same size as 
positive control. 
The serology test for detection of IgA, IgM and IgG antibodies to C. trachomatis 
showed 0.0%, 1.2% and 18.0% respectively positivity (Table 3.2) in sera of male 
partners of infertile couples. Figure 3.2 shows the typical immunofluorescence observed 
in positive and negative samples. The serology test for detection of IgA, IgM and IgG 
antibodies to C. trachomatis showed 0.0%, 4.0% and 15.6% respectively positivity in 
sera of female partners (Table 3.3).                                                                          
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C. trachomatis past exposure, IgG positive, was seen more frequently in the >30 years 
age group for men (Table 3.2) and women (Table 3.3), PCR positivity was seen more 
commonly for both men and women in age group of 20-30 years. Three out of forty five 
IgG positive men were detected positive by PCR (6.6%) and one out of thirty nine IgG 
C. trachomatis past exposure, IgG positive, was seen more frequently in the >30 years 
age group for men (Table 3.2) and women (Table 3.3), PCR positivity was seen more 
positive women were detected positive by PCR (2.5%). 
3.3.3 Prevalence of C. trachomatis in fertile women (control group) 
Using PCR on urine DNA from fertile women (n=250) did not find evidence of C. 
trachomatis. The prevalence of C. trachomatis using serology test in fertile women 
showed 12.8% positivity for IgG. All serum samples were tested for IgM and IgA as 
well but no positive samples were found (Table 3.4).  
3.3.4 Prevalence of M. genitalium in the study population and control group 
Urine samples of all participants (infertile couples & fertile women) and semen DNA 
was tested by PCR to detect 16S rRNA gene of M. genitalium, but no positive samples 
were observed. Figure 3.3 shows a 0.8% (w/v) agarose gel which is testing MgPa and 
16S rRNA gene of M. genitalium DNA with their band size as was expected (see 
section 2.2.3) and was used as positive control. 
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Table 3.1: Demographic characteristic of the study participants 
 
*Manual work refers to working class population. 
†Non-manual work refers to middle class population. 
 
 
 
 
 
 
 
 
 
Variable 
 
 
Infertile group Fertile female 
(n=250) 
           
Male 
(n=250) 
Female 
(n=250) 
 
Age: Median (range) 32 (21-52) 28 (15-35) 28 (16-39) 
Age: N (%) <20 0.0 (0.0) 6 (2.4) 18 (7.2) 
20-30 72 (28.8) 176 (70.4) 196 (78.4) 
>30 178 (71.2) 68 (27.2) 36 (14.4) 
Infertility: N (%) Primary 182 (72.8) n/a 
Secondary 68 (27.2) 
Infertility 
duration:(Mean±SD) 
Primary 5.78±3.48 n/a 
Secondary 6.27±3.58 
Employment: N (%) Employed 247 (98.8) 210 (84.0) 195 (78.0) 
Unemployed 3 (1.2) 40 (16.0) 55 (22.0) 
Employment: N (%) *Manual 107 (42.8) 150 (71.4) n/a 
†Non-Manual 140 (56.0) 60 (28.2) 
Driver:  N (%) 32 (12.9) 0.0 (0.0) n/a 
Smoker:  N (%) 49 (19.6) 0.0 (0.0) n/a 
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         Table 3.2: Prevalence of C. trachomatis infection in male partners. 
 
 
 
 
 
 
 
          Table 3.3: Prevalence of C. trachomatis infection in female partners. 
 
 
 
 
 
 
                      
          Table 3.4: Prevalence of C. trachomatis infection in fertile women (control). 
 
 
 
 
 
 
 
 
 
Age 
(years) 
 
No. Number of C. trachomatis positive samples (%) 
Serology 
IgA 
Serology 
IgM 
PCR Serology 
IgG 
< 20 0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
20-30 72 0 (0.0) 2 (2.7) 6 (8.3) 11 (15.3) 
>30 178 0 (0.0) 1 (0.4) 5 (2.8) 34 (19.1) 
Total 250 0 (0.0) 3 (1.2) 11 (4.4) 45 (18.0) 
Age 
(years) 
 
No. Number of C. trachomatis positive samples (%) 
Serology 
IgA 
Serology 
IgM 
PCR     Serology  
I gG 
<20 6 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
20-30 176 0 (0.0) 7 (3.9) 9 (5.1) 24 (13.6) 
>30 68 0 (0.0) 3 (4.4) 3 (4.4) 15 (22.0) 
Total 250 0 (0.0) 10 (4.0) 12 (4.8) 39 (15.6) 
Age 
(years) 
 
No. Number of C. trachomatis positive samples (%) 
Serology 
IgA 
Serology 
IgM 
PCR     Serology  
I gG 
<20 18 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
20-30 196 0 (0.0) 0 (0.0) 0 (0.0) 20 (10.2) 
>30 36 0 (0.0) 0 (0.0) 0 (0.0) 12 (33.3) 
Total 250 0 (0.0) 0 (0.0) 0 (0.0) 32 (12.8) 
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Figure 3.1: A 1.0% (w/v) agarose gel showing nested plasmid PCR on FVU samples 
(urine DNA) to detect C. trachomatis. Lane 1: DNA Ladder; Lane 2: Positive control; 
Lane 3: Negative control; Lane 4: Negative sample; Lane 5: Positive sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
300bp  
  
320bp 
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Figure 3.2: MIF staining using serum samples to show antibody to C. trachomatis (IgA, IgG, 
and IgM). A: showing positive reactions appear as bright apple-green fluorescent EBs against a 
dark background. B: negative reaction. 
A 
10μm 
10μm 
B 
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Figure 3.3: A 0.8% (w/v) agarose gel showing PCR on M. genitalium DNA. Lane 1: 
DNA Ladder; Lane 2: Positive control MgPa gene; Lane 3: Positive control 16SrRNA 
gene. 
 
 
 
 
 
 
 
 
 
 
 
  
 
16SrRNA 427bp 
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3.3.5 Concordance of C. trachomatis infections within couples 
To examine concordance of C. trachomatis infections within infertile partnerships, the 
incidence of male and female IgM positive results (Table 3.5), DNA positive results 
(Table 3.6) and IgG positive results (Table 3.7) were examined by Chi-square analysis. 
Briefly, among IgM positive female partners (n=10) no positivity was seen in their 
partners (Table 3.5). In only one couple, both partners had positive urine DNA (Table 
3.6), and from 45 men with IgG positive for C. trachomatis, only 9 of their partners 
were positive as well (Table 3.7). There was no statistical difference between the 
incidences of infection among couples using these three diagnostic tests, and clearly 
within partnership concordance was not always seen. 
Although numerical differences did exist, for example, forty five men had chlamydia 
IgG and three of the corresponding 45 specimens (1.2%) were positive by PCR on urine 
DNA. Thirty nine women had chlamydia IgG and one of the corresponding 39 
specimens (0.4%) was positive by PCR urine DNA. Antibody IgM to chlamydia was 
observed in two of forty five men and seven of thirty nine women who had chlamydia 
IgG.  
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Table 3.5: Concordance of IgM antibody to C. trachomatis in infertile     
couples. 
                        
 
 
 
 
 
                    Table 3.6: Concordance of C. trachomatis urine DNA in infertile couples. 
     
 
 
 
 
 
Table 3.7: Concordance of IgG antibody to C. trachomatis in infertile couples. 
                       
 
 
 
 
                * Chi-square tests requires a minimum cell size of 5 observation, therefore the test result 
                 must be regarded with some caution. 
 
 
 
 
 IgM+(♂) IgM−(♂) Total Pearson chi-square 
Value(df)              P-value 
IgM+(♀) 0* 10 10 1.27(1) 0.884 
IgM−(♀) 3 237 240 
Total 3 247 250 
 DNA+(♂) DNA−(♂) Total Pearson chi-square 
Value(df)              P-value 
DNA+(♀) 1* 11 12 0.358(1) 0.450 
DNA−(♀) 10 237 238 
Total 11 239 250 
 IgG+(♂) IgG−(♂) Total Pearson chi-square 
Value(df)              P-value 
IgG+(♀) 9 30 39 0.807(1) 0.245 
IgG−(♀) 36 175 211 
Total 45 205 250 
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3.4 Discussion 
The study was carried out to determine the prevalence of C. trachomatis and/or M. 
genitalium among infertile couples in Yazd and is the first large scale study undertaken 
using NAAT and serology in Iran. The main results of this study show that the 
incidence of C. trachomatis is comparable with other similar studies, but there was no 
evidence of M. genitalium and there is a low level of concordance within couples.  
To assess the prevalence of both micro-organisms, a non-invasive technique was carried 
out using FVU samples. The prevalence of C. trachomatis following NPPCR testing on 
these samples (urine DNA) showed 4.4% of the male partners of infertile couples and 
4.8% of the female partners of infertile couples were infected. Also serum samples were 
obtained from infertile couples to detect IgA, IgM and IgG antibodies to C. trachomatis 
and this showed that the IgM prevalence was 1.2% and 4.0% in the male and female 
partners of infertile couples respectively. The IgG prevalence was 18.0% and 15.6% in 
the male and female partners of infertile couples respectively. The IgA was not 
observed in the serum samples and this might be due to the half-life of IgA antibodies to 
C. trachomatis which is usually less than one week and normally used as an indicator of 
acute infection (Cevenini et al., 1984; Fresse et al., 2010).  
The semen samples (semen DNA) were tested for C. trachomatis by NPPCR, and no 
positive samples were detected. This is similar to a report that showed a higher number 
of positive results are found in urine samples (Hamdad-Daoudi et al., 2004). 
Conversely, Gdoura et al., (2008) found more positivity in semen samples of infertile 
men from Tunisia, and this is similar to previous work carried out in Sheffield (Kokab 
et al., 2010).  In a review article by Eley and Pacey (2011), 11 studies were reviewed 
and C. trachomatis could be detected 56% of the time in semen and urine, but only 20% 
in urine and 23% in semen. To date the preferred test specimens is FVU for men and 
vulvovaginal swab for female (Wiggins et al., 2009). An alternative specimen from men 
in the infertility work up is semen (Wisnieswki et al., 2008; Eley and Pacey, 2011) and 
this could provide more information about upper genital infection but there is no 
currently approved test for C. trachomatis detection in semen specimen (Eley and 
Pacey, 2011).  
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Given the presence of PCR inhibitors in FVU and semen samples including urea in 
urine and polyamines in semen (Eley and Pacey, 2011) there are other explanations for 
the low C. trachomatis detection in this study. First, the kit used for DNA extraction 
was not specific for urine or semen sample but was for general body fluid DNA 
extraction. This might be the main weakness of the study. Furthermore, 
spectrophotometry to measure DNA concentration was not performed in Yazd because 
of was not available, however random DNA concentration was measured for some urine 
samples (n=50) in Sheffield. In addition all of semen DNA were checked by β-globin 
PCR (n=250). Second, quantitative polymerase chain reaction (qPCR) was not used, 
and so the negative specimens (urine or semen) could have contained very low copy 
numbers of C. trachomatis DNA (or M. genitalium) that were not detected in the semi-
quantitative PCR method used. Third, another possible reason is that some DNA might 
suffer degradation (freeze and thaw) following direct sample storage and shipment from 
Iran. Unfortunately, there was clearance delay in the airport in the UK for 36 hours. 
Fourth, volume of specimens (FVU) is a factor that could impact on the sensitivity of 
NAATs, however, Moncada et al., (2003) have stated that PCR performed equally well 
at all volumes (Moncada et al., 2003). The conclusion is that the low positivity might be 
a genuine finding or due to a non-specific DNA extraction kit. Positive results were also 
confirmed by sequencing. 
Both urine and semen DNA were examined by PCR to detect M. genitalium but no 
positive samples were found.  The negative results for M. genitalium might be because: 
(i) M. genitalium does not have cell wall and inducing osmotic lysis following washing 
step during DNA extraction lead to negative result (Jensen, 2006), (ii) very low 
prevalence of infection (iii) the inappropriate kit for DNA extraction from urine and 
semen (discussed above) (iv) the PCR method used (v) the economic situation of 
patients (they could afford to pay for their treatment were recruited into study).  
The prevalence of M. genitalium in Iranian men with NGU was reported to be 0.8% 
(Salari et al., 2003) and in Iranian women with genital tract complain it was reported to 
be 3.3% (Mirnejad et al., 2011). Data from a recent study (Yeganeh et al., 2013) in Iran 
showed 12% and 2% positivity for M. genitalium in symptomatic and asymptomatic 
men respectively. Also they found M. genitalium infection significantly associated with 
low educational level and therefore low economic situation. Therefore our results might 
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be caused of selection bias as poorer people who cannot afford treatment in Iran (as 
people have to pay in a public medical centre) are not recruited then it can affect the 
prevalence of this organism in present study. Therefore, because of the asymptomatic 
study population and the low prevalence of this organism, the conclusion is that the low 
positivity might be genuine finding. This is supported by the fact that the PCR worked 
properly (see Figure 3.3).   
In fertile women as control group only chlamydia IgG was observed (12.8%) with no 
positive urine DNA for C. trachomatis or M. genitalium. As expected the fertile women 
had lower positive serology, however it was not statistically significant (OR=1.26; 
95%CI= 0.75-2.08). Positive IgG serology is suggesting prior exposure to C. 
trachomatis, and because IgA and IgM were negative suggests that infection was not in 
its acute phase. This would also explain why urine DNA was negative for C. 
trachomatis and M. genitalium. In these cases it might be possible that their 
immunologic response has cleared the infection or they had successful treatment. 
There was no concordance within couples with regard to C. trachomatis infection 
positivity. This is in contrast with other studies that found high rate of concordance 
within couples (Quinn et al., 1996; Keane et al., 2000; Idahl et al., 2004, Guerra-Infante 
et al., 2005). The most likely reason for this is the low number of patients with positive 
serology or PCR tests and also the type of specimen which used to detect C. 
trachomatis.  Previous studies which have found concordance have used urethral swab, 
and culture as their diagnostic method. Also it is not a surprising finding, since 
spermatozoa play a vehicle role for C. trachomatis to transport to female genital tract 
(Suarez & Pacey, 2006) and in this study sperm were not infected.  
Other Middle Eastern countries like United Arab Emirates studied C. trachomatis 
prevalence in women that found 2.6% in endocervical swab specimens by rapid 
immunoassay (Ghazal-Aswad et al., 2004). In Jordan, the prevalence of genital 
chlamydia infection in symptomatic and asymptomatic patients (male & female) was 
4.6% in patients with urethritis or cervicitis but no positives were observed in 
asymptomatic patients (Awwad et al., 2003). In infertile women in Egypt, the 
prevalence of chlamydia IgG and IgM antibodies in serum were 8.0% and 2.7% (Abd-
Raboh et al., 2011). The results of serology test in the present study is similar to some 
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European studies (Idahl et al, 2004; Hamdad-Daoudi et al., 2004) and lower than rates 
reported from Germany (Eggert-Kruse et al., 2001).  
With regard to the M. genitalium prevalence in infertile couples, the incidence and role 
of this organism has been less well studied in comparison to C. trachomatis and its role 
on human infertility is still not clear. In infertile men 5% positivity was shown by PCR 
on semen sample and that was a very high concordance between detection of 
mycoplasmas DNA in semen and first void urine (Gdoura et al., 2007). Among 
asymptomatic women and men aged 21-23 the prevalence was reported 2.3% and 1.1% 
respectively (Anderson et al., 2006).  M. genitalium has been implicated in infertility by 
compromising the function of the uterine tubes, and the role of M. genitalium in non-
gonococcal PID (Clausen et al., 2001; Svenstrup et al., 2008). Significant relationship 
between M. genitalium and tubal infertility (confirmed by laparoscope), have been 
observed in two Danish studies (Clausen et al., 2001; Svenstrup et al., 2008). Infertile 
women were more likely than fertile women to have M. genitalium infection in cervical 
swabs using PCR (Grzesko et al., 2009) that predict upper tract infection. As NAAT 
studies show association between current infection and infertility, serological studies 
can be useful in determining recent or long term infections. 
In conclusion, non-invasive screening for C. trachomatis and M. genitalium in infertile 
couples was performed and illustrates the incidence of these infections are comparable 
with other studies. The present study found no M. genitalium positivity and that might 
be caused of the fact that treatment is not free in Iran and people recruited in this study 
from a potentially biased sample who are economically better off.  
After defining the C. trachomatis and/or M. genitalium prevalence in population, this 
study goes on to look at the relationship of this infection and semen parameters and 
semen inflammatory markers. This is in order to see how past and current infections 
might affect male fertility. 
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4 Chapter 4: Correlation between chlamydial infection, 
inflammatory markers and semen quality 
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4.1 Introduction 
There is controversy whether semen quality may be compromised by genitourinary 
infection in men (Gonzales et al., 2004). Studies show that male accessory gland 
infection (MAGI) may negatively interfere with semen parameters. During MAGI many 
inflammatory markers are released in the high levels that lead to the negative effect on 
semen parameters (Rowe et al., 1993; Agarwal et al., 2003, La Vignera et al., 2011). 
White blood cells (WBC) are attracted to the site of infection because of existence of 
pathogens and tissue damage. Macrophages produce inflammatory cytokines in 
response to chronic inflammation, foreign antigens and pathogens (Barratt et al., 1990). 
Cytokines have essential functions in the mediation of inflammatory responses and in 
the reproductive physiology of women and men (Henderson et al., 1996). Cytokines are 
soluble mediators and regulatory protein produced by leucocytes and other cells 
(lymphoid and non-lymphoid cells) that play a key role in both innate and acquired 
immune responses that control inflammation. 
 
The enzyme peroxidase that is inside the phagosomes of polymorphonuclear 
granulocytes (PMN) can make reactive oxygen species from hydrogen peroxide (H2O2) 
hypoclorous acid (HCl), hydroxyl (OH) and superoxide radicals (O2
-
). The aim of these 
oxygen species are to destroy pathogens and this normally takes place inside of 
phagolysosome, but these can leak out of the PMN and damage surrounding tissue. 
These reactive oxygen species (ROS) are neutralized by antioxidants that normally exist 
in the seminal plasma and in the genital tract secretion (Comhaire et al., 1999; Gonzales 
et al., 2004; Tremellen & Tunc, 2010). In normal condition there is a balance between 
generation of ROS and antioxidants. Increasing ROS generation is what happens during 
WBC activation or infiltration that cannot be neutralized by the antioxidant capacity of 
genital fluid. The reason might be accessory sex gland dysfunction because of infection. 
The excessive ROS damage sperm membrane and sperm DNA (Aitken et al., 2003; 
Tremellen & Tunc, 2010). Moreover, tissue damage during infection stimulates an 
inflammatory reaction and the generation of interleukin 1 (IL-1). The effect of IL-1 on 
PMN leads to IL-8 and ROS secretion. Also IL-1 stimulates macrophages, which are a 
source of IL-8 and IL-6. Stimulated macrophage also produces hepatocyte growth factor 
(HGF) see Figure 4.1 (Comhaire et al., 1999).  
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Figure 4.1: The effect of infection on the function of accessory glands (redrawn from 
Comhaire et al., 1999). AFC = antibody-forming cell; B = B lymphocyte; HGF = 
hepatocyte growth factor; M = macrophage; PMN = polymorphonuclear white blood 
cell; PUFA = polyunsaturated fatty acids; ROS = reactive oxygen species. 
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IL-6 is an inflammatory trigger, thus starts the process. Also it causes leucocytes 
activation and differentiation. IL-6 participates to the final toxic effect through ROS 
overproduction. IL-8 participates to the neutrophil chemo-attraction phase in inflamed 
site and causes neutrophil activation and phagocytosis (Rajasekaran et al., 1995) and IL-
6 mainly can cause membrane damage which lead to decrease spermatozoa functional 
capacity (Martinez-Prado, 2010). IL-8 is considered as a marker of MAGI and has a 
negative effect on fertilizing potential of spermatozoa (Depuydt et al., 1998). IL-8 is a 
reliable and prognostic marker (Castro et al., 2004; Penna et al., 2009) to diagnose of 
chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic 
hyperplasia (BPH).  
In an in vitro study (Al-Mously and Eley, 2007) it was suggested that raised levels of 
IL-6 and IL-8 is a useful marker for upper genital tract infection especially prostatitis. 
Therefore, high levels IL-8 in the C. trachomatis infected patients suggest that the 
infection is more likely derived from upper genital tract (Al-Mously and Eley, 2007). C. 
trachomatis can induce the production of IL-8 by infected cells during in vivo and in 
vitro infection (Mpiga et al., 2006). IL-6 plays an important role in host defence against 
different organisms and C. trachomatis as well (Magee et al 1992; Ross et al., 2006). 
Elevated IL-6 and IL-8 levels have been observed in persistent and chronic C. 
trachomatis infection (Mpiga et al., 2006).  High seminal plasma IL-6 and IL-8 were 
associated with C. trachomatis infection (Kokab et al., 2010; Eggert-Kruse et al., 2001). 
Although Eggert-Kruse et al (2003) stated that the role of C. trachomatis is unclear and 
diagnosis test like PCR and serological test does not provide reliable results. They also 
mentioned IL-8 and IL-6 are correlated with the number of leucocytes. IL-6 is the most 
important cytokines in inflammatory disease of seminal tract. Comhaire et al., (1994) 
first reported IL-6 levels in the seminal plasma that were higher in the infertile patients 
with leucocytospermia. In addition IL-8 titre was found higher in seminal plasma of 
infertile patients with leucocytospermia, also there is correlation between levels of IL-8 
and IL-6 in seminal plasma (Shimoya et al., 1995). 
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There is controversy whether certain pro-inflammatory cytokines (such as IL-6 and IL-8 
which are involved in inflammatory processes) in infertile patients are related to semen 
quality (Eggert-Kruse et al., 2001; Kopa et al., 2005). Previous studies suggested that 
there were no relationship (Comhaire et al., 1994; Matalliotakis et al., 2002), whereas 
more recent studies have supported such a relationship (Furuya et al., 2003; Kopa et al., 
2005). 
A positive correlation was found between IL-8 and seminal leucocytes (Eggert-Kruse et 
al., 2001) and Kokab et al (2010) found that high levels of IL-8 related to high semen 
volume that supported the previous study which showed C. trachomatis infected 
patients have increased semen volume (Hosseinzadeh et al., 2004). Bezold et al., (2007) 
found there is no relationship between pathogen DNA in semen and inflammatory 
markers. Also interleukins concentrations are not related to the presence of wide range 
bacteria in semen samples (Eggert-Kruse et al., 2001).  
This Chapter therefore tests the general hypothesis that C. trachomatis infection is 
related to the levels of seminal inflammatory markers and these will also correlate with 
semen quality. 
4.2 Materials and Methods 
In this chapter the C. trachomatis prevalence data from Chapter 3 (PCR and serology 
results) was used to compared to data obtained from semen analysis performed in Yazd 
(see section 2.2.2) and measurements of semen inflammatory markers performed in 
Sheffield (see section 2.3.8.1 & 2.3.8.2). These data were first analysed by histogram to 
confirm normality. According to the distribution histogram and normality plots test on 
all variables, parametric and non-parametric independent t test were performed on 
normal and abnormal distributed data respectively as shown in the footnote of each 
table. Then Descriptive statistics and an independent sample T test were used for data 
with normal distribution and Mann-Whitney U test was used for nan- parametric data. 
Spearman rank correlation test was used to evaluate the relationship between the levels 
of IL-6 and IL-8 with semen parameters (see section 2.5).   
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4.3 Results 
4.3.1 C. trachomatis infection and semen parameters 
Comparisons were made between C. trachomatis-infected and uninfected men as 
defined by the presence of IgM and IgG antibodies in serum (see section 2.3.1) or C. 
trachomatis DNA in urine and their corresponding semen parameters evaluated 
according to WHO (1999) guidelines.  
Table 4.1 shows the relationship between mean (±SD) age, duration of infertility, semen 
parameters of three IgM positive men and 247 IgM negative men. In summary there 
was no significant difference between the two groups and any variable measured. Since 
only three men were positive for IgM, the comparison with IgM negative men is not 
statistically robust.                             
Table 4.2 shows the relationship between mean (±SD) age, duration of infertility, semen 
parameters in C. trachomatis infected and uninfected men according to the PCR of urine 
DNA. Eleven men were positive for C. trachomatis by this method. Statistical analysis 
showed that only semen volume was significantly lower in C. trachomatis infected men 
(P= 0.001).  
Table 4.3 shows the relationship between mean (±SD) age, duration of infertility, semen 
parameters in the IgG positive and IgG negative men. Forty five men were IgG positive 
and 205 were IgG negative. The semen pH was higher in the IgG (+) group compared 
with the IgG negative group and was biological significant (P=0.055, 0.05<P<0.1). Also 
the percentage of immotile sperm was significantly lower in the IgG positive group 
compared with the IgG negative group (P= 0.018).  
In each case anti-sperm antibodies (IgA & IgG) were tested for all individuals (see 
section 2.2.2). However the kits did not work properly, presumably because of shipping 
difficulties to Iran which may have led to them being stored inappropriately.  
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Table 4.1: Age, duration of infertility, semen parameters (mean ± SD) in C. 
trachomatis IgM (+) and IgM (-) men. 
 
 a: parametric independent t test; b: Mann-Whitney U test 
 
 
 
 
 
 
 
 
 
Variable IgM Positive 
 
 (n= 3) 
IgM Negative 
 
(n= 247) 
P-value 
 
Age
a 
(years)
 
 
29.66 ± 3.51 32.76 ± 5.14 P=0.354 
Duration of infertility
a
 
(years) 
2.30 ± 0.57 6.00 ± 3.52 P=0.072 
Semen volume
a 
(ml) 
 
2.00 ± 0.50 3.11 ± 1.52 P=0.078 
pH
a 
 
8.33 ± 0.76 8.20 ± 0.43 P=0.150 
Sperm concentration
a 
million/ml 
35.66 ± 39.71 66.51 ± 51.46 P=0.657 
Percent progressive 
Motile
b 
25.00 ± 25.05 52.24 ± 20.97 P=0.059 
Percent immotile
b 
 
35.66 ± 34.50 34.52 ± 19.63 P=0.812 
Percent normal 
morphology
b 
6.30 ± 8.50 6.06 ± 3.51 P=0.579 
Percent DNA 
fragmentation
b 
8.66 ± 10.66 12.69 ± 8.25 P=0.407 
Leucocytes
a
, million/ml 
 
0.95 ± 0.43 1.56 ± 1.34 P=0.279 
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Table 4.2: Age, duration of infertility, semen parameters and (mean ± SD) in C. 
trachomatis urine DNA (+) and urine DNA (-) men. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  a: parametric independent t test; b: Mann-Whitney U test 
  *P-value≤ 0.05 
 
 
 
 
 
 
 
 
 
 
Variable DNA positive 
 
(n= 11) 
DNA negative 
 
(n= 239) 
P-value 
 
Age
a 
(years)
 
 
31.45 ± 3.53 32.79 ± 5.19 P=0.254 
Duration of infertility
a
 
(years) 
5.27 ± 3.06 5.90 ± 3.49 P=0.406 
Semen volume
a 
(ml) 
 
2.11 ± 0.73 3.15 ± 1.53   P=0.001* 
pH
a 
 
8.22 ± 0.41 8.25 ± 0.43 P=0.829 
Sperm concentration
a 
million/ml 
59.54 ± 45.22 66.45 ± 51.27 P=0.632 
Percent progressive 
Motile
b 
53.63 ± 15.71 51.52 ± 21.86  P= 0.781 
Percent immotile
b 
 
33.36 ± 14.86 34.59 ± 19.98 P=0.923 
Percent normal 
morphology
b 
7.27 ± 3.45 6. 08 ± 3.53 P=0.250 
Percent DNA 
fragmentation
b 
11.18 ± 5.94 12.82 ± 8.31 P=0.673 
Leucocytes
a
, million/ml 
 
1.60 ± 1.18 1.55 ± 1.34 P=0.882 
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Table 4.3: Age, duration of infertility, semen parameters (mean ± SD) in 
C. trachomatis IgG (+) and IgG (-) men. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 a: parametric independent t test; b: Mann-Whitney U test 
 *P-value≤ 0.05 
 ¶0.05<P<0.1- although not slightly significant statistically this deserves consideration as 
being biological significant. 
 
 
 
 
 
 
 
 
 
Variable IgG Positive 
 
(n= 45) 
IgG Negative 
 
(n=205) 
P-value 
 
Age
a 
(years)
 
 
32.00 ± 5.20 32.9 ± 5.10 P=0.273 
Duration of infertility
a
 
(year) 
5.33 ± 3.04 6.09 ± 3.61 P=0.175 
Semen volume
a 
(ml) 
 
3.30 ± 1.90 3.00 ± 1.40 P=0.748 
pH
a 
 
8.40 ± 0.36 8.20 ± 0.44   P=0.055¶ 
Sperm concentration
a 
million/ml 
64.65 ± 42.3 68.54 ± 54.9 P=0.915 
Percent progressive 
motile
b 
56.84 ± 21.4 52.23 ± 19.50 P=0.697 
Percent immotile
b 
 
31.05 ± 19.50 36.20 ± 18.50   P=0.018* 
Percent normal 
morphology
b 
5.60 ± 2.60 6.20 ± 3.70 P=0.672 
Percent DNA 
fragmentation
b 
12.20 ± 8.30 12.7 ± 8.00 P=0.592 
Leucocytes
a
, million/ml 
 
0.98 ± 0.49 1.65 ± 1.41 P=0.152 
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4.3.2 Inflammatory markers in semen 
4.3.2.1 IL-6 and IL-8 levels in seminal fluid 
Comparisons were made between the C. trachomatis-infected and uninfected men and 
the corresponding IL-6 and IL-8 levels in their seminal fluids. The median 
concentration of IL-6 in the seminal fluid from the total 250 male partners of infertile 
couples in the present study was 23.65 pg/ml (range 0.23-367.52 pg/ml), whereas the 
median concentration of IL-8 was 1615.17 pg/ml (range 179.50-41918.62 pg/ml). The 25-
75 centiles and ranges were determined for both cytokines and the results are shown in 
Table 4.4 - 4.9. 
The results from Table 4.4 shows the levels of seminal IL-6 in the male partners with 
genital tract chlamydial infection, as defined by IgM antibody to C. trachomatis in 
serum. However, as only three men were positive for IgM, therefore the comparison 
with IgM negative men is not statistically robust.                             
Table 4.5 shows the levels of seminal IL-6 in men with and without C. trachomatis 
DNA in their urine. Eleven men were positive by this method and 239 were negative. 
The mean ± SD of IL-6 was numerically higher in C. trachomatis infected men, 
however, it was not statistically significant (P= 0.244).  
Table 4.6 shows the levels of seminal IL-6 in the male partners with genital tract 
chlamydial infection as defined by the presence of IgG antibody to C. trachomatis in 
serum. Forty five men were positive for IgG antibody to C. trachomatis. Interestingly, 
the level of IL-6 (mean ± SD) was significantly higher in the IgG positive men (P= 
0.056, 0.05<P<0.1 was considered biological relevant). 
Seminal plasma concentration of IL-6>37.9 pg/ml in an individual male, was defined as 
‘high’ (based on the 75th percentile) and this level was detected in a total 62 of the 250 
samples tested. 9 of 62 men had a history of urethritis. High levels of IL-6 was detected 
in 4 of 11 samples were defined positive by NPPCR (urine DNA) and 14 of 45 samples 
were defined positive by serology (IgG). 
The results from Table 4.7 shows the levels of seminal IL-8 in the male partners with 
genital tract chlamydial infection as defined by the presence of IgM antibody to C. 
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trachomatis in serum. However, as only three men were positive for IgM, therefore the 
comparison is not statistically precise. 
Table 4.8 shows the levels of seminal IL-8 in men with and without C. trachomatis 
DNA in their urine. Eleven men were positive by this method. The mean ± SD of IL-8 
was numerically higher in C. trachomatis infected men, however, it was not statistically 
significant (P= 0.157). 
Table 4.9 shows the levels of seminal IL-8 in the male partners with genital tract 
chlamydial infection as defined by the presence of IgG antibody to C. trachomatis in 
serum. Forty five men were positive for IgG antibody to C. trachomatis. The mean ± 
SD and median of IL-8 was numerically higher in C. trachomatis infected men but these 
were not statistically significant different where compared to men who were IgG 
negative (P=0.680).  
Seminal plasma concentration of IL-8>2966 pg/ml in an individual male, was defined as 
‘high’ (based on the 75th percentile) and this level was detected in a total 62 of the 250 
samples tested. 5 of 62 men had a history of urethritis. High levels of IL-8 was detected 
in 3 of 11 samples were defined positive by NPPCR (urine DNA) and 9 of 45 samples 
were defined positive by serology (IgG). 
4.3.2.2 Correlation between IL-6 and IL-8 levels 
The values of IL-6 and IL-8 cytokine levels irrespective of C. trachomatis infection 
were correlated. Figure 4.2 shows a degree of correlation (Pearson’s correlation 
coefficient=0.38; P<0.001) between these inflammatory cytokines in seminal plasma of 
male partners of infertile couples.  
4.3.2.3 IL-6 and IL-8 levels and semen parameters 
Semen parameters of the 250 male partners of infertile couples were then evaluated 
respect to the IL-6 and IL-8 levels in their seminal fluid. Table 4.10 shows the 
correlation between the levels of IL-6, IL-8 and age, duration of infertility and semen 
parameters. IL-6 and IL-8 both were correlated significantly with the number of 
leucocytes in semen (P=0.012; P=0.001 respectively). Also IL-8 was inversely 
correlated with semen volume (P=0.013) and positively with male age (P=0.039). These 
results are shown graphically in Figures 4.3-4.6. 
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Table 4.4: Relationship between the levels of IL-6 with genital chlamydial    infection 
(IgM) in male partners of infertile couples. 
 
 
Table 4.5: Relationship between the levels of IL-6 with genital chlamydial infection 
(urine DNA) in male partners of infertile couples. 
 
 
Table 4.6: Relationship between the levels of IL-6 with genital chlamydial infection 
(IgG) in male partners of infertile couples. 
 
 
 
 
 
 
IL-6 
 Chlamydia infected 
(n= 3) 
Chlamydia uninfected 
           (n= 247) 
Total 
(n=250) 
Mean ± SD pg/ml 32.61 ± 6.69 34.67 ± 47.42 34.64 ± 47.13 
Median pg/ml 30.16 23.64 23.65 
25
th
-75
th
 percentile 
pg/ml 
n/a 10.26-37.82 10.26-37.91 
Range pg/ml 27.50-40.19 0.23-367.52 0.23-367.52 
IL-6 
 Chlamydia infected 
(n= 11) 
Chlamydia uninfected 
(n= 239) 
Total 
(n=250) 
Mean ± SD pg/ml 70.89 ± 101.19 32.97 ± 42.78 34.64 ± 47.13 
Median pg/ml 28.28 23.64 23.65 
25
th
-75
th
 percentile 
pg/ml 
20.23-72.62 10.05-37.82 10.26-37.91 
Range pg/ml 0.51-327.43 0.23-367.52 0.23-367.52 
IL-6 
 Chlamydia infected 
(n= 45) 
Chlamydia uninfected 
(n= 205) 
Total 
(n=250) 
Mean ± SD pg/ml 54.54 ± 81.46 31.65 ± 34.36 34.64 ± 47.13 
Median pg/ml 29.42 23.25 23.65 
25
th
-75
th
 percentile 
pg/ml 
11.56-55.79 10.16-37.26 10.26-37.91 
Range pg/ml 0.24-367.52 0.23-270.03 0.23-367.52 
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Table 4.7: Relationship between the levels of IL-8 with genital chlamydial infection 
(IgM) in male partners of infertile couples. 
 
 
Table 4.8: Relationship between the levels of IL-8 with genital chlamydial infection   
(urine DNA) in male partners of infertile couples. 
 
 
Table 4.9: Relationship between the levels of IL-8 with genital chlamydial infection 
(IgG) in male partners of infertile couples. 
 
 
 
 
IL-8 
 Chlamydia infected 
(n= 3) 
Chlamydia uninfected 
(n= 247) 
Total 
(n=250) 
Mean± SD pg/ml 2765.45 ± 764.29 3166.81 ± 5477.84 3162.00 ± 5445.32 
Median pg/ml 2457.96 1588.62 1615.17 
25
th
-75
th
 percentile 
pg/ml 
n/a 1003.44-2964.41 1005.50-2966.20 
Range pg/ml 2222.03-3616.67 179.5-41918.62 179.50-41918.62 
IL-8 
 Chlamydia infected 
(n= 11) 
Chlamydia uninfected 
(n= 239) 
Total 
Men=250 
Mean± SD pg/ml 9540.69 ± 14434.28 2868.42 ± 4505.63 3162.00 ± 5445.32 
Median pg/ml 1524.46 1622.21 1615.17 
25
th
-75
th
 percentile 
pg/ml 
982.10-15242.20 1006.18-2849.43 1005.50-2966.20 
Range pg/ml 463.71-37668.35 179.50-41918.62 179.50-41918.62 
   IL-8 
 Chlamydia infected 
(n= 45) 
Chlamydia uninfected 
(n= 205) 
Total 
(n=250) 
Mean± SD pg/ml 3926.82 ± 7670.52 2981.58 ± 4831.22 3162.00 ± 5445.32 
Median pg/ml 1819.92 1588.62 1615.17 
25
th
-75
th
 percentile 
pg/ml 
1024.95-3023.99 1004.81-2968-19 1005.50-2966.20 
Range pg/ml 185.75-37668.35 179.50-41918.62 179.50-41918.62 
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Figure 4.2: Correlation between IL-6 and IL-8 levels in seminal plasma of male 
partners of infertile couples (P<0.001). 
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Table 4.10: Median (range) of age, duration of infertility, semen parameters and their 
correlations with levels of IL-6 & IL-8 in semen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *P-value ≤ 0.05 
 
 
 
 
 
 
 
 
 
 
 
Variable Median(range) Correlation  
with IL6 levels 
Correlation  
with IL8 levels 
Age
 
(years)
 
 
32.7 (21-52) P=0.158 
r=0.090 
  P=0.039* 
r=0.130 
Duration of infertility 
(years) 
5 (1-18) P= 0.290 
r= 0.068 
 p= 0.972 
 r= 0.002 
Semen volume
 
(ml) 
 
2.5 (1-9.5) P=0.175 
r=0.086 
  P=0.013* 
r=-0.157 
pH 
 
8 (6-9.5) P=0.672 
r=0.022 
P=0.241 
r=0.074 
Sperm concentration 
million/ml 
62 (0.5-350) P=0.326 
r=0.062 
P=0.383 
r=0.055 
Percent progressive 
motile 
55 (0-95) P=0.835 
r=0.013 
P=0.394 
r=0.055 
Percent immotile 
 
32 (0-100) P=0.914 
r=0.007 
P=0.882 
r=0.010 
Percent normal 
morphology 
6 (0.5-17.5) P=0.857 
r=-0.012 
P=0.775 
r=0.018 
Percent DNA 
fragmentation 
11 (1-40) P=0.975 
r=0.002 
P=0.951 
       r=0.004 
Leucocytes, million/ml 
 
1.2 (0.05-11.41)   P=0.012* 
      r=0.159 
  P=0.001* 
       r=0.419 
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Figure 4.3: Correlation between concentration of IL-6 (pg/ml) and number of 
leucocytes (million/ml) in seminal plasma of male partners of infertile couples (P<0.05). 
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Figure 4.4: Correlation between concentration of IL-8 (pg/ml) and number of 
leucocytes (million/ml) in seminal plasma of male partners of infertile couples (P<0.05). 
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Figure 4.5: Correlation between concentration of IL-8 (pg/ml) and semen volume (ml) 
in male partners of infertile couples (P<0.05). 
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Figure 4.6: Correlation between concentration of IL-8 (pg/ml) and age of male partners 
(years) of infertile couples (P<0.05). 
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4.4 Discussion 
This chapter examined the relationship between C. trachomatis infection in infected 
men (using PCR and serology) and inflammatory markers (IL-6 & IL-8) in the seminal 
plasma. The main conclusions are: (i) elevated IL-6 and IL-8 are observed in C. 
trachomatis positive men but this is not significant and it varies by diagnostic method; 
and (ii) IL-6 and IL-8 levels were correlated with each other and the concentration of 
leucocytes, but IL-8 was correlated with volume and age. These are discussed in more 
detail below. 
The relationship between semen parameters and chlamydia infection in this study 
showed that men with such an infection in FVU samples (PCR positive) had only lower 
semen volume compared with men without infection. This is because inflammation can 
cause of obstruction of the duct and results to reduce semen volume and this support 
previous works (Wolff et al., 1991) and in contrast with others (Hosseinzadeh et al., 
2004; Al-Mously et al., 2009; Kokab et al., 2010) who explained C. trachomatis 
infection might be cause of increased activity of accessory gland or reproductive 
epithelium secretion. 
Infected men as defined by serology (IgG+) had high level of IL-6 and increased semen 
pH as described by Marconi et al., (2009) and Kokab et al., (2010).  
The seminal plasma IL-6 level were much lower than IL-8 (0.23-367.52 pg/ml versus 
179.50-41918.62 pg/ml) but significantly correlated to each other. These findings 
support the idea of Al-Mously and Eley (2007) who proposed that IL-6 and IL-8 
seminal plasma levels might be useful as a marker of upper genital tract infection (e.g. 
prostatitis).  Given that IL-6 and IL-8 are both markers of prostate inflammation and IL-
8 is also related to infection of urethra (Al-Mously and Eley, 2007) the results might 
suggest that patients with high levels of ILs are more likely to have prostatitis and this is 
confirmed with the positive correlation of IL-8 with male age. Both ILs were also 
associated with high number of leucocytes in semen and this suggest the probability of 
inflammation and/or infection and this is similar to previous studies (Eggert-Kruse et 
al., 2001; Kokab et al., 2010).   
Increasing IL-8 levels were associated with lower semen volume in C. trachomatis 
infected men (urine DNA+) and this is contrary to previous observations that found high 
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semen volume in infected men (Hosseinzadeh et al., 2004; Al-Mously et al., 2009; 
Kokab et al., 2010). It is unclear why this is the case although a simple explanation is 
that semen DNA was not infected in the present study and some men had only a history 
of urethritis (see Chapter 6). It might also be caused by unequal abstinence periods 
between the two groups, although this seems unlikely. IL-8 was also associated directly 
with male age in the present study, and this might be a sign of genital accessory gland 
infection (Al-Mously and Eley, 2007) or benign prostatic hyperplasia (BPH) without 
damage to spermatogenesis. There are studies about the role of IL-8 to trigger BPH 
(Berry et al., 1984; Castro et al., 2004; Penna et al., 2009) and developing BPH and 
male age (Berry et al., 1984; Glynn et al., 1984; Meigs et al., 2001). Since there is no 
correlation between age and semen volume were observed in the current study, the 
correlation between IL-8 and semen volume must be caused by accessory gland 
inflammation and/or infection by C. trachomatis or other infectious agent and the 
obstruction of the ductus epididymis (Marconi et al., 2009). The fact that the other 
microorganisms in semen are responsible for altered cytokines levels might be a 
complicating factor in interpreting these results.  
These finding do not confirm previous studies on male infertility and C. trachomatis 
which have been carried out in Sheffield that found increased semen volume in infected 
men (Hosseinzadeh et al., 2004; Kokab et al., 2010). This might be because these 
studies undertook C. trachomatis diagnosis on semen samples which was not achieved 
in this study (see Chapter 3). However, these do confirm and extend the previous 
finding by Eggert-Kruse et al (2001) who found high level of ILs in leucocytospermic 
samples and no association with bacterial colonization of semen samples.  
Therefore these correlations confirmed that C. trachomatis infection can result in high 
level of seminal plasma interleukins and statistically significant high level of IL-6 might 
suggest the effect of this organism on prostate and support the previous work in 
Sheffield (Al-Mously and Eley, 2007). Low semen volume in C. trachomatis infected 
men defined by positive urine DNA indicate current infection and can be indirectly 
related to high level IL-8 and inflammation of the prostate. Given the relationship 
between C. trachomatis infection and chronic prostatitis (Ouzounova et al., 2010) 
indicates the probability of a risk factor with prostate cancer (Stasiewicz et al., 2012) 
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and should be examined in future studies. However there is not an accepted aetiological 
link and the view is highly controversial.  
The weakness of this study is the lack of a fertile group of males as control to see the 
level of ILs and their relationship with C. trachomatis. Extensive attempts were made to 
recruit fertile male participants in number of locations. These locations included 
antenatal and vasectomy clinic, however, despite these attempts no fertile male 
participant volunteered. These problems have been recognized in other studies (Cohn et 
al., 2002; Stewart et al., 2009, Eiser et al., 2011) and it is suggested they are too 
concerned about their fertility or suspected infertility to volunteer.  Also they may have 
experience of testicular cancer treatment or anxiety of cancer diagnosis.  
In the following chapters, the effect of C. trachomatis on sperm DNA and fertilizing 
capacity under in vivo and in vitro conditions of conception will be examined.  
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5 Chapter 5: Correlation between sperm DNA fragmentation and 
sperm chromatin integrity with C. trachomatis in infertile men 
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5.1 Introduction 
This chapter investigates the role of C. trachomatis infection on sperm DNA in male 
partners of infertile couples. A direct effect of C. trachomatis EBs on spermatozoa that 
can lead to infertility is premature sperm death (Hosseinzadeh et al., 2001) through an 
apoptosis mechanism which is induced by C. trachomatis lipopolysaccharide (LPS) 
(Eley et al., 2005a; 2005b). The mechanism as defined in different studies (Aitken, 
1994; Gorga et al., 2001; Eley et al., 2005b) involves excessive production of reactive 
oxygen species (ROS) in leucocytes which has been induced by C. trachomatis 
lipopolysaccharide and ROS is mediator of apoptosis (Eley et al., 2005b).  
Patients with genitourinary infection by C. trachomatis and M. genitalium showed 
increased sperm DNA fragmentation in comparison with fertile controls (Gallegos et 
al., 2008). This increase is proportionally greater than the influence on classical semen 
parameters and could result in a decreased fertility potential (Gallegos et al., 2008). 
Elevated levels of sperm DNA fragmentation are related to morphological abnormalities 
(Benchaib et al., 2007) and it is believed that normal sperm morphology can be a 
valuable predictor of the fertilization rate if it is evaluated by strict criteria (Kruger et 
al., 1999; Van Waart et al,. 2001). Assessment of DNA integrity may be a valuable 
marker of fertility for both animals and men. High level of chromatin damage has 
negative impact on both natural and ART conception (Evenson et al., 1980; Larson et 
al, 2000).  
Although experimentally induced in vivo DNA damage of sperm is not possible in 
humans, strong associations have been shown between paternal genome damage by 
chemotherapeutic agents and embryo development in animals (Fernandez-Gonzales et 
al., 2008). The importance of studying sperm DNA integrity has been further intensified 
by the growing concern about transmission of genetic disease through ICSI (Barroso et 
al., 2000; Agarwal, 2003). Therefore in this chapter the effects of C. trachomatis on 
sperm DNA integrity was evaluated by different tests to examine the percentage of 
sperm DNA abnormality in infected males of infertile couples. The hypothesis that high 
levels of sperm DNA abnormality would be related to C. trachomatis infection was 
tested.   
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5.2 Materials and Methods 
Spermatozoa from male partners of infertile couples were examined for DNA 
fragmentation using slides prepared during semen analysis (see section 2.2.1). Four 
different tests were used to detect sperm DNA abnormalities. Briefly, in Yazd/Iran tests 
for the detection of residual histones (section 2.3.7.2), evaluation of protamination 
(section 2.3.7.3) and detection of sperm chromatin condensation anomalies (section 
2.3.7.4) were performed. A further test to detect sperm single or double DNA strand 
breaks (section 2.3.7.1) was performed using the TUNEL assay on slides shipped to 
Sheffield. 
5.3 Results 
5.3.1 Sperm DNA measurements 
Comparison were made between C. trachomatis-infected and uninfected men with 
respect to the percentage of sperm DNA fragmentation (TUNEL assay) and the 
percentage of sperm with chromatin abnormality using the different DNA integrity tests. 
The results are shown in Table 5.1-5.4.  
Table 5.1 shows the result obtained using the TUNEL assay (Figure 5.1) for C. 
trachomatis diagnoses made using (i) IgM, (ii) PCR of urine DNA, and (iii) IgG. 
Briefly, the results show no significant differences in terms of DNA fragmentation 
between C. trchomatis positive and negative men, regardless of whether this was 
diagnosed by IgM, PCR or IgG. 
Table 5.2 shows the results obtained using AB staining (Figure 5.2) for the detection of 
residual histones for C. trachomatis diagnoses made using (i) IgM, (ii) PCR of urine 
DNA, and (iii) IgG. Briefly, the results show no significant differences in terms of 
chromatin abnormality between C. trchomatis positive and negative men, regardless of 
whether this was diagnosed by PCR or IgG. Unfortunately no results were available for 
diagnoses made using IgM (see below). 
Table 5.3 shows the results obtained using AO staining (Figure 5.3) for detection of 
sperm chromatin condensation anomalies for C. trachomatis diagnoses made using (i) 
IgM, (ii) PCR of urine DNA, and (iii) IgG. Briefly, the results show no significant 
differences in terms of chromatin abnormality between C. trachomatis positive and 
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negative men, regardless of whether this was diagnosed by PCR or IgG. Again no 
results were available for diagnoses made using IgM (see below). 
Table 5.4 shows the results obtained using CMA3 staining (Figure 5.4) for evaluation of 
protamination for C. trachomatis diagnoses made using (i) IgM, (ii) PCR of urine DNA, 
and (iii) IgG. Briefly, the results show no significant differences in terms of chromatin 
abnormality between C. trchomatis positive and negative men, regardless of whether 
this was diagnosed by PCR or IgG. IgM results were unavailable. 
The study measured IgM for all serum samples. However, sperm chromatin studies 
were not performed on all 250 men. The fixed slides have been prepared for a sub-
sample of 180 men. The matched samples for the three different staining (AB, AO and 
CMA3) were only achieved for a sub-sample of 80 men and therefore did not include 
any of the IgM positives. 
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                           Table 5.1: Sperm DNA fragmentation (TUNEL assay) in  
C. trachomatis positive men for: (i) IgM; (ii) DNA and (iii) IgG. 
 
(i) 
 
Mean ± SD 
IgM+ (n=3) 
Mean ± SD 
IgM− (n=247) 
P-value 
TUNEL 8.66 ± 10.66 12.69 ± 8.25 P=0.407 
 
 
 
 
 
 
 
 
 
                                    Table 5.2: Detection of residual histone (Aniline Blue) in  
                             C. trachomatis positive men for: (i) IgM; (ii) DNA and (iii) IgG. 
 
(i) 
 
Mean ± SD 
IgM+ (n=0) 
Mean ± SD 
IgM− (n=80) 
P-value 
Aniline Blue n/a 
 
29.81± 15.6 n/a 
 
(ii) 
 
Mean ± SD 
DNA+ (n=11) 
Mean ± SD 
DNA− (n=69) 
P-value 
Aniline Blue 28.0 ± 15.2 30.10 ± 14.8 
 
P=0.657 
 
(iii) Mean ± SD 
IgG+(n=21) 
Mean ± SD 
IgG− (n=59) 
P-value 
Aniline Blue 28.0 ± 13.9 28.85 ± 15.4 P=0.689 
 
 
 
 
 
(ii) 
 
Mean ± SD 
DNA+ (n=11) 
Mean ± SD 
DNA− (n=239) 
P-value 
TUNEL 11.18 ± 5.94 12.82 ± 8.31  P=0.673 
 
(iii) 
 
Mean ± SD 
IgG+ (n=45) 
Mean ± SD 
IgG− (n=205) 
P-value 
TUNEL 12.21 ± 8.28 12.71± 8.01 P=0.592 
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                   Table 5.3: Sperm chromatin condensation anomalies (AO)  
                     in C. trachomatis positive men for: (i) IgM; (ii) DNA and (iii) IgG. 
 
 
 
 
 
 
 
 
 
                                      
           
                 Table 5.4: Evaluation of protamination (Chromomycine A3) in  
                   C. trachomatis positive men for: (i) IgM; (ii) DNA and (iii) IgG. 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
(i) 
 
Mean ± SD 
IgM+ (n=0) 
Mean ± SD 
IgM− (n=80) 
P-value 
Acridine Orange n/a 35.68 ± 12.20 n/a 
(ii) Mean ± SD 
DNA+ (n=11) 
Mean ± SD 
DNA− (n=69) 
P-value 
Acridine Orange 
 
37.54 ± 7.90 35.42 ± 12.60 P=0.462 
(iii) 
 
Mean ± SD 
IgG+ (n=17) 
Mean ± SD 
IgG− (n=63) 
P-value 
Acridine Orange 
 
35.52 ± 12.90 35.71 ± 12.17 P=0.957 
(i) 
 
Mean ± SD 
IgM+ (n=0) 
Mean ± SD 
IgM− (n=80) 
P-value 
CMA3 
 
n/a 39.87 ± 10.6  n/a 
(ii) 
 
Mean ± SD 
DNA+ (n=11) 
Mean ± SD 
DNA− (n=69) 
P-value 
CMA3 
 
35.0±8.2 
 
39.80 ± 10.6 
 
P=0.156 
(iii) 
 
Mean ± SD 
IgG+ (n=31) 
Mean ± SD 
IgG- (n=49) 
P-value 
CMA3 
 
38.54 ± 8.22 
 
40.63 ± 12.3 
 
  P=0.299 
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Figure 5.1: DNA fragmentation assay using TUNEL. Panels A & B show sperm with 
intact DNA, whereas C-H show sperm with damaged DNA. Upper panels show 
fluorescent signal and lower panels show corresponding image using visible light. 
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Figure 5.2: Sperm DNA integrity measurement using AB staining for detection of 
residual histones: (a) = abnormal spermatozoa (dark blue) and (b) = normal 
spermatozoa (pale blue or unstained). 
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Figure 5.3: Sperm DNA integrity measurement using AO staining to detect sperm 
chromatin condensation anomalies: (a) = abnormal spermatozoa (orange-red; denatured 
DNA) and (b) = normal spermatozoa (green; double stranded DNA). 
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Figure 5.4: Sperm DNA integrity measurement using CMA3 staining for evaluation of 
protamination: (a) = abnormal spermatozoa (bright yellow) and (b) = normal 
spermatozoa (yellowish-green). 
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5.3.2 Semen parameters and sperm DNA fragmentation 
Table 5.5 shows the relationship between DNA fragmentation using TUNEL assay and 
age, duration of infertility and semen parameters for the 250 male partners of infertile 
couples based the high (> 17%) and low (< 6%) level of DNA fragmentation as defined 
by 25
th
 and 75
th
 percentiles. Semen volume and the percentage of sperm with normal 
morphology were lower in the group of men with high percentage of sperm DNA 
fragmentation and this was statistically significant (P= 0.046, P= 0.003 respectively). In 
addition, percentage of immotile sperm was higher in this group and this was also 
statistically significant (P=0.044). 
5.3.3 Semen parameters and sperm DNA integrity 
Table 5.6 shows the correlation between three different tests used to measure sperm 
DNA integrity and age, duration of infertility and semen parameters of a sub-sample of 
80 male partners of infertile couples for which these additional data were available. 
Briefly, the only significant correlation was seen between the percentage of CMA3 
(evaluation of protamination) and male age (P=0.025). There was no correlation 
between age, duration of infertility and semen parameters with Aniline Blue staining 
(detection of residual histones) or Acridine Orange staining (sperm chromatin 
condensation anomalies). 
5.4 Discussion 
In this chapter, sperm DNA was assessed by different tests to examine whether it was 
related to C. trachomatis infection in the male partner of infertile couples. The main 
conclusions of the results are: (i) sperm DNA fragmentation (TUNEL) and chromatin 
studies (AB, AO & CMA3) were not correlated with C. trachomatis diagnosis; (ii) the 
percentage of DNA fragmentation is positively correlated with the percentage of 
immotile sperm but negatively with semen volume, normal morphology; and (iii) in 
sperm chromatin measurements only the percentage of protamination was related to 
male age. 
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Table 5.5: Age, duration of infertility, semen parameters (mean ± SD) in low and high 
levels of DNA fragmentation using TUNEL assay (based on 25
th
 and 75
th
 percentiles). 
 
 a: parametric independent t test; b: Mann-Whitney U test 
*P-value≤ 0.05 
 
 
 
 
 
 
 
 
 
Variable DNA fragmentation 
25
th
 percentile 
(n=64) 
DNA fragmentation 
75
th
 percentile 
(n=67)  
P-value 
 
Age
a 
(years)
 
 
32.53 ± 4.51 32.22 ± 5.29 P=0.717 
Duration of infertility
a
 
(years) 
5.72 ± 2.85 6.27 ± 3.91 P=0.360 
Semen volume
a 
(ml) 
 
3.48 ± 1.78 2.92 ± 1.48 P=0.046* 
pH
a 
 
8.26 ± 0.49 8.20 ± 0.42 P=0.843 
Sperm concentration
a 
million/ml 
62.37 ± 66.82 68.13 ± 39.53 P=0.548 
Percent progressive 
Motile
b 
45.63 ± 25.64 54.15 ± 18.96 P=0.094 
Percent immotile
b 
 
33.12 ± 14.61 44.97 ± 28.57 P=0.044* 
Percent normal 
morphology
b 
6.95 ± 3.78 5.05 ± 3.45 P=0.003* 
Leucocytes
a
, million/ml 
 
1.35 ± 1.57 1.58 ± 1.29 P=0.349 
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Table 5.6: Age; duration of infertility; semen parameters (median) and their      
corresponding correlation with DNA integrity measured by Aniline Blue (AB), Acridine 
Orange (AO) and Chromomycine A3 (CMA3) for a sub-sample of 80 men. 
 
    *P-value≤ 0.05 
 
 
 
 
 
 
 
 
 
Variable Median(range) 
 
(n=80) 
Correlation  
 
with %AB 
Correlation  
 
with %AO 
Correlation 
with 
%CMA3 
Age
 
(years)
 
 
33 (22-49) P=0.961 
r=0.006 
P=0.157 
r=0.160  
  P=0.025* 
r=0.252 
Duration of 
infertility (years) 
4.3 (1-18) P=0.765 
r=0.034 
P=0. 280 
r=0.122 
P=0.179 
r=0.115 
Semen volume
 
(ml) 
 
3.5 (1.0-9.5) P=0.496 
r=0.077 
P=0.182 
r=0.151 
P=0.643 
r=0.053 
pH 
 
8.5 (6.0-9.0) P=0.897 
r=0.015 
P=0.857 
r=0.020 
P=0.203 
r=0.145 
Sperm concentration 
million/ml 
74.0 (3.0-310.0) P=0.124 
r=0.173 
P=0.982 
r=0.003 
P=0.466 
r=0.083 
Percent progressive 
motile 
59.5 (0.0-95.0) P=0.099 
r=0.186 
P=0.912 
r=0.012 
P=0.611 
r=0.058 
Percent immotile 
 
32.0 (6.0-100.0) P=0.574 
r=0.064 
P=0.447 
r=0.086 
P=0.422 
r=0.092 
Percent normal 
morphology 
6.3 (0.5-14.5) P=0.390 
r=0.097 
P=0.450 
r=0.086 
P=0.264 
r=0.127 
Leucocytes, 
million/ml 
 
1.1(0.15-14.4) P=0.092 
r=0.192 
P=0.818 
r=0.027 
P=0.061 
r=0.215 
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Sperm DNA fragmentation assessed by TUNEL assay was not related to C. trachomatis 
infection in the male partners of infertile couples as defined by serology (IgM & IgG) or 
PCR of urine samples. In addition to the results for DNA fragmentation, the results of 
this present study also showed C. trachomatis infection was not associated with various 
measures of sperm chromatin condensation such as AB, CMA3 and AO staining. This is 
in contrast with previous studies that showed sperm DNA fragmentation is higher in C. 
trachomatis infected infertile men (Satta et al., 2006; Gallegos et al., 2008). This is not 
a surprise because in this study semen samples were not infected by C. trachomatis 
using PCR which suggests there was no infection in the upper genital tract to affect 
spermatogenesis (see Chapter 3). The positive results for infection (urine DNA) indicate 
lower genital tract infection such as urethritis. 
The results of TUNEL assay showed semen volume and percentage of normal 
morphology were significantly lower in infertile men with a “high” level of DNA 
fragmentation (based on 75
th
 percentiles) and the percentage of immotile sperm was 
significantly higher in “high” level of DNA fragmentation. These findings cannot be 
compared to other studies because as they used different methods including flow 
cytometry instead of assessing fixed slides and sperm chromatin investigation rather 
than double strand  DNA break (TUNEL assay).  
In this chapter sperm chromatin integrity was investigated by three methods and showed 
that the percentage of stained sperm was not directly associated with any semen 
variable. The results only suggested that the level of protamination as men get older is 
reduced compared to younger men. CMA3 competes with protamine in the same site of 
DNA (Plastira et al., 2007); therefore our results can be explained by age-related 
alteration of semen parameters that is similar to the work of Plastira et al., (2007) and 
their support of Wyrobek et al., (2006). Although Kidd et al., (2001) showed that 
increasing male age was associated with a decreasing in semen volume, sperm motility 
and morphology; they did not evaluate sperm DNA measurements. In contrast, Nijs et 
al., (2009) did not find any male age-related influences on routine semen parameters or 
sperm DNA measurements. There is an extensive literature about the relationship 
between semen parameters and sperm DNA damage (Zini et al., 2001; Shen et al., 
2002; Saleh et al., 2002). For example, Zini and colleagues found DNA damage was 
negatively correlated with semen parameters and the strongest correlation was with 
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sperm motility (Zini et al., 2001), whereas Shen et al., (2002) found overall poor sperm 
quality in apoptotic samples. Saleh et al., (2002) have not found relationship between 
semen parameters and DNA fragmentation; however Saleh et al., (2002) found higher 
level of DNA fragmentation in infertile men compared to a fertile group. However, 
these investigations are between infertile men and DNA damage without taking into 
account C. trachomatis infection.  
The limitations of this study were (i) lack of control group as this was not easy to get 
fertile men to take part in the study as discussed in Chapter four and (ii) sperm DNA 
chromatin assessment was performed only on a sub-sample of n=80 men and this did 
not include any of the IgM positive men and (iii) the method used for TUNEL assay 
was only assessing fixed slides and not flow cytometry which is more accurate. This is 
because flow cytometry was not available.  
Implication of sperm DNA testing is controversial in infertility investigations. It might 
help couples with a history of long term unexplained infertility and ART failure (Sakkas 
& Alvarez, 2010). The American Society for Reproductive Medicine (ASRM) guideline 
(2013) suggested that although sperm DNA damaging is more common in infertile men, 
however, the clinical utility of testing is not recommended in routine infertility work-up, 
as these tests are not reliable to predict outcome of pregnancy (ASRM, 2013). In 
addition, due to lack of efficient treatment there is no more help for couples even if 
sperm DNA abnormalities were detected (ASRM, 2006). Also ASRM Practice 
Committee (2006) did not find relationship between sperm DNA damage and 
reproductive outcome either in spontaneous or assisted conception. Barratt et al., (2010) 
reported the results of an ESHRE workshop in 2009 which concluded sperm DNA 
abnormalities may have most effect on IUI pregnancy rates and pregnancy loss after 
IVF and ICSI. However, there are clinical and assay uncertainties because of the lack of 
a robust clinical test. The larger issues including: who to test, when to test and how to 
treat patients with abnormal results have not yet been resolved. To confirm the results of 
literatures, further larger, well designed and controlled prospective studies will be 
required (Barratt et al., 2010).  
In the next chapter, C. trachomatis infection is considered with regard to pregnancy 
rate, pregnancy outcome of the 250 infertile couples.  
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6  Chapter 6: C. trachomatis infection, pregnancy rate, pregnancy 
outcome 
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6.1 Introduction 
Infertility is one of the serious complications of C. trachomatis infection among women 
in reproductive age, due to the sequelae of PID following genital tract infection (Low et 
al., 2006; Haggerty et al., 2010) that can lead to tubal factor infertility (TFI). In 
addition, semen parameters can be affected by C. trachomatis infection (Hosseinzadeh 
et al., 2000; 2001; 2003; 2004; Idahl et al., 2004; 2007) and this may also contribute to 
infertility. Therefore it might be hypothesized that the pregnancy rate and/or pregnancy 
outcome in infected couples is poorer than in those without infection. 
With regard to conception, there are controversial studies showing the presence of C. 
trachomatis in female genital tract was associated with poor IVF outcome (Fanchin et 
al., 1998) and two Swedish studies by Idahl et al., (2004; 2007) showing that the C. 
trachomatis positive serology was negatively associated with semen parameters and 
lower pregnancy rate (unassisted) in infertile couples (Idahl et al., 2004; 2007). In 
contrast, de Barberyac et al., (2006) found in subfertile couples that C. trachomatis 
infection was not associated with semen parameters and pregnancy outcome by IVF (de 
Barberyac et al., 2006).  
With regards to assisted pregnancy in infected men, as C. trachomatis is not removed 
from sperm by washing methods (Al-Mously et al., 2009) it might potentially result in 
contamination of IVF culture system and negatively affect embryo quality. Although, 
some microbes can be removed by sperm washing (Wong et al., 1986) and other may be 
sensitive to the antibiotics used in IVF culture media, C. trachomatis is not sensitive to 
all antibiotics that are added to culture media (Storey and Chopra, 2001; Pacey and 
Eley, 2004). Moreover, when pregnancy is established, C. trachomatis infection as an 
asymptomatic and persistent infection that can result in serious complication during 
pregnancy such as preterm premature rapture of membranes (PPROM), preterm birth 
(Gravett et al., 1986; Sweet et al., 1987) and ectopic pregnancy (Low et al., 2006; 
Haggerty et al., 2010).  
In the present study the pregnancy rate, pregnancy outcome were investigated in the 250 
infertile couples recruited to this study. As well as their C. trachomatis status, their past 
medical and reproductive history was taken into account in order to evaluate any 
relationship between these data and pregnancy rate and outcome. 
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6.2 Materials and Methods 
In this chapter the past reproductive and general history of the 250 infertile couples 
enrolled to study was correlated with their C. trachomatis status defined by IgM, PCR 
and IgG. For this analysis infertility was divided into primary and secondary infertility. 
Primary infertility is defined as the lack of ability to conceive a child that results in a 
live birth after a year of unprotected coitus (Shaw, 2003). Whereas secondary infertility 
is defined as inability of a couple to conceive after a year or two of unprotected and 
appropriately timed intercourse when one or both partners have previously conceived 
children (Shaw, 2003). TFI was defined as the occlusion of one or both tubes as 
diagnosed either by laparoscopy and/or HSG (Joseph, 2011). Endometriosis was 
confirmed by laparoscopy using European Society of Human Reproduction and Embryology 
(ESHRE) guideline for diagnosis and treatment of endometriosis (Kennedy et al., 2005). 
PCOS was diagnosed by vaginal sonography and/or laparoscopy and considering 
hirsutism (hyperandrogenism) and oligo-amenorrhea in a general examination as 
described in the Rotterdam 2003 guideline (Fauser et al., 2004). The regular menstrual 
cycle was considered based on regular intervals. Miscarriage indicates loss an embryo 
or fetus before the 20th week of pregnancy, according to the definition published by 
Shaw (2003). The male partners were examined by a urologist and the data for any 
urogenital abnormality and varicocele was obtained from patient notes. Varicocele was 
diagnosed by exam and/or scan. Male factor infertility was defined based on semen 
parameters (WHO, 1999). Men who drove for more than 2 hours daily were classified 
as drivers.  
In addition to the above, follow up data obtained 24 months after enrollment, was also 
correlated with C. trachomatis status. Follow up details included the outcome of any 
pregnancy (spontaneous or assisted) including live birth, still birth, miscarriage and 
ongoing pregnancy. Also the sex and weight of baby was born during follow up (see 
section 2.4). To explore confounding factors among the past medical histories of both 
partners logistic regression was used (see section 2.5). 
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6.3 Results 
6.3.1 Past medical history and C. trachomatis prevalence in infertile men  
Table 6.1-6.3 show the past history of urethritis, varicocelectomy, driving (>2 
hours/day), smoking, opium addict and mumps as a function and C. trachomatis 
infection were assessed by serum IgM status (Table 6.1) PCR (Table 6.2) and serum 
IgG status (Table 6.3). 
Briefly, no statistical correlations were seen between the incidences of either condition 
in relation to IgM antibody status (Table 6.1). But when these clinical data were 
examined with respect to C. trachomatis positivity by PCR of urine DNA (Table 6.2), it 
was found urethritis was more likely in infertile males who had C. trachomatis DNA in 
their urine (OR= 34.82; 95%CI= 8.45-143.40). This was not observed (Table 6.3) in 
men diagnosed by IgG status (OR= 1.50; 95%CI= 0.56–4.02). Among male partners of 
infertile couples, drivers were more likely to have exposure to C. trachomatis as defined 
by IgG (OR=2.37; 95%CI= 1.03-5.45), but no other variable were found to be 
significant. 
6.3.2 Reproductive History and C. trachomatis prevalence in infertile women  
Table 6.4-6.6 show the clinical data for the female partners, including type of infertility 
(primary or secondary), past history of miscarriage, use of ART, menstruation 
(regular/irregular), history of infection, PCOS, TFI and endometriosis which were 
examined for possible correlation with the presence of C. trachomatis infection as 
defined by serum IgM status (Table 6.4) urine PCR (Table 6.5) and serum IgG status 
(Table 6.6).  
Briefly, only PCOS was statistically more common (OR= 3.70; 95%CI= 1.03-13.3) in 
relation to IgM antibody status (Table 6.4) but this was not observed (Table 6.5) in 
women diagnosed by PCR (urine DNA).  However, when this was examined by IgG 
antibody status (Table 6.6) women with IgG antibody to chlamydia were 2.5, times 
more likely to have a past medical history of PCOS (OR= 2.59; 95%CI= 1.24-5.27). 
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Table 6.1: Past medical history and C. trachomatis prevalence (IgM) in infertile men. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Past Medical History 
 
 
No. (%) C. trachomatis     
infected 
 
No.    (%) 
Odds 
ratio 
 
95% (CI) 
Urethritis  Yes  25 (10.0) 0 (0.0) 3.08 0.31- 30.81 
No  225 (90.0) 3 (1.3) 
Varicocelectomy Yes  61 (24.4) 1 (16.4) 1.55 0.14-17.49 
No 189 (75.6) 2 (1.05) 
Driver Yes 32 (12.8) 1 (3.1) 3.48 0.31-39.56 
No 218 (87.2) 2 (0.91) 
Smoker  Yes 49 (19.6) 1 (2.04) 2.07 0.18-23.33 
No 201 (80.4) 2 (0.99) 
Opium addict Yes 14 (5.6) 0 (0.0) 5.97 0.58-61.46 
No 236 (94.4) 3 (1.3) 
Mumps  Yes 5 (1.2) 0 (0.0) 8.96 0.39-206.2 
No 245 (98.8) 3 (1.2) 
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Table 6.2: Past medical history and C. trachomatis prevalence (urine DNA) 
 in infertile men. 
 
 
 
 
 
 
 
 
   
 
*Significant odds ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Past Medical History 
 
 
No. (%) C. trachomatis     
infected 
 
No.(%) 
Odds 
ratio 
  
95% (CI) 
Urethritis  Yes  25 (10.0) 8 (32.0) 34.82* 8.45-143.40 
No  225 (90.0) 3 (1.3) 
Varicocelectomy Yes  61 (24.4) 4 (6.5) 1.82 0.68-3.44 
 No 189 (75.6) 7 (3.7) 
Driver Yes 32 (12.8) 2 (6.3) 1.44 0.39-5.30 
No 218 (87.2) 9 (41.3) 
Smoker  Yes 49 (19.6) 4 (81.6) 1.93 0.85-4.40 
No 201 (80.4) 7 (3.5) 
Opium addict Yes 14 (5.6) 0 (0.0) 0.75 0.04-13.59 
No 236 (94.4) 11 (4.6) 
Mumps  Yes 5 (1.2) 0 (0.0) 5.36 0.22-126.10 
No 245 (98.8) 11 (4.5) 
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Table 6.3: Past medical history and C. trachomatis prevalence (IgG) in infertile men. 
 
 
 
                
 
 
 
 
 
 
*significant odds ratio 
 
 
 
 
 
 
 
 
 
 
 
Past Medical History 
 
 
 
No. (%) C. trachomatis     
infected 
 
No.    (%) 
Odds 
ratio 
  
95% (CI) 
Urethritis  Yes  25 (10.0) 6 (24.0) 1.50 0.56-4.02 
No  225 (90.0) 39 (17.3) 
Varicocelectomy Yes  61 (24.4) 13 (21.3) 1.32 0.65-2.73 
No 189 (75.6) 32 (16.9) 
Driver Yes 32 (12.8) 10 (31.2) 2.37* 1.03-5.45 
No 218 (87.2) 35 (16.0) 
Smoker  Yes 49 (19.6) 5 (10.2) 0.45 0.17-1.23 
No 201 (80.4) 40 (19.9) 
Opium addict Yes 14 (5.6) 2 (14.3) 0.74 0.16-3.46 
No 236 (94.4) 43 (18.2) 
Mumps  Yes 5 (2.0) 1 (20.0) 1.14 0.12-10.47 
No 245 (98.0) 44 (17.9) 
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Table 6.4: Reproductive history and C. trachomatis prevalence (IgM) in infertile 
women. 
  
       * Significant odds ratio 
  
Reproductive 
    history 
 
 
No. (%) C. 
trachomatis 
infected 
 
No. (%) 
Odds 
ratio 
 
95% (CI) 
Infertility Primary 182 (73.0) 8 (4.4) 1.51 0.31-7.33 
Secondary 68 (27.2) 2 (2.9) 
Miscarriage  Yes  41 (16.4) 2 (2.4) 1.28 0.26-6.29 
No  209 (83.6) 8 (3.8) 
ART Yes  54 (21.6) 2 (3.7) 0.90 0.18-4.39 
No 196 (78.4) 8 (4.0) 
Menstruation Regular 164 (65.6) 6 (3.6) 0.77 0.21-2.84 
Irregular 86 (34.4) 4 (4.6) 
Infection Yes 137 (54.8) 6 (4.4) 1.24 0.34-4.53 
No 113 (45.2) 4 (3.5) 
PCOS Yes 56 (22.4) 5 (8.9) 3.70* 1.03-13.3 
No 194 (77.6) 5 (2.5) 
TFI Yes 41 (16.4) 2 (4.9) 1.28 0.26-6.29 
No 209 (83.6) 8 (3.8) 
Endometriosis Yes 22 (8.8) 2 (9.0) 2.75 0.54-13.83 
No 228 (91.2) 8 (3.5) 
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Table 6.5: Reproductive history and C. trachomatis prevalence (urine DNA) in infertile 
women.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Reproductive 
    history 
 
 
No. (%) C. trachomatis 
infected 
 
No. (%) 
Odds 
ratio 
    
95% (CI) 
Infertility Primary 182 (73.0) 10 (5.5) 1.91 0.40-8.98 
Secondary 68 (27.2) 2 (2.9) 
Miscarriage  Yes  41 (16.4) 2 (4.9) 1.02 0.21-4.83 
No  209 (83.6) 10 (4.8) 
ART Yes  54 (21.6) 4 (7.4) 1.88 0.54-6.49 
No 196 (78.4) 8 (4.1) 
Menstruation Regular 164 (65.6) 6 (3.6) 0.50 0.15-1.62 
Irregular 86 (34.4) 6 (6.9) 
Infection Yes 137 (54.8) 8 (5.8) 1.69 0.49-5.76 
No 113 (45.2) 4 (3.5) 
PCOS Yes 56 (22.4) 5 (8.9) 2.61 0.79-8.59 
No 194 (77.6) 7 (3.6) 
TFI Yes 41 (16.4) 2 (4.9) 1.02 0.21-4.83 
No 209 (83.6) 10 (4.8) 
Endometriosis Yes 22 (8.8) 0 (0.0) 0.40 0.02-7.16 
No 228 (91.2) 12 (5.3) 
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Table 6.6: Reproductive history and C. trachomatis prevalence (IgG) in infertile 
women. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *Significant odds ratio 
 
 
 
 
 
 
 
 
 
 
 
Reproductive 
    history 
 
 
No. (%) C. trachomatis 
infected 
IgG 
No. (%) 
Odds 
ratio 
 
95% (CI) 
Infertility Primary 182 (73.0) 27 (14.8) 0.81 0.38-1.71 
Secondary 68 (27.2) 12 (17.6) 
Miscarriage  Yes  41 (16.4) 6 (14.6) 0.91 0.35-2.34 
No  209 (83.6) 33 (15.8) 
ART Yes  54 (21.6) 12 (22.2) 1.78 0.83-3.82 
No 196 (78.4) 27 (13.7) 
Menstruation Regular 164 (65.6) 28 (17.0) 1.40 0.66-2.97 
Irregular 86 (34.4) 11 (12.8) 
Infection Yes 137 (54.8) 20 (14.6) 0.84 0.42-1.67 
No 113 (45.2) 19 (16.8) 
PCOS Yes 56 (22.4) 15 (26.8) 2.59* 1.24-5.37 
No 194 (77.6) 24 (12.4) 
TFI Yes 41 (16.4) 6 (14.6) 0.91 0.36- 2.34 
No 209 (83.6) 33 (15.8) 
Endometriosis Yes 22 (8.8) 6 (27.2) 2.21 0.80-6.07 
No 228 (91.2) 33 (14.5) 
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6.3.3 Follow up  
6.3.3.1 Summary of diagnoses, treatment and outcome of n=250 infertile couples 
Table 6.7 summarises diagnoses, treatment and treatment outcome of the 250 infertile 
couples recruited to the study. Briefly, the most common single reason for infertility 
was male factor infertility (40%) with PCOS (22.4%) tubal damage (16.4%) and 
unexplained (12.4%) being the next most common. Since couples could have more than 
one reason for their infertility, the list of diagnoses adds up to more than 100%. 
With regard to the use of assisted conception, 123 couples received some kind of ART 
during the two year follow up including IVF (15.6%), ICSI (26.4%) and IUI (7.2%). Of 
those couples that underwent ART, 59 achieved a pregnancy and of those that did not 
56 couples conceived pregnancy spontaneously. After 24 months, 25 couples were still 
undergoing treatment (data not shown).   
6.3.3.2 Pregnancy outcome in C. trachomatis infected women 
Table 6.8 shows (i) the number of women who achieved a pregnancy with or without 
infection either spontaneously or treatment assisted, and (ii) the pregnancy outcome 
respect with live birth or pregnancy loss in both ART and spontaneously conceived 
pregnancies. In summary, there were no statically differences with regard to achieving 
pregnancy or pregnancy outcome and C. trachomatis positivity, regardless of how this 
was defined (IgM, PCR, and IgG). 
6.3.3.3 Pregnancy outcome in women with a C. trachomatis infected partner 
Table 6.9 shows (i) the number of women who achieved pregnancy either 
spontaneously or treatment assisted who had partners with or without infection. The 
table also shows (ii) the pregnancy outcome respect with live birth or pregnancy loss in 
both ART and spontaneously conceived pregnancies. Briefly, there were no differences 
with regard to achieving pregnancy or pregnancy outcome in women whose partners 
were C. trachomatis positive regardless of how this was defined (IgM, PCR, and IgG).  
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          Table 6.7: Diagnoses, treatment and outcome summary of the infertile  
women (n=250) after 24 months follow up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
               Diagnoses  
 
No of couples. 
 
Percentage (%) 
 
Principal diagnoses:                                                           
Male factor 
                                PCOS 
   Tubal damage (adhesions) 
                      Unexplained 
                Oligomenorrhea 
                   Endometriosis 
 
 
             100 
56 
41 
               31 
30 
22 
 
 
40.0 
22.4 
16.4 
12.4 
12.0 
  8.8 
 
 
                       Treatments: 
                                  None 
          Ovulation induction 
                                    ICSI 
                                     IVF 
                                      IUI 
 
 
 
64 
63 
66 
39 
18 
 
 
25.6 
25.2 
26.4 
15.6 
  7.2 
 
 
        Achieved pregnancy: 
                   Spontaneously 
             Treatment related 
 
 
115 
56 
59 
 
46.0 
48.7 
51.3 
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Table 6.8: Chlamydia trachomatis antibodies (IgM & IgG) and PCR of urine DNA in the female partner showing: (i) probability of achieving 
pregnancy and (ii) pregnancy outcome. 
 
 
 
 
 
 
(i) Achieved pregnancy 
 
Odds Ratio (95%CI) 
Spontaneous ART Spontaneous ART 
IgM Pos 2/10 4/10 0.88 (0.19-4.15) 1.80 (0.54-5.98) 
Neg 54/240 55/240 
DNA Pos 4/12 1/12 1.56 (0.48-5.08) 0.33 (0.04-2.59) 
Neg 52/238 58/238 
IgG Pos 11/39 13/39 1.22 (0.56-2.67) 1.92 (0.96-4.09) 
Neg 45/211 46/211 
(ii) Pregnancy outcome Odds Ratio (95%CI) 
 
 
Spontaneous ART                 Spontaneous                                       ART 
Live 
birth 
Pregnancy 
loss 
Live 
birth 
Pregnancy 
loss 
Live birth Pregnancy loss Live birth Pregnancy loss 
IgM Pos 2/10 0/10 3/10 1/10 1.00 (0.21-4.71) 2.09 (0.10-40.48) 1.64 (0.63-6.22) 2.55 (0.29-22.17) 
Neg 48/240 6/240 45/240 10/240 
DNA Pos 4/12 0/12 1/12 0/12 1.72 (0.53-5.68) 2.09 (0.10-41.41) 0.34 (0.04-3.02) 1.25 (0.06-23.12) 
Neg 47/238 5/238 50/238 8/238 
IgG Pos 9/39 2/39 11/39 2/39 1.24 (0.54-2.80) 4.41( 0.60-32.28) 1.79 (0.82-3.92) 1.47 (0.28-7.56) 
Neg 41/211 4/211 38/211 8/211 
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Table 6.9: Chlamydia trachomatis antibodies (IgM & IgG) and PCR of urine DNA in the male partner and: (i) probability of achieving 
pregnancy and (ii) pregnancy outcome. 
 
 
 
 
 
 
(i) Achieved pregnancy 
 
Odds Ratio (95%CI) 
Spontaneous ART Spontaneous ART 
IgM Pos 0/3 1/3 0.73 (0.04-14.83) 1.42 (0.15-13.97) 
Neg 56/247 58/247 
DNA Pos 4/11 2/11 1.72 (0.52-5.65) 0.75 (0.16-3.49) 
Neg 52/239 57/239 
IgG 
 
Pos 14/45 12/45 1.77 (0.86-3.65) 1.21 (0.58-2.54) 
Neg 42/205 47/205 
(ii) Pregnancy outcome Odds Ratio (95%CI) 
 
Spontaneous ART Spontaneous ART 
Live  
birth 
Pregnancy  
loss 
Live  
birth 
Pregnancy 
 loss 
Live birth Pregnancy loss Live birth Pregnancy loss 
IgM Pos 0/3 0/3 1/3 0/3 0.83 (0.04-17.00) 6.25 (0.28-138.0) 1.78 (0.17-17.37) 3.87 (0.18-82.34) 
Neg 49/247 7/247 47/247 11/247 
DNA Pos 4/11 0/11 2/11 0/11 1.97 (0.60-6.49) 1.84 (0.09-36.27) 0.94 (0.20-4.39) 0.98 (0.05-17.95) 
Neg 46/239 6/239 46/239 11/239 
IgG Pos 14/45 0/45 11/45 1/45 1.55 (0.76-3.16) 0.32 (0.02-5.95) 1.05 (0.69-3.27) 0.39 (0.05-3.20) 
Neg 36/205 6/205 37/205 10/205 
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6.3.4 Risk of TFI and C. trachomatis positivity in both partners 
Table 6.10 shows the relationship between C. trachomatis infection in both infertile 
females and males, with the diagnosis of tubal factor infertility in the female partner. In 
summary, this shows that TFI, in the female partner was unrelated to the status of C. 
trachomatis in either herself or her partner, as defined by PCR or serology (IgM & 
IgG). 
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Table 6.10: Chlamydia trachomatis antibodies and urine DNA in the female and male 
partner and chances of TFI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C. trachomatis 
Status in female 
TFI Odds Ratio 
(95%CI) 
C. trachomatis 
Status in male 
Partner’s 
TFI 
 
Odds Ratio 
(95%CI) 
IgM Positive 2/10 1.24(0.26-5.92) IgM Positive 0/3 1.93(0.04-13.59) 
Negative 39/240 Negative 41/247 
DNA Positive 0/12 0.20(0.01-3.61) DNA Positive 2/11 1.14(0.23-5.47) 
Negative 41/238 Negative 39/239 
IgG 
 
Positive 6/39 1.22(0.46-3.19) IgG 
 
Positive 9/45 1.35(0.60-3.14) 
Negative 35/211 Negative 32/205 
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6.4 Discussion 
The main findings of this chapter were that the history of urethritis and working as a 
driver in the men and PCOS in women were statistically related to C. trachomatis 
infection. However, C. trachomatis infection was not related either to TFI or the 
chances of achieving pregnancy, experiencing pregnancy loss, or the chances of a live 
birth. 
To examine the first of these findings, it is perhaps no surprise that a history C. 
trachomatis infection by urine DNA was significantly associated with the history of 
urethritis in the male partners (OR= 34.82; 95%CI= 8.45-143.40). This observation is 
similar to other studies (Holms et al., 1975; Schachter, 1999; Gonzales et al., 2004; 
Taylor and Haggerty, 2011) and confirms the infection of the genitourinary tract is the 
most common clinical appearances in men following C. trachomatis infection. The 
presence of C. trachomatis DNA in urine samples indicates a current infection. The 
reason that urethritis was not observed in antibody positive men, could be that in 
individuals with a normal immune response, it is usual that a high infectious dose of C. 
trachomatis would result in an antibody response of IgM after two weeks and IgG a few 
weeks later. In an infection with a low dose of C. trachomatis it is still possible to detect 
DNA because of the high sensitivity of the test. However as the antibody test is not as 
sensitive as the DNA test it may not be possible to detect antibodies in these cases. 
Interestingly the male partners who are drivers, were more likely to have exposure to C. 
trachomatis (OR=2.37; 95%CI= 1.03-5.45) as defined by IgG positivity. This is in 
agreement with the findings of Leung et al., (2009) that investigated C. trachomatis 
prevalence between cross-border truck drivers in Hong Kong. The prevalence was not 
extremely high, but it was suggested that such drivers could have been more 
promiscuous and engaged in sex with commercial sex worker and extramarital sex 
partners therefore increasing the chances of infection. 
In female partners, the results showed C. trachomatis positive serology (IgM & IgG) 
was associated with PCOS (IgM (+): OR= 3.70; 95% CI= 1.03-13.3; IgG (+): OR= 
2.59; 95%CI= 1.24-5.37). This is similar to the finding of Morin-Papunen et al., (2010) 
who investigated the correlation of systemic inflammation induced by chlamydia 
infection and symptoms of PCOS. PCOS is the most common cause of hyperandrogenic 
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anovulatory infertility and is also associated with hyperinsulinemia due to resistance to 
insulin (metabolic disorder). They found the chronic inflammation because of C. 
trachomatis could contribute in the metabolic and hormonal disorder of PCOS (Morin-
Papunen et al., 2010) as chlamydial infection can be cause of insulin resistance and 
systemic inflammation (Fernandez-real et al., 2006).  
In the present study the most common reason for primary and secondary infertility was 
male factor (40.0%). This is as expected, since in most other studies male infertility is 
the most common reason for a couple’s infertility (Farhi and Ben-Haroush, 2011; 
Eisenberg et al., 2012). The second and third most common reason for infertility were 
for PCOS and tubal damage and this is also as expected (Farhi and Ben-Haroush, 2011; 
Eisenberg et al., 2012). This suggests that the infertile couple enrolled to the study are 
representative of those recruited to other studies. It also suggests that the aetiology of 
infertility in Iran is similar to other countries. 
In the present study, IgG positivity was not associated with TFI in women, when either 
women or their partners were positive (see Table 6.10). This is in contrast to Idahl and 
colleagues who found a relationship between of IgG positive and TFI where women but 
not their partners were serology positive (Idahl et al., 2004). Different studies have 
shown the relationship of C. trachomatis antibodies and TFI (Dabekausen et al., 1994; 
Eggert-Kruse et al., 1997; Paavonen and Eggert-Kruse, 1999, Akande et al., 2003, 
Mardh, 2004; Coppus et al., 2007, El Akande et al., 2010; Hakim et al., 2010). Apart 
from different diagnostic methods among these studies (Dabekausen et al., 1994; El 
Hakim et al. 2010), they also investigated the efficiency of doing laparoscopy based on 
the positive result for chlamydia and medical history (Coppus et al., 2007; El Hakim et 
al. 2010), or they investigated tubal damage with special regard to chlamydial 
salpingitis (Mardh, 2004). In this study, women were not symptomatic and the serology 
results were obtained after patient recruitment and the completion of all diagnostic 
procedures. Therefore is arguably better than other studies by recruiting couples blindly 
without reference to their diagnosis or reason for infertility. Among 41 women with a 
TFI diagnosis, only 6 female and 9 male partners were IgG positive, with only one 
couple where both were IgG positive. The rest (26 women) were negative for IgG 
antibody to chlamydia. MIF staining is the gold standard of C. trachomatis detection, 
(see section 2.3.1). The low number of positive results from this method might be the 
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most important cause of low concordance within couples. The method used in this study 
did not measure the different titre and level of antibody that could be considered 
positive with other studies. According to the kit instructions the dilution rate for IgG 
serum antibody was only 1:64 and did not include different dilution rates. Although this 
is weakness of our study, the total number of IgG positives (n=39 women) is 
comparable with other previous studies (Idahl et al., 2004; 2007). Therefore, the present 
study draws attention to the interesting finding that antibody IgG to chlamydia was not 
related to TFI and this could be genuine finding or due to a high number of negative 
results that can effect on the odds ratio.  
Other infection (e.g. TB) and multiple reasons including ovarian endometriosis, the 
history of abortion and curettage, history of using intra-uterine contraceptive device 
(IUD) must also be considered as a possible aetiology of tubal damage. Although, these 
reasons might be the cause of tubal damage or a masking factor (antibiotic treatment in 
the early stage of lower genital tract infection) of the IgG results in any study, in Iran 
genital tuberculosis (TB) is specifically common cause of infertility (Namvar Jahromi et 
al., 2001). The incidence (per 100,000 people) of TB in Iran (17), UK (13), Sweden 
(6.8), Germany (4.8) and USA (4.1) was last reported in 2010; according to a World 
Bank report (WHO, 2012). 
Of 250 infertile couples, one hundred and fifteen got pregnant either spontaneously 
(48.7%) or by use of ART (51.3%). Idahl et al., (2004), who followed up 244 infertile 
couples for a mean of 37 (range 14-54 months), found that pregnancy was achieved 
spontaneously in 58.7% of couples and 41.3% following treatment. The higher 
spontaneous pregnancy rate may be explained by Idahl’s longer follow-up time (14-54 
months) but this study’s increase in ART success might be because more couples 
received treatment. In this study 25.6% had not received treatment at the end of follow-
up whereas in Idahl’s it was 48.3%. Also in this study, the male factor was most 
common reason and this could be treated by ICSI, but in Idahl’s study unexplained 
infertility was most common reason. 
To see how C. trachomatis infection was related to pregnancy rate, the results for 
serology and PCR in both partners were considered against the chances of achieving 
pregnancy and pregnancy outcome (including pregnancy loss). Interestingly, the 
infection was not associated with chances of achieving pregnancy and live birth or 
 
  
 
133 
 
pregnancy loss when either of the female or male partners were positive for C. 
trachomatis (by any method). The results were in contrast with Idahl et al., (2004) who 
found that IgG positivity in the male partner was associated with not achieving 
pregnancy in their partner, whereas the positivity in female partners was not associated 
with achieving pregnancy (Idahl et al., 2004).  
In conclusion, this study provides little evidence for the role of C. trachomatis in the 
fertility of couples and the incidence of TFI in women referred for infertility. In the next 
and final chapter of this thesis the results across all chapters will be considered and 
discussed in context with wider the literature.    
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7 Chapter 7: General discussion 
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This thesis set out to evaluate the role of C. trachomatis and M. genitalium in infertile      
couples in a region of Iran. No previous work has been reported in this area in Iran and 
the study evaluated the prevalence and the relationship of these infections with semen 
quality, semen inflammatory markers and sperm DNA measurements, also the effect of 
C. trachomatis infection on pregnancy rate and pregnancy outcome. 
 
7.1 Summary of findings 
The starting point of this work was a population-based prevalence study of infertile 
couples and fertile women using PCR and serology. The main strength of this study is 
the information about prevalence of C. trachomatis & M. genitalium among 
asymptomatic population who were not seeking treatment. Moreover, a second strength 
was the PCR based diagnoses on urine samples of all infertile couples compared to 
Idahl et al., (2004) who performed PCR only on IgG positive patients. Finally, this 
study also achieved an excellent follow-up rate of 95%. However our cohort was small 
to investigate the impact of C. trachomatis infection and the relatively short follow-up 
period (24 months) may be two weaknesses of the study.  
The study in Chapter 3 showed low prevalence of C. trachomatis infection as 
determined by NPPCR and serology, and a zero incidence of M. genitalium as defined 
by PCR. Previous studies show variable rates according to the population tested and the 
methods used. The prevalence of C. trachomatis found in this thesis was low but 
comparable to other studies (Eggert-Kruse et al., 1997; 2003; Hosseinzadeh et al., 2004; 
Idahl et al., 2004; Hamdad-Daoudi et al., 2004). In addition to low prevalence of C. 
trachomatis, the results also showed a low concordance within couples. The most likely 
reason for this is the low number of patients with positive serology or PCR tests and this 
was discussed in section 3.4. Moreover, the PCR results from urine samples might have 
lower positivity than the actual incidence because urine samples do not include many 
cells and the presence of PCR inhibitor and also the kit which used (see section 3.4). 
The results of the study supported previous studies suggesting that FVU is a more 
practical specimen in asymptomatic men to detect C. trachomatis (Chernesky et al., 
1994; Michel et al., 2007; Wiggins et al., 2009) as no positive was observed in semen 
samples of men that had past exposure to C. trachomatis determined by serology. 
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As anticipated, the results in Chapter 3 showed an increased prevalence of C. 
trachomatis IgG antibody in the infertile population compared to women with proven 
fertility that was not statistically significant. No M. genitalium was observed in urine 
and semen samples. As discussed in Chapter 3 the reason might be the inappropriate kit 
and nature of samples. That also might be caused of selection bias as poorer people 
(who are reported to have higher prevalence of M. genitalium) cannot afford treatment 
in Iran, as people should pay in public medical centre and that can affect the prevalence 
of this organism (Yeganeh et al., 2013). To achieve cost-effectiveness in Iran further 
multi- central studies will be needed on younger infertile couples. 
In the fourth chapter, this thesis evaluated the relationship between C. trachomatis 
infection and semen parameters and seminal inflammatory markers. The main strength 
of this study, compared to previous studies, was that it evaluated serology (IgA, IgM, 
and IgG) and PCR (semen & urine DNA) both to detect past and current infection. The 
conclusion was that the only semen parameter affected by C. trchomatis infection as 
defined by PCR, was semen volume which is in contrast with Hosseinzadeh et al., 
(2004) but in support Kokab et al., (2010). However mean semen pH was significantly 
higher in IgG positive men in support of Marconi et al., (2009) and Kokab et al., (2010). 
The results for seminal inflammatory markers were comparable with other previous 
work (Eggert-Kruse et al., 2001; Kokab et al., 2010) and high IL-6 and IL-8 levels 
suggested that these cytokines may be a marker of upper genital tract infection 
especially prostatitis (Al-Mosley and Eley, 2007). As C. trachomatis is treatable, it 
could be diagnosed by screening infertile couples earlier to detect this infection. Taylor 
et al., (2005) found a link between STD infections including chlamydia and prostate 
cancer and Nelson et al., (2003) showed link between prostatic inflammation and 
prostate cancer. However there is controversial idea about the infection sequelae such as 
BPH and cancer of the prostate among experts.   
 
In Chapter five, sperm DNA measurements were studied in infected men as defined by 
serology and PCR. The TUNEL assay was performed on semen samples from all 250 
males recruited and additional measures of sperm chromatin were undertaken on a sub-
population of 80 men. The percentage of DNA fragmentation using the TUNEL assay 
showed 12.75±8.36 (mean±SD) overall among infertile men. As DNA damage can be 
underestimated by the TUNEL assay (Mitchell et al., 2011), the results may not have 
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showed the true percentage of fragmentation. The study weakness is that the results 
were obtained by microscopic examination of stained smears, whereas other researchers 
(Marchetti et al., 2002; Shen et al., 2002; Gillan et al., 2005; Mitchell et al., 2011) have 
used flow cytometry to examine a greater number of cells. Flow cytometry is more 
statistically reliable as it analyses a high number of cells and therefore is considered 
more accurate and more discriminative. Recently, studies on DNA integrity that focuses 
on the genomic integrity of the male gamete has been further increased because of the 
growing concern about transmission of genetic disease through ICSI (Barroso et al., 
2000). However, there was no evidence in the patients recruited to this study that they 
had infertility because of high levels of DNA damage in sperm. There is controversy 
about the role sperm DNA testing has in the infertility work up and this is because there 
is no strong evidence (Barratt et al., 2010; ASRM, 2013) that sperm DNA abnormality 
results in ART failure or pregnancy outcome. Couples with long term unexplained 
infertility are more likely to gain more advantage of using these tests (Sakkas & 
Alvarez, 2010). On the other hand, it has been suggested that sperm DNA damage 
evaluation may be better than semen analysis (Zini et al., 2001) for prediction of 
outcome of spontaneous pregnancy and assisted reproductive techniques. Also DNA 
fragmentation levels more than 30% are considered as a cut off level that spontaneous 
pregnancy is not achievable and is linked to ART failure (Zini et al., 2001; Evenson et 
al., 1991, 2002; Borini et al., 2006; Nallella et al., 2006). 
The results from chromatin assessment (in a sub-population of 80 men) showed higher 
percentage damage (AB: 29.16±14.75; AO: 38.24±11.77 and CMA3: 38.11±9.17) 
compare with TUNEL results. Another study weakness was that the semen sample on 
which sperm DNA measurements were made, was not the same as the one used in the 
ART cycle or the ejaculate which lead to any spontaneous pregnancy. However, we 
know that DNA damage can highly vary in multiple samples and is influenced by 
environmental or lifestyle factors as well (Pacey, 2010) and therefore the measures 
reported here may not be representative. 
In Chapter six, the thesis investigated the relationship between past reproductive and 
medical history and C. trachomatis infection. In the male partner, as anticipated, a 
history of urethritis was associated with C. trachomatis DNA in urine and the infection 
was more likely to be present in men who worked as drivers. In the female partners, C. 
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trachomatis positive serology was associated with PCOS as observed by Morin-
Papunen et al., (2010). In contrast with other studies (Sellors et al., 1988; Dabekausen 
et al., 1994; Mardh, 2004) this study did not support the relationship between C. 
trachomatis and TFI. This may be because previous studies have investigated C. 
trachomatis using culture among women that showed TFI, by taking samples of uterine 
tube or cervix by biopsy or swab. However, other studies (Dabekausen et al., 1994; 
Eggert-Kruse et al., 1997) used serology to determine chlamydial infection in women 
with abnormal HSG results. Given that the sperm can be stored in uterine tubes (Suarez 
& Pacey, 2006) and C. trachomatis is able to attach to sperm (Hosseinzadeh et al., 
2000) then it was perhaps not surprising that TFI was not related to these organisms 
since in the population of men recruited to this study, neither C. trachomatis or M. 
genitalium were detected in semen (see section 3.3.2 & 3.3.4). Also the women who 
were infected may only have had lower genital tract infection that had either been 
treated or had been cleared by their immune system and therefore this could explain 
why that C. trachomatis infection was not related to either pregnancy rate (assisted or 
unassisted) or pregnancy outcome in this population. 
7.2 Implications of the thesis findings 
In the following sections, the thesis will conclude with a wider discussion about the 
topic with some suggestions for further future work. 
7.2.1 Is C. trachomatis a problem? 
When chlamydia is diagnosed, women will understandably be concerned about their 
future fertility. In the Western countries the relationship between C. trachomatis and 
future fertility is often reported in the media or through National Health Service (NHS) 
campaigns and women are generally informed about the consequence of STDs. 
However this is not the same in Iran where the media does not report STDs and the 
general population are relatively uninformed about any relationship between chlamydia 
and infertility. Since the findings of this thesis showed this infection is not related to 
infertility, it must be questioned whether C. trachomatis infection really causes 
infertility?  
There is a significant body of literature showing the relationship between PID, TFI and 
ascending chlamydia infection (discussed in Chapter 6), however, this thesis supports 
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previous studies (Mardh, 2004; Geisler et al., 2008) which show that even in 
unrecognized infection, there is no evidence of serious complication and sequelae 
(Mardh, 2004) without upper genital tract infection and reinfection. Also spontaneous 
clearance occurs in 30-50% of lower genital tract infection (Geisler et al., 2008) and 
only persistent infections develop to complications. In addition, in adverse pregnancy 
outcome the host immunological response is more important than micro-organisms 
(Land et al., 2010) and also previous work is based on retrospective studies as 
prospective studies are unethical to conduct (Wallace et al., 2008; Land et al., 2010). 
For example, in the systematic review by Wallace et al., (2008) of 3,349 studies 
evaluated only one study met the inclusion criteria and this was found to have 
methodological flaws. Therefore, Wallace et al., (2008) concluded that the current 
assumptions of prevalence and relationship of C. trachomatis and tubal damage were 
incorrect with a poor evidence base. Moreover, the role of epididymitis as a result of 
developing lower genital tract infection is not well understood in male infertility 
(Karinen, 2005). C. trachomatis infection among the working class, in stable 
relationships, infertile population of this study was not a cause of their infertility. 
However, it should be recognized that this conclusion might be different in other 
populations and locations. Further future studies will be needed to make clear the 
magnitude of C. trachomatis infection in infertility. 
7.2.2 Why we are screening?  
The primary aim of screening is reduce morbidity by the early detection of infection and 
the secondary aim is to decrease of overall prevalence of infection. Opportunistic and 
proactive screening programmes in Western countries screen women < 25 years when 
they are sexually active (SIGN, 2009, Low et al., 2011). As this study did not show 
association between chlamydia and infertility, this thesis would seem to undermine the 
very logic of such screening programmes.  
It has been suggested by previous literature that current screening programme are not 
based on strong evidence (Katz et al., 1994; van Valkengoed et al., 2004; Low et al., 
2006, 2007; Wallace et al., 2008; Land et al., 2010). For example, the assertion that C. 
trachomatis screening reduced morbidity in Sweden is not supported by data from other 
countries (Low et al., 2007). A recent cross-sectional survey in Europe stated that using 
an appropriate diagnostic method is essential for effective screening (Low et al., 2011) 
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and this is more likely to be achieved by using national guidelines and regular audit. 
Therefore if the aim of screening is reduce morbidity related to fertility issues; it should 
consider selected population and couple screening rather than only women as our results 
showed poor concordance within couples. In Iran, there are no screening programmes 
based on national guidelines or regular audit for the prevalence of STDs, but our result 
showed the prevalence of C. trachomatis is comparable with other countries. 
Considering that our results have not found any relationship with chlamydia infection 
and its consequences such as PID, EP and infertility, this may suggest screening 
programmes are only needed in Iran for early detection of disease and prevent of spread 
disease in sexual active people (< 25 years) or in pregnant women to prevent of neonatal 
infection as this infection could be persistent.  
7.2.3 Is screening cost-effective? 
To evaluate cost-effectiveness of screening, selective screening is strongly 
recommended (Mylonas, 2012). Since prevalence data is not reliable, estimation of 
screening cost is problematic and also cost of clinical approaches to infertility are less 
than screening (Hu et al., 2004). This is because the model that is used for cost-effective 
ness is based on an overestimate assumption of complications (van Valkengoed et al., 
2004; Low et al., 2007) and there is no evidence of serious complications (Wallace et 
al., 2008, Garnett, 2008; Low et al., 2007). Therefore this is an expensive intervention 
under assumption. The reason for high rates assumption is that prospective studies are 
unethical and most predictions for cost-saving come from the costs of treatment and 
complications prevented (van Valkengoed et al., 2001). Moreover, most studies were 
performed in high risk populations and these are at greater risk of complications (van 
Valkengoed et al., 2004). As high risk of complications have only been observed with 
repeated infection and are less than expected in the general population, it has been 
argued that the benefit of screening programmes have been exaggerated (Low et al., 
2006). 
For example, screening in Western countries seems expensive. Estimation of screening 
cost per quality-adjusted life-years (QALY) gained every 2 years in Netherlands would 
cost €20,000 (de Vries et al., 2008), and annual QALY gained in the UK would cost 
£27,000 (Adams et al., 2007). In both of these studies men as well as women were 
included. Chlamydia screening programme in Ireland was found to be expensive 
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(€94,717 per QALY gained) and is unlikely to be considered by policy makers 
(Gillespie et al., 2012). Researchers in the USA found the cost of screening only young 
women was US$25,000 per QALY gained annually (Hu et al., 2004). In fact all of these 
reports were performed based on the overestimate of complications like PID, TFI and 
EP. The calculation based on observed occurrence of complications in Amsterdam 
showed very low rates of complications (van Valkengoed et al., 2004) compared to 
calculation based assumptions. Considering the lack of diagnostic quality in the 
diagnosis of PID and high burden impact of its diagnoses and treatment on the NHS 
(and also for IVF treatment), it has been suggested that it would be more cost effective 
to spend money on diagnosis and treatments rather than screening (Simms et al., 2000). 
In low prevalence population some people believed chlamydia testing is “wasting 
money” (BBC News/Health, 2009). 
Few studies have shown cost-effectiveness of screening and treatment (Land et al., 
2010). To improve the evaluation of screening activities, it has been suggested that 
future research should consider the risk of reinfection, persistent and PID after C. 
trachomatis infection (Hu et al., 2006). Proactive screening was suggested to selected 
population with high prevalence of infection that might be cost effective and cost-saving 
(Fenton & Ward, 2004; Land et al., 2010; Mylonas, 2012).  
7.2.4 Future work 
The findings of this thesis suggested that C. trachomatis is not a problem in infertile 
couples who were recruited from the Yazd IVF centre in Iran. However there is no data 
about the effect of long term persistent infection and horizontal spreading neonatal 
infections that may have a large health burden impact. 
There are no national guidelines available for chlamydia screening in Iran in the same 
way that there are in Western countries such as the UK. Therefore to convince the 
Iranian Ministry of Health to consider developing screening guidelines and funding 
screening strategies, stronger and larger studies will be needed to evaluate the benefits 
and disadvantage of screening programme including side effect of screening or 
treatment of long term complications. This study only illustrates the prevalence and 
effect of C. trachomatis among infertile couples from the working or lower classes, who 
were in stable relationships in central and South of Iran. It is suggested that future multi-
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centre studies of young couples are needed to find more accurate prevalence data using 
PCR on FVU samples as the specimen of choice in both males and females. It would be 
necessary to evaluate the cost of treating complications (i.e., infertility) and screening 
cost in patients over a long term follow up to optimize better screening strategy. As 
Western countries spend a huge amount of money (section 7.2.3) and also people 
involved with their screening programme, study like the present study might be a good 
start to change and review their guidelines. 
On the other hand, this thesis did not show M. genitalium infection among infertile 
couples. Further future studies will be needed in different level of people without any 
selection bias to find robust prevalence data.  
7.2.5 Conclusions 
The findings of this thesis indicate in the study population, C. trachomatis infection was 
not related to either female or male infertility. The results suggest a comparable 
incidence of this infection with other studies; however, the present study does not 
support opportunistic screening for early detection to reduce morbidity of complications 
because there were no complications related to this infection in the women recruited. 
This study was the first of its kind in Iran and it will be need to be repeated in other 
Iranian cities to find the probability of any complication related to infection. The role of 
C. trachomatis and/or M. genitalium as infectious agent is still controversial and long 
term follow up studies will be needed to clarify their significance.  
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Treatment Chemotherapy      Radiotherapy         Combined 
Site of Radiotherapy:  
Date  
Occupation  
Endocrine Problem Thyroid            Galactorrhoea 
Hyperprolactinemia                 PCOS 
                                               
Follow up (Infertile Couples) 
Diagnostic test: Ultrasonography              Biopsy 
Laparoscopy             Hysteroscopy      HSG  
Result: 
 
 
Treatment(after diagnose) Antibiotic             Hormonal        Surgery        
ART* 
ART* 
Assisted Reproductive Technology 
IVF              ICSI        IUI              Zift 
Pregnancy Normal             ART 
Embryo quality  
 
Success Rate  
Miscarriage  Yes                    No      
Delivery Vaginal             C/S  
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Yazd Research &Clinical Centre for Infertility 
No=1084 
Date: 27/8/2009 
 
The meeting was held in IVF centre, that was 68
th
 research committee, on Wednesday 
(26/8/2009).Those are present in this meeting: Prof Aflatoonian, Dr Ghasemi, Dr Davar, 
Dr Abdoli, Dr Mohamad hasan Sheikhha, Dr Dehghani, Dr Anvary. 
 There are presented some research proposal by investigators or their supervisor. One of 
research proposal that was presented by Prof Aflatoonian, which is a joint program 
between The University of Sheffield and Shahid Sadughi Medical University of Yazd. 
The title of research proposal: Testing for Chlamydia trachomatis and/or Mycoplasma 
genitalium including serology to determine pregnancy rates in infertile couples from 
Yazd.  The investigator is Dr Laleh Dehghan Marvast who is a PhD student in The 
University of Sheffield, and this research is a part of her PhD. 
This project was approved by committee, also because of sending samples to UK, it 
needs to be approved by Ministry of Health Ethic Committee. 
 
This is a translation of pages which follow. 
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No=686/P88S 
Date: 2/1/2010 
To: Dr Fatemeh Ezaaddini, Research Deputy, Yazd Medical University, Yazd 
From: Dr Kazem Zendedel, Secretary of Ethic Committee for Medical Research, Tehran  
Ethic Committee for Medical research 
Ethic Committee approval 
Declaration no=11P/88k-A                                         Date: 9/9/2009 
Inspected at: Ministry of Health Ethic Committee     Date: 23/12/2009 
Decision: conditional acceptance 
Inspection type: regular 
This project has been approved in 46
th
 meeting of Ethic Committee for Medical research 
if only all of experiments carry out on samples that have been mentioned in proposal 
and the remainder of samples must be discarded. 
Title of research project: Testing for Chlamydia trachomatis and/or Mycoplasma 
genitalium including serology to determine pregnancy rates in infertile couples from 
Yazd.   
Investigator details: 
Name: Dr Laleh Dehghan Marvast 
E-mail: Laleh.dm236@gmail.com 
Tel: 0351-8247085 
Address: Yazd Research &Clinical Centre for Infertility 
 
This is a translation of pages which follow. 
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Sample size calculation: 
Type 1 error (alpha): 5%. 
Power: 80% (probability you reject the null when it is false). 
There are 3 assumptions: 
 
Infection rate in fertile couples:              4%                         8%                11% 
Infection rate in infertile couples:           8%                       12%                15% 
Number of couples (patients) required:  65 (130)             199(398)           253(506)     
    
These sets of infection rates give the population prevalence of 12% if 15% of couples 
are infertile. 
 
For a quantitative measure (comparing two groups) standardised mean difference of 0.5 
standard deviations would require 64 in each group. Standardised mean of difference of 
.28 would require 202 in each group. 
Statistical advice was provided by Dr. Dawn Teare who used the reference blew: 
Sample Size Tables for clinical studies. Third edition, Machin D, Campbell MJ, Tan 
SB, Tan SH. Wiley-Blackwell 2009. 
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Prevalence of C. trachomatis in different studies. 
References Specimen Method Population Country Prevalence 
Domes et al., 2012 Urine & semen SDA Men (infertile) Canada      0.3% 
de Lima Freitas et al., 2011 Endocervical PCR Women (infertile ) Brazil    52.8% 
Mahmud et al., 2011 Serum Serology Women (young) Bangladesh      4.6% 
Mahmud et al., 2011 Serum Serology Women (pregnant ) Bangladesh    24.1% 
Ikeme et al., 2011 Serum Serology Women (different age) Nigeria    29.4% 
Idahl et al., 2004 Urine & semen PCR Infertile men Sweden      7.1% 
Idahl et al., 2004 Urine  PCR Infertile women Sweden      6.8% 
Idahl et al., 2004 Serum Serology Infertile men Sweden    20.1% 
Idahl et al., 2004 Serum Serology Infertile women Sweden    24.2% 
Eggert-Kruse et al., 2003 Urine  PCR Men (infertile) Germany      1.8% 
Eggert-Kruse et al., 2003 Urine PCR Women (subfertile) Germany      1.0% 
Bollmann et al., 2001 Semen LCR Men (infertile) Germany      4.0% 
Eggert-Kruse et al., 1997 Semen LCR Men (infertile) Germany      0.0% 
Eggert-Kruse et al., 1997 Serum Serology Men (subfertile) Germany    12.6% 
Eggert-Kruse et al., 1997 Serum Serology Women (subfertile) Germany    20.8% 
 
 
 
